[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, a synonym for Acrokeratosis paraneoplastica is Bazex's syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Acrokeratosis paraneoplastica is also known as Bazex's syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Acrokeratosis paraneoplastica is also known as Bazex's syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, Weaver syndrome is similar to Sotos syndrome in that both are characterized by childhood overgrowth, advanced bone age, and developmental delay. However, Weaver syndrome has its own distinctive facial gestalt, which sets it apart from Sotos syndrome. Additionally, recent studies have shown that intragenic mutations in the NSD1 gene are the major cause of Sotos syndrome, with a minority of cases having large deletions of the NSD1 gene. Weaver syndrome is also associated with NSD1 mutations, but these are typically found in a smaller proportion of cases compared to Sotos syndrome. Therefore, while Weaver syndrome shares some similarities with Sotos syndrome, it has distinct differences in terms of its facial appearance and genetic causes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Both Weaver syndrome and Sotos syndrome are characterized by childhood overgrowth.\n2. Both syndromes exhibit advanced bone age and developmental delay.\n3. Intragenic mutations in the NSD1 gene are the major cause of Sotos syndrome.\n4. A smaller proportion of Weaver syndrome cases are associated with NSD1 mutations compared to Sotos syndrome.\n5. Weaver syndrome has a distinctive facial appearance that differentiates it from Sotos syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Both Weaver syndrome and Sotos syndrome are characterized by childhood overgrowth.",
      "Both syndromes exhibit advanced bone age and developmental delay.",
      "Intragenic mutations in the NSD1 gene are the major cause of Sotos syndrome.",
      "A smaller proportion of Weaver syndrome cases are associated with NSD1 mutations compared to Sotos syndrome.",
      "Weaver syndrome has a distinctive facial appearance that differentiates it from Sotos syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the passage, the releases of the JASPAR database are:\n1. First major release\n2. Second major release\n3. Third major release\n4. Fourth major release (the largest expansion of the core database to date)\nIn the fourth major release, the database now holds 457 non-redundant, curated profiles, including the first batch of profiles derived from ChIP-seq and ChIP-chip whole-genome binding experiments, and 177 yeast TF binding profiles. Additionally, the database has introduced a yeast division, improved classification of TF families by adopting a new DNA-binding domain nomenclature, and provided a curated catalog of mammalian TFs.",
    "llama-2-7b-chat-hf_fact_raw": "1. The JASPAR database has had at least four major releases.\n2. The fourth major release is described as the largest expansion of the core database to date.\n3. As of the fourth major release, the JASPAR database contains 457 non-redundant, curated profiles.\n4. The fourth major release includes profiles derived from ChIP-seq and ChIP-chip whole-genome binding experiments.\n5. The fourth major release introduced a yeast division and an improved classification of TF families with a new DNA-binding domain nomenclature.",
    "llama-2-7b-chat-hf_fact": [
      "The JASPAR database has had at least four major releases.",
      "The fourth major release is described as the largest expansion of the core database to date.",
      "As of the fourth major release, the JASPAR database contains 457 non-redundant, curated profiles.",
      "The fourth major release includes profiles derived from ChIP-seq and ChIP-chip whole-genome binding experiments.",
      "The fourth major release introduced a yeast division and an improved classification of TF families with a new DNA-binding domain nomenclature."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The JASPAR database, which is a widely-used open-access database for transcription factor binding profiles, has had multiple major releases, the first of which occurred in 2004. Since then, it has had several updates and expansions, indicating at least four major releases.\n2. UNKNOWN: Without specific details regarding each release, it is difficult to confirm whether the fourth major release was indeed the largest expansion of the core database to date.\n3. FALSE [correction]: Without knowing the specific release referred to and the exact number of profiles in that release, or without a confirmed source, the statement about the number of profiles cannot be verified. The actual count may differ.\n4. TRUE: Previous major updates to the JASPAR database have typically included profiles derived from high-throughput technologies such as ChIP-seq (chromatin immunoprecipitation followed by sequencing) and ChIP-chip (chromatin immunoprecipitation combined with microarray technology) experiments.\n5. UNKNOWN: Specific details about the content of the fourth major release, such as the introduction of a yeast division and an improved classification of transcription factor (TF) families with a new DNA-binding domain nomenclature, cannot be confirmed without additional information or access to the release notes/documentation of that release.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the function of the viral KP4 protein is to regulate viral gene expression through sumoylation. The KP4 protein is sumoylated with SUMO1 in both transfected and infected cells, and the K254 residue within a consensus sumoylation motif is specifically modified. Mutation of the K254 residue to arginine (P-K254R) reduces PIV5 minigenome activity and the sumoylation level of the P protein, indicating that sumoylation of the KP4 protein at K254 is important for PIV5 growth. Additionally, incorporation of K254R into a recombinant PIV5 virus results in a lower titer and lower levels of viral RNA synthesis and protein expression, suggesting that sumoylation of the KP4 protein at K254 regulates PIV5 gene expression through a host protein. Overall, the study suggests that sumoylation of the KP4 protein plays a critical role in regulating PIV5 gene expression and viral replication.",
    "llama-2-7b-chat-hf_fact_raw": "1. The KP4 protein functions to regulate viral gene expression through sumoylation.\n2. The KP4 protein is sumoylated with SUMO1 in transfected and infected cells.\n3. The K254 residue within a consensus sumoylation motif of the KP4 protein is specifically modified.\n4. Mutation of the K254 residue to arginine (P-K254R) reduces PIV5 minigenome activity and the sumoylation level of the P protein.\n5. Incorporation of the K254R mutation into a recombinant PIV5 virus results in lower virus titer and reduced levels of viral RNA synthesis and protein expression.",
    "llama-2-7b-chat-hf_fact": [
      "The KP4 protein functions to regulate viral gene expression through sumoylation.",
      "The KP4 protein is sumoylated with SUMO1 in transfected and infected cells.",
      "The K254 residue within a consensus sumoylation motif of the KP4 protein is specifically modified.",
      "Mutation of the K254 residue to arginine (P-K254R) reduces PIV5 minigenome activity and the sumoylation level of the P protein.",
      "Incorporation of the K254R mutation into a recombinant PIV5 virus results in lower virus titer and reduced levels of viral RNA synthesis and protein expression."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement is specific, and without additional context or domain knowledge on the particular protein KP4 (which might not even be real or could be referring to a protein related to a specific study), determining the truth of this statement is not possible.\n2. UNKNOWN: Similar to statement 1, the truthfulness of this statement depends on specific scientific data regarding sumoylation of the KP4 protein with SUMO1. Without the relevant information or publication, this cannot be verified.\n3. UNKNOWN: This statement again refers to specific scientific information about a residue within the KP4 protein. Without access to the relevant study or data, the truthfulness cannot be determined.\n4. UNKNOWN: The reference to PIV5 minigenome activity and sumoylation level related to a mutation of a residue indicates a detailed scientific finding. Without the proper context or validation through scientific literature, the truth of this statement cannot be assessed.\n5. UNKNOWN: This statement involves the outcome of introducing a mutation into a recombinant virus, which would require experimental evidence to verify. Without that evidence or context, the statement's truthfulness remains unknown.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the patent application WO2008106213, DITPA (3,5-diiodothyropropionic acid) is indeed a thyroid hormone analog that has been studied for its potential therapeutic effects on weight loss, metabolic syndrome, and other metabolic disorders. The patent application highlights the beneficial effects of DITPA in experimental and clinical studies in mammals, including its ability to stimulate weight loss, lower triglycerides, and improve metabolic abnormalities in obese adults.\nThe human clinical studies mentioned in the patent application involved a population of patients with a body mass index (BMI) greater than 25, which is a common criteria used to define obesity. The studies demonstrated the safety and efficacy of DITPA in reducing body weight and improving metabolic abnormalities in these patients.\nOverall, the information provided in the patent application suggests that DITPA is a promising thyroid hormone analog that may have potential therapeutic applications in the treatment of obesity and related metabolic disorders. However, it is important to note that the studies mentioned in the patent application were conducted in a controlled laboratory and clinical settings, and further research is needed to confirm the safety and efficacy of DITPA in larger, more diverse populations.",
    "llama-2-7b-chat-hf_fact_raw": "1. DITPA (3,5-diiodothyropropionic acid) is a thyroid hormone analog.\n2. DITPA has been studied for potential therapeutic effects on weight loss and metabolic syndrome.\n3. The patent application WO2008106213 describes the beneficial effects of DITPA in experimental and clinical studies.\n4. Human clinical studies of DITPA involved patients with a body mass index (BMI) greater than 25.\n5. The studies demonstrated the safety and efficacy of DITPA in reducing body weight and improving metabolic abnormalities in obese adults.",
    "llama-2-7b-chat-hf_fact": [
      "DITPA (3,5-diiodothyropropionic acid) is a thyroid hormone analog.",
      "DITPA has been studied for potential therapeutic effects on weight loss and metabolic syndrome.",
      "The patent application WO2008106213 describes the beneficial effects of DITPA in experimental and clinical studies.",
      "Human clinical studies of DITPA involved patients with a body mass index (BMI) greater than 25.",
      "The studies demonstrated the safety and efficacy of DITPA in reducing body weight and improving metabolic abnormalities in obese adults."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN - Without access to the specific content of the patent application WO2008106213, it cannot be confirmed whether this application actually describes the beneficial effects of DITPA in experimental and clinical studies.\n4. UNKNOWN - The statement does not provide enough information to determine the eligibility criteria of the human clinical studies of DITPA.\n5. UNKNOWN - Without specific data or results from the studies, it cannot be verified whether the studies demonstrated the safety and efficacy of DITPA in reducing body weight and improving metabolic abnormalities in obese adults.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the COUGER tool appears to be a sharpening tool used for maintaining the sharpness of scalers and curettes. The authors recommend using powered rotary stones to grind the sides of the blade, and discuss various sharpening materials and techniques for extending the useful life of the armamentarium. A regular sharpening schedule is also recommended to simplify the process and ensure the best results.",
    "llama-2-7b-chat-hf_fact_raw": "1. The COUGER tool is used for maintaining the sharpness of scalers and curettes.\n2. Powered rotary stones are recommended for grinding the sides of the blade.\n3. Various sharpening materials and techniques are discussed for extending the useful life of the armamentarium.\n4. A regular sharpening schedule is recommended to ensure the best results.\n5. The information about the COUGER tool comes from Document-0.",
    "llama-2-7b-chat-hf_fact": [
      "The COUGER tool is used for maintaining the sharpness of scalers and curettes.",
      "Powered rotary stones are recommended for grinding the sides of the blade.",
      "Various sharpening materials and techniques are discussed for extending the useful life of the armamentarium.",
      "A regular sharpening schedule is recommended to ensure the best results.",
      "The information about the COUGER tool comes from Document-0."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The correct spelling is CUREGuard, and it is a tool used for maintaining the sharpness of scalers and curettes.\n2. FALSE [correction]: Powered rotary stones are not recommended for sharpening scalers and curettes as they can produce excessive heat and alter the temper of the metal, which can damage the instrument.\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are drugs that can be used to treat tick-borne encephalitis. The document mentions the use of cytoflavin as a drug for pathogenetic treatment of neuroinfections with modifying effect of NO. The authors suggest that cytoflavin can reduce the general brain, focal brain, and neuropsychological disorders, as well as the endogenous hyperproduction of NO metabolites in the blood and cerebrospinal fluid. The recommended dose of cytoflavin is 10.0 ml once a day intravenously in drops during 7-10 days. Therefore, based on the information provided, cytoflavin is a drug that can be used to treat tick-borne encephalitis.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cytoflavin is a drug used for the pathogenetic treatment of neuroinfections.\n2. Cytoflavin has a modifying effect on Nitric Oxide (NO).\n3. The use of cytoflavin can reduce general brain, focal brain, and neuropsychological disorders in patients with neuroinfections.\n4. Cytoflavin administration can lower the endogenous hyperproduction of NO metabolites in blood and cerebrospinal fluid.\n5. The recommended dose of cytoflavin for treating such conditions is 10.0 ml once a day intravenously in drops for 7-10 days.",
    "llama-2-7b-chat-hf_fact": [
      "Cytoflavin is a drug used for the pathogenetic treatment of neuroinfections.",
      "Cytoflavin has a modifying effect on Nitric Oxide (NO).",
      "The use of cytoflavin can reduce general brain, focal brain, and neuropsychological disorders in patients with neuroinfections.",
      "Cytoflavin administration can lower the endogenous hyperproduction of NO metabolites in blood and cerebrospinal fluid.",
      "The recommended dose of cytoflavin for treating such conditions is 10.0 ml once a day intravenously in drops for 7-10 days."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Cytoflavin is indeed used for the pathogenetic treatment of various cerebral disorders, including neuroinfections, by improving metabolic processes in the brain.\n2. TRUE: Cytoflavin has been reported to modulate the effects of Nitric Oxide (NO), which can be involved in the pathogenesis of brain damage.\n3. TRUE: Cytoflavin is used to reduce symptoms in patients with neuroinfections, including general brain symptoms, focal brain symptoms, and neuropsychological disorders.\n4. TRUE: Cytoflavin administration has been found to influence the endogenous production of NO metabolites, which may be elevated during certain disease states.\n5. UNKNOWN: Without specific dosage information from reliable medical guidelines or prescribing information, the recommended dose stated cannot be confirmed as true or corrected as false. The appropriate dosage can vary based on specific circumstances and is something that should be determined by a healthcare professional.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the genome browser database for DNA shape annotations that is available is the University of California, Santa Cruz Genome Browser Database. According to the information, this database contains sequence and annotation data for a wide range of species, including vertebrates and invertebrates, and provides a variety of annotations at different scales, including assembly data, genes and gene predictions, mRNA and EST alignments, and comparative genomics data. The database is optimized for fast interactive performance and includes web tools for visualization and querying the data. Additionally, the database has been updated in the past year with new features such as VisiGene, a fully integrated in situ hybridization image browser, and phyloGif, a tool for drawing evolutionary tree diagrams. The database and its associated tools can be found at <http://genome.ucsc.edu/>.",
    "llama-2-7b-chat-hf_fact_raw": "1. The University of California, Santa Cruz Genome Browser Database is available for DNA shape annotations.\n2. This database contains sequence and annotation data for a range of species, including vertebrates and invertebrates.\n3. Annotations provided by the database include assembly data, genes and gene predictions, mRNA and EST alignments, and comparative genomics data.\n4. The UCSC Genome Browser Database includes web tools for visualization and querying the data.\n5. New features such as VisiGene and phyloGif have been added to the database in the past year.",
    "llama-2-7b-chat-hf_fact": [
      "The University of California, Santa Cruz Genome Browser Database is available for DNA shape annotations.",
      "This database contains sequence and annotation data for a range of species, including vertebrates and invertebrates.",
      "Annotations provided by the database include assembly data, genes and gene predictions, mRNA and EST alignments, and comparative genomics data.",
      "The UCSC Genome Browser Database includes web tools for visualization and querying the data.",
      "New features such as VisiGene and phyloGif have been added to the database in the past year."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nNote: Statement 5 is designated as UNKNOWN without additional context regarding the specific features and their release dates. \"Past year\" is a time-dependent claim and would require a current reference point and verification from recent update logs or announcements from the UCSC Genome Browser administrators.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, mutations in the EZH2 gene are associated with Weaver syndrome. The document reports on the results of trio-based whole-exome sequencing in two families affected by Weaver syndrome, which identified two de novo mutations in the EZH2 gene in the affected probands. Additionally, Sanger sequencing of EZH2 in a third classically-affected proband identified a third de novo mutation in this gene, further supporting the conclusion that mutations in EZH2 cause Weaver syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the EZH2 gene are associated with Weaver syndrome.\n2. Trio-based whole-exome sequencing in two families with Weaver syndrome identified two de novo mutations in the EZH2 gene.\n3. Sanger sequencing identified a third de novo mutation in the EZH2 gene in a classically-affected proband with Weaver syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the EZH2 gene are associated with Weaver syndrome.",
      "Trio-based whole-exome sequencing in two families with Weaver syndrome identified two de novo mutations in the EZH2 gene.",
      "Sanger sequencing identified a third de novo mutation in the EZH2 gene in a classically-affected proband with Weaver syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n\nAll three statements are consistent with what is known about the EZH2 gene and its association with Weaver syndrome. Weaver syndrome is a rare genetic disorder, and mutations in the EZH2 (enhancer of zeste homolog 2) gene have been identified as one of its causes. Trio-based whole-exome sequencing, which involves sequencing the exomes of the affected individual and their parents, can identify de novo mutations that may be responsible for the condition. Sanger sequencing is another method to confirm the presence of specific mutations. Therefore, without contradictory information about these specific instances, these statements can be considered true.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following human proteins are known to undergo a dimer-to-tetramer transition:\n1. Human pregnancy zone protein (PZP): As mentioned in the document, PZP forms dimeric/tetrameric species with a molecular weight of 360/720 kDa. The binding of proteinases to PZP leads to a transition to a new conformational state.\n2. Alpha-2 macroglobulin (A2M): While not directly mentioned in the document, A2M is a human protein that also undergoes a dimer-to-tetramer transition. A2M is related to PZP and shares some structural features with it.\nIt is important to note that the document focuses on the conformational changes of PZP and its derivatives, and does not provide information on the dimer-to-tetramer transition of other human proteins. Therefore, this list may not be exhaustive, and other human proteins may also undergo similar conformational changes.",
    "llama-2-7b-chat-hf_fact_raw": "1. Human pregnancy zone protein (PZP) is known to form dimeric/tetrameric species with molecular weights of 360/720 kDa.\n2. Human pregnancy zone protein (PZP) undergoes a dimer-to-tetramer transition upon the binding of proteinases.\n3. Alpha-2 macroglobulin (A2M) is a human protein that undergoes a dimer-to-tetramer transition.\n4. Alpha-2 macroglobulin (A2M) is related to PZP and shares some structural features with it.",
    "llama-2-7b-chat-hf_fact": [
      "Human pregnancy zone protein (PZP) is known to form dimeric/tetrameric species with molecular weights of 360/720 kDa.",
      "Human pregnancy zone protein (PZP) undergoes a dimer-to-tetramer transition upon the binding of proteinases.",
      "Alpha-2 macroglobulin (A2M) is a human protein that undergoes a dimer-to-tetramer transition.",
      "Alpha-2 macroglobulin (A2M) is related to PZP and shares some structural features with it."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Human pregnancy zone protein (PZP) is known to form dimeric/tetrameric species with molecular weights of approximately 330/660 kDa, not 360/720 kDa.\n2. TRUE\n3. FALSE [correction]: Alpha-2 macroglobulin (A2M) is a human protein that is already a tetramer; it does not undergo a dimer-to-tetramer transition.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the protein that has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein is troponin.\nTroponin is a protein that is known to interact with PLN and is also involved in regulating intracellular calcium levels in heart muscle cells. The interaction between troponin and PLN occurs through multiple sites within the cytoplasmic and membrane domains, and it has been shown to play a pivotal role in the regulation of cardiac contractility and relaxation.\nStudies have shown that troponin can bind to PLN in the absence of the membrane domains, and that modifications of the cytoplasmic domain of troponin can activate SERCA2a. Additionally, the removal of troponin inhibition of SERCA2a has been shown to rescue cardiac function and morphology in the mouse dilated cardiomyopathy model.\nTherefore, based on the information provided, troponin is the protein that has been found to interact with PLN and is also an anti-apoptotic protein.",
    "llama-2-7b-chat-hf_fact_raw": "1. Troponin has been found to interact with phospholamban (PLN).\n2. Troponin is involved in regulating intracellular calcium levels in heart muscle cells.\n3. The interaction between troponin and PLN plays a role in the regulation of cardiac contractility and relaxation.\n4. Troponin can bind to PLN in the absence of the membrane domains.\n5. Modifications of the cytoplasmic domain of troponin can activate SERCA2a.",
    "llama-2-7b-chat-hf_fact": [
      "Troponin has been found to interact with phospholamban (PLN).",
      "Troponin is involved in regulating intracellular calcium levels in heart muscle cells.",
      "The interaction between troponin and PLN plays a role in the regulation of cardiac contractility and relaxation.",
      "Troponin can bind to PLN in the absence of the membrane domains.",
      "Modifications of the cytoplasmic domain of troponin can activate SERCA2a."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Troponin does not bind to phospholamban (PLN); it is the interaction between PLN and SERCA (sarcoplasmic/endoplasmic reticulum calcium ATPase) that is relevant for the regulation of cardiac contractility and relaxation. Troponin binds to tropomyosin and is involved in the regulation of muscle contraction by controlling the access of actin to myosin.\n5. FALSE [correction]: Modifications of the cytoplasmic domain of phospholamban (not troponin) can affect SERCA2a activity. Troponin itself is not known to directly activate SERCA2a; it serves a regulatory function in muscle contraction.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, there is no evidence to suggest that vitamin D supplementation has been shown to reduce the incidence of falls in older people in clinical trials. The randomized trial in elderly women living at home who had fallen during the previous year found that regular exercise reduced the incidence of falls resulting in injury, but routine vitamin D supplementation did not. Therefore, it is unlikely that vitamin D supplementation will have a significant effect on reducing falls in older people.",
    "llama-2-7b-chat-hf_fact_raw": "1. In the referenced randomized trial, vitamin D supplementation has not been shown to reduce the incidence of falls in elderly women who had fallen in the previous year.\n2. The same trial found that regular exercise reduced the incidence of falls resulting in injury among elderly women.\n3. The document suggests it is unlikely that vitamin D supplementation will significantly reduce falls in older people.",
    "llama-2-7b-chat-hf_fact": [
      "In the referenced randomized trial, vitamin D supplementation has not been shown to reduce the incidence of falls in elderly women who had fallen in the previous year.",
      "The same trial found that regular exercise reduced the incidence of falls resulting in injury among elderly women.",
      "The document suggests it is unlikely that vitamin D supplementation will significantly reduce falls in older people."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n\nWithout access to the specific randomized trial being referenced or additional information about its findings, it is not possible to verify the accuracy of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is an association between Jarid2 and miR-155 in Th17 cells. The study found that miR-155 inhibition reduced the expression of Jarid2 in Th17 cells, and that this reduction was associated with an increase in the expression of the Notch1 protein. These findings suggest that miR-155 regulates the differentiation and function of Th17 cells by modulating the expression of Jarid2 and Notch1.\nIn particular, the study found that miR-155 inhibition reduced the proportion of Th17 cells in the spleens and mesenteric lymph nodes (MLNs) and decreased the levels of Th17 cell-associated cytokines in colon tissues. This suggests that miR-155 plays a negative regulatory role in the differentiation and function of Th17 cells in the context of inflammatory bowel disease (IBD).\nFurthermore, the study found that Jarid2 was significantly elevated by miR-155 inhibition, and that the expression of Jarid2 was inversely correlated with the expression of Notch1. These findings suggest that Jarid2 is a downstream target of miR-155 and that the regulation of Jarid2 by miR-155 may play a role in the differentiation and function of Th17 cells.\nOverall, the study provides evidence for an association between Jarid2 and miR-155 in Th17 cells, and suggests that miR-155 regulates the differentiation and function of Th17 cells by modulating the expression of Jarid2 and Notch1.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is an association between Jarid2 and miR-155 in Th17 cells.\n2. Inhibition of miR-155 reduced the expression of Jarid2 in Th17 cells.\n3. Reduction in Jarid2 expression due to miR-155 inhibition was associated with an increase in Notch1 protein expression.\n4. Inhibition of miR-155 reduced the proportion of Th17 cells in the spleens and mesenteric lymph nodes.\n5. Inhibition of miR-155 decreased levels of Th17 cell-associated cytokines in colon tissues.",
    "llama-2-7b-chat-hf_fact": [
      "There is an association between Jarid2 and miR-155 in Th17 cells.",
      "Inhibition of miR-155 reduced the expression of Jarid2 in Th17 cells.",
      "Reduction in Jarid2 expression due to miR-155 inhibition was associated with an increase in Notch1 protein expression.",
      "Inhibition of miR-155 reduced the proportion of Th17 cells in the spleens and mesenteric lymph nodes.",
      "Inhibition of miR-155 decreased levels of Th17 cell-associated cytokines in colon tissues."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided are specific to molecular biology and immunology, particularly involving the interaction between Jarid2 and miR-155 in Th17 cells and the subsequent effects on various immunologic outcomes. Without access to the specific research study or expert knowledge in the field, it is not possible to confirm the accuracy of these statements. Further investigation into the relevant scientific literature would be required to verify these claims.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the human hoxD cluster contains 4 clusters or arrays. These are:\n1. Hox cluster: The document mentions that the Hox genes are arranged into four clusters in the human genome, which are thought to have duplicated in the ancestry of the human genome to yield four Hox clusters.\n2. NKL cluster: The document also mentions that the NKL (including NK1, NK3, NK4, Lbx, Tlx, Emx, Vax, Hmx, NK6, Msx) cluster is present in the human genome and is thought to have duplicated in the ancestry of the human genome to yield four NKL clusters.\n3. ParaHox cluster: The document mentions that the ParaHox (Cdx, Xlox, Gsx) cluster is present in the human genome and is thought to have duplicated in the ancestry of the human genome to yield four ParaHox clusters.\n4. EHGbox cluster: The document mentions that the EHGbox (En, HB9, Gbx) cluster is present in the human genome and is thought to have duplicated in the ancestry of the human genome to yield at least two EHGbox clusters.\nTherefore, the human hoxD cluster contains 4 clusters or arrays of genes: Hox, NKL, ParaHox, and EHGbox.",
    "llama-2-7b-chat-hf_fact_raw": "1. The human hoxD cluster contains 4 different clusters or arrays of genes.\n2. The Hox genes are arranged into four clusters in the human genome, which have duplicated in human ancestry.\n3. The NKL cluster is present in the human genome and has duplicated to yield four NKL clusters.\n4. The ParaHox cluster is present in the human genome and has duplicated to yield four ParaHox clusters.\n5. The EHGbox cluster is present in the human genome and has duplicated to yield at least two EHGbox clusters.",
    "llama-2-7b-chat-hf_fact": [
      "The human hoxD cluster contains 4 different clusters or arrays of genes.",
      "The Hox genes are arranged into four clusters in the human genome, which have duplicated in human ancestry.",
      "The NKL cluster is present in the human genome and has duplicated to yield four NKL clusters.",
      "The ParaHox cluster is present in the human genome and has duplicated to yield four ParaHox clusters.",
      "The EHGbox cluster is present in the human genome and has duplicated to yield at least two EHGbox clusters."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The human HOXD cluster is one of the four different clusters of Hox genes, but it is not correct to say the HOXD cluster itself contains four different clusters or arrays of genes. The four clusters in humans are HOXA, HOXB, HOXC, and HOXD.\n2. TRUE\n3. FALSE [correction]: The NK homeobox (NKL) genes are present in the human genome, but they do not form a cluster called the \"NKL cluster,\" and it is not accurate to say they have duplicated to yield four NKL clusters. The NKL genes are spread across various chromosomes and have evolved through duplication events, but they do not form a specific duplicated cluster arrangement like the Hox clusters.\n4. UNKNOWN (While the ParaHox gene cluster does exist and is thought to be an evolutionary cousin to the Hox clusters, the statement specifically about duplication to yield exactly four ParaHox clusters in the human genome isn't a widely established fact and needs more specific information to determine its truthfulness.)\n5. FALSE [correction]: There is no widely recognized cluster in the human genome known as the EHGbox cluster. While homeobox genes, which include many different types of genes with the \"Hox\" motif, are indeed present in the human genome, they are not typically referred to as \"EHGbox,\" making the statement about the existence and duplication of the EHGbox cluster incorrect.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are some of the phosphorylation consensus motifs for Casein Kinase 1 (CK1):\n1. Ser/Thr-Pro-Ser/Thr (SPS/T) motifs: These are the most common phosphorylation sites for CK1, and are often found in the activation loop and the regulatory domain of the enzyme.\n2. Thr-Gly-Tyr (TGT) motifs: These motifs are also commonly found in the activation loop and regulatory domain of CK1, and are important for the enzyme's activity.\n3. Ser-Pro-Ser (SPS) motifs: These motifs are found in the substrate binding site of CK1 and are important for the enzyme's substrate specificity.\n4. Pro-Gly-Pro (PGP) motifs: These motifs are found in the regulatory domain of CK1 and are important for the enzyme's regulation.\n5. Ser-Gly-Ser (SGS) motifs: These motifs are found in the activation loop of CK1 and are important for the enzyme's activity.\nIt is important to note that these consensus motifs are not exclusive to CK1 and may be found in other proteins as well. Additionally, the specific phosphorylation sites and consensus motifs may vary depending on the isoform of CK1 and the cellular context in which it is expressed.",
    "llama-2-7b-chat-hf_fact_raw": "1. The phosphorylation consensus motif Ser/Thr-Pro-Ser/Thr (SPS/T) is common for Casein Kinase 1 (CK1).\n2. The Thr-Gly-Tyr (TGT) motif is found in the activation loop and regulatory domain of Casein Kinase 1 (CK1).\n3. The Ser-Pro-Ser (SPS) motif is present in the substrate binding site of Casein Kinase 1 (CK1).\n4. Casein Kinase 1 (CK1) has the Pro-Gly-Pro (PGP) motif in its regulatory domain.\n5. The Ser-Gly-Ser (SGS) motif is located in the activation loop of Casein Kinase 1 (CK1).",
    "llama-2-7b-chat-hf_fact": [
      "The phosphorylation consensus motif Ser/Thr-Pro-Ser/Thr (SPS/T) is common for Casein Kinase 1 (CK1).",
      "The Thr-Gly-Tyr (TGT) motif is found in the activation loop and regulatory domain of Casein Kinase 1 (CK1).",
      "The Ser-Pro-Ser (SPS) motif is present in the substrate binding site of Casein Kinase 1 (CK1).",
      "Casein Kinase 1 (CK1) has the Pro-Gly-Pro (PGP) motif in its regulatory domain.",
      "The Ser-Gly-Ser (SGS) motif is located in the activation loop of Casein Kinase 1 (CK1)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The phosphorylation consensus motif for Casein Kinase 1 (CK1) is not commonly Ser/Thr-Pro-Ser/Thr (SPS/T). CK1 generally prefers substrates with acidic amino acids at the +1, +3, and sometimes +4 positions relative to the phospho-acceptor site. A common motif is pSer/pThr-X-X-[Acidic residues].\n2. FALSE [correction]: The Thr-Gly-Tyr (TGT) motif is not associated with Casein Kinase 1 (CK1). This motif is instead related to the insulin receptor and many other protein kinases in their activation loop, not CK1.\n3. UNKNOWN: The statement regarding the presence of Ser-Pro-Ser (SPS) motif in the substrate binding site of Casein Kinase 1 (CK1) is very specific, and without access to more detailed biochemical information or scientific literature, the truth of this statement cannot be determined.\n4. FALSE [correction]: The Pro-Gly-Pro (PGP) motif is a common feature associated with the collagen triple helix sequence, not the regulatory domain of Casein Kinase 1 (CK1).\n5. UNKNOWN: The Ser-Gly-Ser (SGS) motif being located in the activation loop of Casein Kinase 1 (CK1) is also specific, and without detailed information about the structure and function of the protein, it is not possible to verify the accuracy of this statement.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are two isoforms of the ASPH (aspartate beta-hydroxylase) gene encoded in humans:\n1. hAspH: The full-length cDNA encodes a protein of 757 amino acids (85 kDa) with a N-terminal difference compared to the bovine AspH (bAspH).\n2. A shorter transcript of 2.6 kb: The shorter transcript encodes a protein of approximately 56 kDa.\nBoth isoforms are produced through transcription of the ASPH gene in human cells, and they are post-translationally modified through cleavage of the catalytic C-terminus in the lumen of the endoplasmic reticulum.",
    "llama-2-7b-chat-hf_fact_raw": "1. The ASPH gene in humans codes for two isoforms of the protein.\n2. hAspH is the full-length isoform encoded by the ASPH gene, consisting of 757 amino acids and approximately 85 kDa in size.\n3. The hAspH protein has a N-terminal difference compared to the bovine AspH (bAspH).\n4. There is a shorter transcript of the ASPH gene of 2.6 kb encoding a protein that is approximately 56 kDa.\n5. Both isoforms of the ASPH protein are post-translationally modified through cleavage of the catalytic C-terminus in the lumen of the endoplasmic reticulum.",
    "llama-2-7b-chat-hf_fact": [
      "The ASPH gene in humans codes for two isoforms of the protein.",
      "hAspH is the full-length isoform encoded by the ASPH gene, consisting of 757 amino acids and approximately 85 kDa in size.",
      "The hAspH protein has a N-terminal difference compared to the bovine AspH (bAspH).",
      "There is a shorter transcript of the ASPH gene of 2.6 kb encoding a protein that is approximately 56 kDa.",
      "Both isoforms of the ASPH protein are post-translationally modified through cleavage of the catalytic C-terminus in the lumen of the endoplasmic reticulum."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The full-length isoform encoded by the ASPH gene is known as human aspartate β-hydroxylase (hASPH) and consists of 758 amino acids and approximately 86 kDa in size, not 757 amino acids and 85 kDa.\n3. UNKNOWN: Without specific information about the differences between the N-termini of human and bovine AspH proteins, it is not possible to determine the accuracy of this statement.\n4. TRUE: A shorter transcript of the ASPH gene can encode a protein of a smaller size, which could correspond to the 56 kDa mentioned.\n5. UNKNOWN: The post-translational modification of ASPH protein isoforms through cleavage, specifically at the catalytic C-terminus and its occurrence in the endoplasmic reticulum, requires more specific information from scientific literature or databases.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, empagliflozin was FDA approved in 2014. According to the document, the study was conducted in 2017, which means that empagliflozin had already been approved by the FDA for at least 3 years before the study began.",
    "llama-2-7b-chat-hf_fact_raw": "1. Empagliflozin was FDA approved in 2014.",
    "llama-2-7b-chat-hf_fact": [
      "Empagliflozin was FDA approved in 2014."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the loss of the protein Lon1 in the plant Arabidopsis has several consequences. Here are some of the key results:\n1. Reduced protein half-life: Lon1 is involved in protein degradation, and its loss leads to a decrease in the half-life of proteins in Arabidopsis. The study found that the protein half-life in lon1 mutants is shorter than in wild-type plants, indicating that Lon1 plays a role in regulating protein turnover.\n2. Rapid degradation of specific protein complexes: The study identified rapidly degrading subunits in a variety of protein complexes in plastids, including those involved in photosynthesis and other metabolic processes. The loss of Lon1 leads to an increase in the degradation rate of these protein complexes.\n3. Changes in protein turnover energy costs: The study calculated the protein turnover energy costs in different leaves of the rosette and identified the key determinants within the proteome. The loss of Lon1 leads to changes in the energy costs of protein turnover, which may impact the overall metabolism of the plant.\n4. Correlation with leaf growth rate: The study found that the degradation rate of proteins in different leaves of the rosette correlates with leaf growth rate. This suggests that Lon1 plays a role in regulating protein turnover in response to changes in growth rate.\nIn summary, the loss of Lon1 in Arabidopsis leads to changes in protein turnover rates, including reduced half-lives, increased degradation of specific protein complexes, and changes in protein turnover energy costs. These changes may impact the overall metabolism and growth of the plant.",
    "llama-2-7b-chat-hf_fact_raw": "1. Lon1 is involved in protein degradation in Arabidopsis plants.\n2. The loss of Lon1 results in a shorter protein half-life in lon1 mutants compared to wild-type plants.\n3. Loss of Lon1 leads to an increase in the degradation rate of protein complexes in plastids, affecting photosynthesis and other metabolic processes.\n4. There is a correlation between the degradation rate of proteins and leaf growth rate in Arabidopsis.\n5. Loss of Lon1 affects the energy costs of protein turnover in the leaves of Arabidopsis plants.",
    "llama-2-7b-chat-hf_fact": [
      "Lon1 is involved in protein degradation in Arabidopsis plants.",
      "The loss of Lon1 results in a shorter protein half-life in lon1 mutants compared to wild-type plants.",
      "Loss of Lon1 leads to an increase in the degradation rate of protein complexes in plastids, affecting photosynthesis and other metabolic processes.",
      "There is a correlation between the degradation rate of proteins and leaf growth rate in Arabidopsis.",
      "Loss of Lon1 affects the energy costs of protein turnover in the leaves of Arabidopsis plants."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Lon1 is indeed involved in protein degradation within plastids of Arabidopsis plants.\n2. FALSE [correction]: The loss of Lon1 would likely result in a longer protein half-life in lon1 mutants compared to wild-type plants since Lon1 is involved in protein degradation; without it, degradation is slower or disrupted.\n3. FALSE [correction]: Loss of Lon1 leads to a decrease in the degradation rate of protein complexes in plastids since Lon1 is involved in the degradation process. This can affect photosynthesis and other metabolic processes due to the accumulation of misfolded or damaged proteins that are not properly degraded.\n4. UNKNOWN: Without specific evidence or studies, we cannot confidently assert there is a correlation between protein degradation rates and leaf growth rate in Arabidopsis.\n5. TRUE: It is reasonable to assume that loss of Lon1 would affect the energy costs of protein turnover in the leaves of Arabidopsis plants, given that protein turnover involves degradation, which Lon1 is a part of. However, this is a general inference and the specifics would depend on empirical data.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is a linker histone in the yeast genome, specifically the histone Hho1. The document states that the expression of Hho1 resulted in a severe growth defect in yeast, despite only subtle changes in chromatin structure. Additionally, the document notes that genome-wide analysis of linker histone occupancy revealed an inverse correlation with histone tail acetylation in both yeast and mouse embryonic stem cells. These findings suggest that histone acetylation negatively regulates linker histone binding in both yeast and other organisms, and provide important insight into how chromatin structure is regulated and maintained to facilitate and repress transcription. Therefore, the answer to the user's question is yes, a linker histone exists in the yeast genome and its interaction with chromatin is regulated by histone acetylation.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is a linker histone in the yeast genome identified as histone Hho1.\n2. The expression of Hho1 in yeast resulted in a severe growth defect.\n3. There were only subtle changes in chromatin structure as a result of Hho1 expression in yeast.\n4. Genome-wide analysis revealed an inverse correlation between linker histone occupancy and histone tail acetylation in yeast.\n5. This inverse correlation between linker histone occupancy and histone tail acetylation is observed in both yeast and mouse embryonic stem cells.",
    "llama-2-7b-chat-hf_fact": [
      "There is a linker histone in the yeast genome identified as histone Hho1.",
      "The expression of Hho1 in yeast resulted in a severe growth defect.",
      "There were only subtle changes in chromatin structure as a result of Hho1 expression in yeast.",
      "Genome-wide analysis revealed an inverse correlation between linker histone occupancy and histone tail acetylation in yeast.",
      "This inverse correlation between linker histone occupancy and histone tail acetylation is observed in both yeast and mouse embryonic stem cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE\n\nAs of my knowledge cutoff date in March 2023, here's the rationale for the responses:\n1. It's true that the yeast Saccharomyces cerevisiae has a linker histone identified as Hho1.\n2. Some studies have shown that overexpression of Hho1 can result in severe growth defects, but the severity can depend on the context, so without specific details, assuming this is based on typical results, the statement can be considered true.\n3. The impact of Hho1 on chromatin structure in yeast is a specific detail that would require knowledge of the results of particular studies. Without a specific reference, the truth of this statement is difficult to confirm, hence UNKNOWN.\n4. The general concept that histone occupancy, particularly with linker histones, can inversely correlate with histone acetylation is a trend observed in chromatin biology studies. If the statement is reflecting findings from a study, then it would be true.\n5. This concept is part of a broader understanding that the principles of chromatin structure and histone modification conservation apply across different eukaryotic models, including yeast and mammalian cells. Thus, this statement is likely to be true based on these biological principles.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, there is no evidence to suggest that tomato juice specifically lowers cholesterol levels. The study you mentioned found that tomato juice consumption resulted in a significant reduction in total cholesterol and LDL-C only in the control group at the end of the study, but no significant differences were observed in the remainder of the assessed parameters along the study. This suggests that tomato juice may have favorable effects on lipid metabolism, but further research is needed to confirm this finding. Additionally, the study did not investigate the effects of tomato juice on cholesterol levels specifically, so it is unclear whether the observed reduction in total cholesterol and LDL-C was due to the tomato juice itself or other factors. Therefore, while there is some evidence to suggest that tomato juice may have beneficial effects on lipid metabolism, there is currently no conclusive evidence to support the claim that tomato juice lowers cholesterol levels.",
    "llama-2-7b-chat-hf_fact_raw": "1. A study found that tomato juice consumption resulted in a significant reduction in total cholesterol and LDL-C in the control group at the end of the study.\n2. The study did not find significant differences in the remainder of the assessed parameters regarding lipid metabolism.\n3. The study did not specifically investigate the effects of tomato juice on cholesterol levels.\n4. The reduction in total cholesterol and LDL-C observed in the study could be due to factors other than tomato juice consumption.\n5. There is currently no conclusive evidence that tomato juice lowers cholesterol levels.",
    "llama-2-7b-chat-hf_fact": [
      "A study found that tomato juice consumption resulted in a significant reduction in total cholesterol and LDL-C in the control group at the end of the study.",
      "The study did not find significant differences in the remainder of the assessed parameters regarding lipid metabolism.",
      "The study did not specifically investigate the effects of tomato juice on cholesterol levels.",
      "The reduction in total cholesterol and LDL-C observed in the study could be due to factors other than tomato juice consumption.",
      "There is currently no conclusive evidence that tomato juice lowers cholesterol levels."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The statement that tomato juice consumption resulted in a significant reduction in total cholesterol and LDL-C in the control group at the end of the study directly implies that the study investigated the effects of tomato juice on cholesterol levels.\n4. UNKNOWN (without further context or details about the study, it is not possible to accurately assess whether the observed reductions could be attributed to other factors)\n5. UNKNOWN (without access to the broader scientific literature and consensus on the topic, it's impossible to determine the truthfulness of this statement)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, Hsp70 and Hsp110 can affect mRNA stability by recognizing and stabilizing ARE-containing mRNAs. Hsp70, in particular, was shown to bind and stabilize ARE-containing mRNAs through its ATP- and peptide-binding domains, and this process was found to be independent of its protein chaperone function. The study found that suppressing Hsp70 in HeLa cells destabilized an ARE reporter mRNA, indicating a novel ARE-directed mRNA-stabilizing role for this protein. Additionally, Hsp70 was shown to bind and stabilize endogenous ARE-containing mRNAs encoding VEGF and Cox-2, and this process was found to involve an ARE-like sequence in the proximal 3'UTR. Finally, the study found that the stabilization of VEGF mRNA coincided with the accumulation of Hsp70 protein in HL60 promyelocytic leukemia cells recovering from acute thermal stress.\nOverall, the study suggests that Hsp70 and Hsp110 can play a role in regulating mRNA stability by recognizing and stabilizing ARE-containing mRNAs, which may contribute to the cytoprotective effects of Hsp70 following cellular stress. However, the study also suggests that constitutively elevated Hsp70 expression may contribute to the development of aggressive neoplastic phenotypes, highlighting the complex and context-dependent nature of Hsp70's role in mRNA stability.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hsp70 and Hsp110 can stabilize ARE-containing mRNAs.\n2. Hsp70 binds and stabilizes ARE-containing mRNAs independently of its protein chaperone function.\n3. Suppression of Hsp70 in HeLa cells leads to destabilization of an ARE reporter mRNA.\n4. Hsp70 binds and stabilizes endogenous ARE-containing mRNAs encoding VEGF and Cox-2.\n5. VEGF mRNA stabilization occurs alongside the accumulation of Hsp70 protein in HL60 cells after acute thermal stress.",
    "llama-2-7b-chat-hf_fact": [
      "Hsp70 and Hsp110 can stabilize ARE-containing mRNAs.",
      "Hsp70 binds and stabilizes ARE-containing mRNAs independently of its protein chaperone function.",
      "Suppression of Hsp70 in HeLa cells leads to destabilization of an ARE reporter mRNA.",
      "Hsp70 binds and stabilizes endogenous ARE-containing mRNAs encoding VEGF and Cox-2.",
      "VEGF mRNA stabilization occurs alongside the accumulation of Hsp70 protein in HL60 cells after acute thermal stress."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Heat shock proteins (Hsps), such as Hsp70 and Hsp110, have been shown in some studies to interact with and stabilize AU-rich element (ARE)-containing mRNAs, which are known for controlling the stability of many regulatory proteins.\n\n2. TRUE: Hsp70 is known to bind specifically to ARE-containing mRNAs and this interaction is suggested to be independent of its protein chaperone activities, signifying a direct role in mRNA stabilization.\n\n3. TRUE: Knockdown or suppression of Hsp70 has been shown in studies to lead to the destabilization of ARE-containing mRNAs, using ARE reporter systems in cell lines such as HeLa cells.\n\n4. TRUE: There is evidence indicating that Hsp70 can bind to and stabilize endogenous ARE-containing mRNAs, with VEGF and Cox-2 frequently cited as examples in the literature.\n\n5. TRUE: Several studies have reported that mRNA stabilization for VEGF and other stress-induced genes can occur concurrently with the accumulation of Hsp70 protein in cells like HL60 after thermal stress or other types of stress.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following deiodinases are present in skeletal muscle:\n1. Type 2 deiodinase (D2) - The document mentions that D2 is present in skeletal muscle and that it has a low K(m) for T4 and rT3, indicating that it is an efficient deiodinase for removing iodine from T4 and rT3.\nTherefore, the answer to the user's question is:\nType 2 deiodinase (D2) is present in skeletal muscle.",
    "llama-2-7b-chat-hf_fact_raw": "1. Type 2 deiodinase (D2) is present in skeletal muscle.\n2. Type 2 deiodinase (D2) has a low K(m) for T4 and rT3.",
    "llama-2-7b-chat-hf_fact": [
      "Type 2 deiodinase (D2) is present in skeletal muscle.",
      "Type 2 deiodinase (D2) has a low K(m) for T4 and rT3."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Type 2 deiodinase (D2) has a high affinity for T4, typically indicated by a low K(m), but it preferentially deiodinates T4 rather than rT3 (reverse T3). It is the Type 3 deiodinase (D3) that has a low K(m) for rT3 and deiodinates it.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are some of the inflammatory caspase proteins:\n1. Caspase-1 (also known as C1 or EC 3.4.21.16)\n2. Caspase-12 (also known as C12 or EC 3.4.21.17)\nThese two proteins are essential effectors of inflammation and cell death in the gut, and play a critical role in the regulation of intestinal homeostasis, inflammation, and tumorigenesis. Caspase-1 is involved in the activation of interleukin-18 (IL-18), which is a potent stimulator of inflammation, while caspase-12 is involved in the derepression of the inflammasome, a protein complex that plays a key role in the activation of pro-inflammatory cytokines.\nThe document suggests that both caspase-1 and caspase-12 are important in the induction of inflammation in the gut after injury, which is necessary for tissue repair and maintenance of immune tolerance. However, the document also suggests that an imbalance in the expression of these proteins can lead to increased susceptibility to colorectal cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. Caspase-1 is also known as EC 3.4.21.16.\n2. Caspase-12 is also known as EC 3.4.21.17.\n3. Caspase-1 is involved in the activation of interleukin-18 (IL-18), which stimulates inflammation.\n4. Caspase-12 is involved in the derepression of the inflammasome.\n5. An imbalance in the expression of caspase-1 and caspase-12 can lead to increased susceptibility to colorectal cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Caspase-1 is also known as EC 3.4.21.16.",
      "Caspase-12 is also known as EC 3.4.21.17.",
      "Caspase-1 is involved in the activation of interleukin-18 (IL-18), which stimulates inflammation.",
      "Caspase-12 is involved in the derepression of the inflammasome.",
      "An imbalance in the expression of caspase-1 and caspase-12 can lead to increased susceptibility to colorectal cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Caspase-12 is also known as EC 3.4.22.61.\n3. TRUE\n4. FALSE [correction]: Caspase-12 actually functions to downregulate inflammation by inhibiting the inflammasome, not derepressing it.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, there is a potential link between the Aurora B kinase and the polycomb protein Ring1B.\nAurora B kinase is a key protein that regulates many events during cell mitosis, including chromosome segregation and cytokinesis. The document reports the discovery of a novel splicing variant of Aurora C, named Aurora C-SV, which encodes a 290-amino-acid protein that is expressed at high levels in human testis. The in vitro kinase assay shows that Aurora C-SV phosphorylates MBP, and its T179A mutant loses the kinase activity. During cell mitosis, Aurora C-SV-EGFP associates with chromosomes in prophase and metaphase, and then transfers to the central spindle midzone and the cortex where the contract ring forms during the transition from anaphase to telophase. It remains in the midbody during cytokinesis.\nRing1B is a polycomb protein that is involved in the regulation of chromatin modification and gene expression during cell differentiation and development. It has been shown to play a role in the maintenance of pluripotency in embryonic stem cells and the regulation of cell fate decisions in various tissues.\nGiven the role of Aurora C-SV in chromosome segregation and cytokinesis, it is possible that Ring1B may interact with Aurora C-SV to regulate these processes. For example, Ring1B may modulate the activity of Aurora C-SV during cell division, or the two proteins may work together to ensure proper chromosome segregation and cytokinesis. However, further research is needed to confirm this hypothesis.\nIn summary, while there is no direct evidence linking Aurora B kinase and Ring1B, the discovery of Aurora C-SV and its role in cell mitosis suggests that there may be a connection between these two proteins that warrants further investigation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Aurora B kinase regulates chromosome segregation and cytokinesis during cell mitosis.\n2. A novel splicing variant of Aurora C, named Aurora C-SV, encodes a 290-amino-acid protein that is expressed at high levels in human testis.\n3. An in vitro kinase assay indicated that Aurora C-SV phosphorylates MBP and that its T179A mutant loses kinase activity.\n4. During cell mitosis, Aurora C-SV-EGFP associates with chromosomes in prophase and metaphase, and then moves to the central spindle midzone and the cortex during the transition from anaphase to telophase.\n5. Ring1B, a polycomb protein, is involved in chromatin modification and gene expression regulation during cell differentiation and development.",
    "llama-2-7b-chat-hf_fact": [
      "Aurora B kinase regulates chromosome segregation and cytokinesis during cell mitosis.",
      "A novel splicing variant of Aurora C, named Aurora C-SV, encodes a 290-amino-acid protein that is expressed at high levels in human testis.",
      "An in vitro kinase assay indicated that Aurora C-SV phosphorylates MBP and that its T179A mutant loses kinase activity.",
      "During cell mitosis, Aurora C-SV-EGFP associates with chromosomes in prophase and metaphase, and then moves to the central spindle midzone and the cortex during the transition from anaphase to telophase.",
      "Ring1B, a polycomb protein, is involved in chromatin modification and gene expression regulation during cell differentiation and development."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - Aurora B kinase is indeed involved in the regulation of chromosome segregation and cytokinesis during cell mitosis.\n2. TRUE - The statement appears to be specific and suggests that it is based on research findings that show the existence of a splicing variant named Aurora C-SV, which is consistent with scientific discoveries around splicing variants in genes.\n3. TRUE - This statement asserts specific biochemical properties of Aurora C-SV and its mutant, which are typical details reported in scientific literature following experimental evidence.\n4. UNKNOWN - The statement presents detailed localization of a protein fusion (Aurora C-SV-EGFP) during cell mitosis, which is plausible, but without additional context or source information, the truth of this claim cannot be validated.\n5. TRUE - Ring1B is part of the polycomb group of proteins and is indeed involved in chromatin modification and gene expression regulation, which are crucial processes during cell differentiation and development.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates are:\nDonor splice sites:\n1. Pairs with a site shift of four nucleotides: These are the most abundant type of non-canonical donor splice sites and introduce a frameshift in the protein-coding region. Despite this, they are often conserved in other mammalian genomes.\n2. Overlapping alternative donor sites: These sites may have different functional roles, such as yielding major differences in the protein sequence and structure or generating nonsense-mediated decay-inducing mRNA isoforms involved in regulated unproductive splicing pathways.\nAcceptor splice sites:\n1. Pairs with a site shift of four nucleotides: Similar to donor splice sites, these pairs are the most abundant type of non-canonical acceptor splice sites and introduce a frameshift in the protein-coding region.\n2. Overlapping alternative acceptor sites: Like donor splice sites, these sites may have different functional roles, such as yielding major differences in the protein sequence and structure or generating nonsense-mediated decay-inducing mRNA isoforms involved in regulated unproductive splicing pathways.\nIt is important to note that the conservation of these non-canonical splice sites can vary depending on their location and the consensus requirements. Additionally, the functional roles of these sites may differ depending on the specific context in which they are found.",
    "llama-2-7b-chat-hf_fact_raw": "1. Non-canonical donor splice sites with a site shift of four nucleotides are the most abundant type and can result in a frameshift.\n2. Non-canonical donor splice sites can be conserved across mammalian genomes.\n3. Overlapping alternative donor splice sites can generate major differences in protein sequence and structure.\n4. Overlapping alternative acceptor splice sites may play a role in generating mRNA isoforms that induce nonsense-mediated decay.\n5. Non-canonical acceptor splice sites with a site shift of four nucleotides are also abundant and can result in frameshift mutations.",
    "llama-2-7b-chat-hf_fact": [
      "Non-canonical donor splice sites with a site shift of four nucleotides are the most abundant type and can result in a frameshift.",
      "Non-canonical donor splice sites can be conserved across mammalian genomes.",
      "Overlapping alternative donor splice sites can generate major differences in protein sequence and structure.",
      "Overlapping alternative acceptor splice sites may play a role in generating mRNA isoforms that induce nonsense-mediated decay.",
      "Non-canonical acceptor splice sites with a site shift of four nucleotides are also abundant and can result in frameshift mutations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe first and fifth statements are highly specific and would require access to current and detailed scientific research or data for verification. Without this context, it's not possible to confidently evaluate their veracity. The second, third, and fourth statements are generally true according to current knowledge in molecular biology regarding non-canonical splice sites, alternative splicing, and its implications in protein structure and function, as well as mRNA isoform generation and nonsense-mediated decay.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the event that results in the acetylation of S6K1 is growth factor stimulation. The document states that acetylation of endogenous S6K1 at lysine 516 is potently induced upon growth factor stimulation, and that this event appears to be functionally independent of phosphorylation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Acetylation of S6K1 occurs upon growth factor stimulation.\n2. Acetylation of endogenous S6K1 at lysine 516 is induced by growth factor stimulation.\n3. The acetylation of S6K1 is functionally independent of phosphorylation.",
    "llama-2-7b-chat-hf_fact": [
      "Acetylation of S6K1 occurs upon growth factor stimulation.",
      "Acetylation of endogenous S6K1 at lysine 516 is induced by growth factor stimulation.",
      "The acetylation of S6K1 is functionally independent of phosphorylation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The acetylation of S6K1 can be functionally linked with its phosphorylation; in many signaling pathways, phosphorylation and acetylation are interconnected post-translational modifications that can regulate enzyme activity, localization, and protein-protein interactions.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the cause of episodic ataxia type 6 is likely to be related to mutations in the calcium channel (CACNA1A) gene, similar to episodic ataxia type 2 (EA2). The article mentions that EA2 is caused by CACNA1A mutations and typically begins before the age of 20 years. However, the molecular basis of late-onset EA2 is unclear, and the authors describe a case of late-onset EA2 associated with a multiple-base pair insertion in CACNA1A. This suggests that genetically induced reduction in calcium channel function may associate with cases of late-onset EA2. Therefore, it is likely that the cause of episodic ataxia type 6 is also related to mutations in the CACNA1A gene, although more research is needed to confirm this.",
    "llama-2-7b-chat-hf_fact_raw": "1. Episodic ataxia type 6 is likely related to mutations in the calcium channel (CACNA1A) gene.\n2. Episodic ataxia type 2 (EA2) is caused by mutations in the CACNA1A gene.\n3. Episodic ataxia type 2 typically begins before the age of 20 years.\n4. A case of late-onset episodic ataxia type 2 was associated with a multiple-base pair insertion in the CACNA1A gene.\n5. Reduction in calcium channel function due to genetic mutations may be associated with late-onset episodic ataxia type 2.",
    "llama-2-7b-chat-hf_fact": [
      "Episodic ataxia type 6 is likely related to mutations in the calcium channel (CACNA1A) gene.",
      "Episodic ataxia type 2 (EA2) is caused by mutations in the CACNA1A gene.",
      "Episodic ataxia type 2 typically begins before the age of 20 years.",
      "A case of late-onset episodic ataxia type 2 was associated with a multiple-base pair insertion in the CACNA1A gene.",
      "Reduction in calcium channel function due to genetic mutations may be associated with late-onset episodic ataxia type 2."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Episodic ataxia type 6 is related to mutations in the SLC1A3 gene, not the calcium channel (CACNA1A) gene.\n2. TRUE\n3. TRUE\n4. UNKNOWN: Without specific research references or more context, it is difficult to confirm or deny an association of a multiple-base pair insertion in the CACNA1A gene specifically with late-onset episodic ataxia type 2.\n5. TRUE: Reduction in calcium channel function due to genetic mutations, such as those found in the CACNA1A gene, can be associated with episodic ataxia type 2, including cases with a late onset.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, chromomethylases are not present in animal genomes. The document specifically focuses on the genome of the fruit fly Bactrocera dorsalis and its chitin metabolism, and does not mention the presence of chromomethylases. The term \"chromomethylase\" is not used anywhere in the document, and the enzymes discussed are all related to chitin metabolism, such as chitinases and chitin deacetylases. Therefore, it can be concluded that chromomethylases are not present in the genome of Bactrocera dorsalis or any other animal species.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromomethylases are not present in animal genomes.\n2. The genome of the fruit fly Bactrocera dorsalis was analyzed for the presence of chromomethylases.\n3. Chromomethylases were not mentioned in the document that focuses on Bactrocera dorsalis genome.\n4. Enzymes related to chitin metabolism, such as chitinases and chitin deacetylases, are discussed in the document.\n5. The document concludes that chromomethylases are not present in the genome of Bactrocera dorsalis or any other animal species.",
    "llama-2-7b-chat-hf_fact": [
      "Chromomethylases are not present in animal genomes.",
      "The genome of the fruit fly Bactrocera dorsalis was analyzed for the presence of chromomethylases.",
      "Chromomethylases were not mentioned in the document that focuses on Bactrocera dorsalis genome.",
      "Enzymes related to chitin metabolism, such as chitinases and chitin deacetylases, are discussed in the document.",
      "The document concludes that chromomethylases are not present in the genome of Bactrocera dorsalis or any other animal species."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: While chromomethylases are not present in animal genomes, the document does not make a definitive conclusion about their presence in all animal species; it specifically refers to the genome of Bactrocera dorsalis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-2-7b-chat-hf_response": "Based on the information provided, here are some packages available in R/Bioconductor for transcription factor binding site (TFBS) analysis:\n1. TFBSTools: This package provides a toolkit for handling TFBS profile matrices, scanning sequences and alignments including whole genomes, and querying the JASPAR database. It also offers easy extension to include advanced statistical analysis, data visualization, and data integration.\n2. JASPAR: This package provides a comprehensive collection of TFBS matrices from the JASPAR database, which can be used for the analysis of TFBSs.\n3. TRANSFAC: This package provides a comprehensive collection of TFBS matrices from the TRANSFAC database, which can be used for the analysis of TFBSs.\n4. ChEA: This package provides a tool for the prediction of TFBSs in DNA sequences using a combination of sequence motifs and chromatin environment features.\n5. TFSEARCH: This package provides a tool for the prediction of TFBSs in DNA sequences using a combination of sequence motifs and structural bioinformatics methods.\n6. GTF2TFBS: This package provides a tool for the conversion of GTF (Genome-wide TFBS) files to TFBS matrices, which can be used for the analysis of TFBSs.\n7. TFBS-Rank: This package provides a tool for the ranking of TFBSs based on their predicted binding affinity, which can be used for the prioritization of TFBSs for further analysis.\n8. TFBS-Cluster: This package provides a tool for the clustering of TFBSs based on their predicted binding affinity, which can be used for the identification of functional TFBS clusters.\nThese packages can be installed and used in R/Bioconductor environment for the analysis of TFBSs.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFBSTools is a package in R/Bioconductor that provides a toolkit for handling TFBS profile matrices and scanning sequences.\n2. The JASPAR package in R/Bioconductor includes a collection of TFBS matrices from the JASPAR database.\n3. The TRANSFAC package in R/Bioconductor includes a collection of TFBS matrices from the TRANSFAC database.\n4. ChEA is a package in R/Bioconductor designed for the prediction of transcription factor binding sites.\n5. TFSEARCH is a package in R/Bioconductor that offers predictions of TFBS in DNA sequences using sequence motifs and structural bioinformatics methods.",
    "llama-2-7b-chat-hf_fact": [
      "TFBSTools is a package in R/Bioconductor that provides a toolkit for handling TFBS profile matrices and scanning sequences.",
      "The JASPAR package in R/Bioconductor includes a collection of TFBS matrices from the JASPAR database.",
      "The TRANSFAC package in R/Bioconductor includes a collection of TFBS matrices from the TRANSFAC database.",
      "ChEA is a package in R/Bioconductor designed for the prediction of transcription factor binding sites.",
      "TFSEARCH is a package in R/Bioconductor that offers predictions of TFBS in DNA sequences using sequence motifs and structural bioinformatics methods."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: TRANSFAC is not a package in R/Bioconductor, but it is a privately maintained database of transcription factor binding sites. The package that provides an interface to TRANSFAC data in R/Bioconductor is typically referred to as `rtransfac`.\n4. FALSE [correction]: ChEA is not a package in R/Bioconductor; it is a transcription factor enrichment analysis tool available through other platforms like the Harmonizome or Enrichr.\n5. FALSE [correction]: TFSEARCH is not known as a package in R/Bioconductor. It is an online tool that provides predictions of transcription factor binding sites using a TRANSFAC database of sequence motifs. There is no Bioconductor package directly associated with it by that name.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "llama-2-7b-chat-hf_response": "Based on the information provided, here are some clinical trials for the prevention of sarcopenia:\n1. The Sarcopenia Prevention and Exercise Trial (SPaRET) - This trial, conducted in the UK, aimed to assess the effectiveness of a 12-month exercise program in preventing sarcopenia in older adults. The program included both resistance training and aerobic exercise.\n2. The European Project on Sarcopenia Research (EPSR) - This project, conducted across several European countries, investigated the effectiveness of different exercise interventions in preventing sarcopenia in older adults. The interventions included both resistance training and aerobic exercise, as well as nutritional interventions.\n3. The Sarcopenia Prevention and Treatment Trial (SPaRT) - This trial, conducted in the US, evaluated the effectiveness of a 12-month exercise program in preventing sarcopenia in older adults with mild cognitive impairment. The program included both resistance training and aerobic exercise.\n4. The Australian Sarcopenia Management and Exercise (ASME) Trial - This trial, conducted in Australia, investigated the effectiveness of a 12-month exercise program in preventing sarcopenia in older adults. The program included both resistance training and aerobic exercise, as well as nutritional interventions.\n5. The Sarcopenia Prevention and Intervention Trial (SPaIT) - This trial, conducted in Canada, evaluated the effectiveness of a 12-month exercise program in preventing sarcopenia in older adults with chronic obstructive pulmonary disease (COPD). The program included both resistance training and aerobic exercise.\nThese are just a few examples of clinical trials for the prevention of sarcopenia. It is important to note that the results of these trials may vary depending on the specific population being studied, the type of intervention being tested, and other factors. It is also important to consult with a healthcare professional before starting any exercise program or making significant changes to your diet or lifestyle.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Sarcopenia Prevention and Exercise Trial (SPaRET) was a trial conducted in the UK assessing a 12-month exercise program's effectiveness in preventing sarcopenia in older adults.\n2. The European Project on Sarcopenia Research (EPSR) investigated exercise and nutritional interventions for sarcopenia prevention across several European countries.\n3. The Sarcopenia Prevention and Treatment Trial (SPaRT) in the US evaluated a 12-month exercise program for preventing sarcopenia in older adults with mild cognitive impairment.\n4. The Australian Sarcopenia Management and Exercise (ASME) Trial examined a 12-month exercise program including resistance training, aerobic exercise, and nutritional interventions in Australia.\n5. The Sarcopenia Prevention and Intervention Trial (SPaIT) in Canada evaluated the prevention of sarcopenia with a 12-month exercise program in older adults with chronic obstructive pulmonary disease (COPD).",
    "llama-2-7b-chat-hf_fact": [
      "The Sarcopenia Prevention and Exercise Trial (SPaRET) was a trial conducted in the UK assessing a 12-month exercise program's effectiveness in preventing sarcopenia in older adults.",
      "The European Project on Sarcopenia Research (EPSR) investigated exercise and nutritional interventions for sarcopenia prevention across several European countries.",
      "The Sarcopenia Prevention and Treatment Trial (SPaRT) in the US evaluated a 12-month exercise program for preventing sarcopenia in older adults with mild cognitive impairment.",
      "The Australian Sarcopenia Management and Exercise (ASME) Trial examined a 12-month exercise program including resistance training, aerobic exercise, and nutritional interventions in Australia.",
      "The Sarcopenia Prevention and Intervention Trial (SPaIT) in Canada evaluated the prevention of sarcopenia with a 12-month exercise program in older adults with chronic obstructive pulmonary disease (COPD)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific information about the trials mentioned (which are not well-known or commonly referenced studies that could be verified with general knowledge), it's not possible to accurately classify the statements as true or false. These statements would require further research or context to verify their accuracy.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the database of molecular recognition features in membrane proteins is called \"mpMoRFsDB\". It is a publicly available database that stores information on all membrane proteins that contain MoRFs, including their secondary structure, position in the protein topology, and interactions with partners. The database is hosted on a MySQL database with a user-friendly web interface and includes a Jmol applet for visualization of the structures. The aim of the database is to provide valuable information related to disorder-based protein-protein interactions in membrane proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. mpMoRFsDB is a database of molecular recognition features in membrane proteins.\n2. The database includes information such as secondary structure, position in protein topology, and interactions with partners.\n3. mpMoRFsDB is hosted on a MySQL database.\n4. The database has a user-friendly web interface.\n5. mpMoRFsDB includes a Jmol applet for visualization of structures.",
    "llama-2-7b-chat-hf_fact": [
      "mpMoRFsDB is a database of molecular recognition features in membrane proteins.",
      "The database includes information such as secondary structure, position in protein topology, and interactions with partners.",
      "mpMoRFsDB is hosted on a MySQL database.",
      "The database has a user-friendly web interface.",
      "mpMoRFsDB includes a Jmol applet for visualization of structures."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific details about the mpMoRFsDB database's technical implementations or features, the truth of statements 3, 4, and 5 cannot be ascertained without additional information.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, rivaroxaban is metabolized in the kidneys. The study states that rivaroxaban is metabolized by the cytochrome P450 (CYP) 3A4/5, 2J2 pathways and excreted via kidneys. This suggests that the kidneys play a role in the metabolism of rivaroxaban, and that the drug's pharmacokinetics may be affected by renal function. The study also notes that hepatic clearance and drug-drug interactions (DDI) are important factors affecting rivaroxaban pharmacokinetics, but does not provide information on the role of the liver in rivaroxaban metabolism. Therefore, based on the information provided, it can be concluded that rivaroxaban is metabolized in the kidneys, but the liver may also play a role in its metabolism.",
    "llama-2-7b-chat-hf_fact_raw": "1. Rivaroxaban is metabolized by the cytochrome P450 (CYP) 3A4/5 and 2J2 pathways.\n2. Rivaroxaban is excreted via the kidneys.\n3. Renal function may affect the pharmacokinetics of rivaroxaban.\n4. Hepatic clearance is a factor affecting rivaroxaban pharmacokinetics.\n5. Drug-drug interactions are important in the pharmacokinetics of rivaroxaban.",
    "llama-2-7b-chat-hf_fact": [
      "Rivaroxaban is metabolized by the cytochrome P450 (CYP) 3A4/5 and 2J2 pathways.",
      "Rivaroxaban is excreted via the kidneys.",
      "Renal function may affect the pharmacokinetics of rivaroxaban.",
      "Hepatic clearance is a factor affecting rivaroxaban pharmacokinetics.",
      "Drug-drug interactions are important in the pharmacokinetics of rivaroxaban."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the genes that are regulated by TRalpha2 in the heart are:\n1. TRalpha1: Decreased expression in the right atrium (RA) and left ventricular wall (LVW) by about 50% with both amiodarone (AM) and dronedarone (Dron).\n2. TRbeta1: Decreased expression in the LVW by about 50% with both AM and Dron.\n3. TRalpha2: Increased expression in the apex by about 50% with AM.\nIt is worth noting that the changes in gene expression observed in this study are reminiscent of foetal reprogramming, which suggests that the effects of AM and Dron on TR- and T3-dependent gene expression in the left ventricle may be more profound than their effects on TR isoforms in other parts of the heart.",
    "llama-2-7b-chat-hf_fact_raw": "1. TRalpha1 expression is decreased by about 50% in the right atrium (RA) and left ventricular wall (LVW) with the use of amiodarone (AM) and dronedarone (Dron).\n2. TRbeta1 expression is decreased by about 50% in the left ventricular wall (LVW) with the use of amiodarone (AM) and dronedarone (Dron).\n3. TRalpha2 expression is increased by about 50% in the apex with the use of amiodarone (AM).\n4. The observed changes in gene expression are indicative of foetal reprogramming.\n5. The effects of amiodarone (AM) and dronedarone (Dron) on TR- and T3-dependent gene expression in the left ventricle may be different from their effects on TR isoforms in other parts of the heart.",
    "llama-2-7b-chat-hf_fact": [
      "TRalpha1 expression is decreased by about 50% in the right atrium (RA) and left ventricular wall (LVW) with the use of amiodarone (AM) and dronedarone (Dron).",
      "TRbeta1 expression is decreased by about 50% in the left ventricular wall (LVW) with the use of amiodarone (AM) and dronedarone (Dron).",
      "TRalpha2 expression is increased by about 50% in the apex with the use of amiodarone (AM).",
      "The observed changes in gene expression are indicative of foetal reprogramming.",
      "The effects of amiodarone (AM) and dronedarone (Dron) on TR- and T3-dependent gene expression in the left ventricle may be different from their effects on TR isoforms in other parts of the heart."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nThe statements about TRalpha1, TRbeta1, and TRalpha2 expressions are very specific and would require access to a scientific study or data to confirm their accuracy. Without the specific context in which these statements are made, it's not possible to validate them.\n\nThe fourth statement is also specific and requires detailed background knowledge or access to the particular research findings about gene expression and fetal reprogramming in relation to amiodarone (AM) and dronedarone (Dron).\n\nThe fifth statement is generally true because the effects of drugs on gene expression can vary in different tissues, hence the effects on the left ventricle could indeed be different from those on other parts of the heart. However, this statement, while true in a broad sense, may not accurately reflect the findings of the particular context or study referenced.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "llama-2-7b-chat-hf_response": "Based on the information provided, here are some available biomedical question answering systems:\n1. PubMedQA: PubMedQA is a biomedical question answering system that uses natural language processing (NLP) techniques to extract answers from the PubMed database of biomedical literature. It has been shown to be effective in answering a wide range of biomedical questions, including those related to disease mechanisms, drug interactions, and clinical trials.\n2. BioASQ: BioASQ is a large-scale biomedical question answering system that has been developed to answer questions from various biomedical domains, including gene expression, protein-protein interactions, and drug discovery. It uses a combination of NLP and machine learning techniques to identify relevant answers from a large corpus of biomedical literature.\n3. Biomedical Information Retrieval and Question Answering System (BIRQA): BIRQA is a biomedical question answering system that uses a combination of NLP and machine learning techniques to retrieve and rank relevant answers from a large corpus of biomedical literature. It has been shown to be effective in answering a wide range of biomedical questions, including those related to disease diagnosis, treatment, and prevention.\n4. Medical Information Retrieval and Question Answering System (MIRQA): MIRQA is a biomedical question answering system that uses a combination of NLP and machine learning techniques to retrieve and rank relevant answers from a large corpus of biomedical literature. It has been shown to be effective in answering a wide range of biomedical questions, including those related to disease mechanisms, drug interactions, and clinical trials.\n5. Biomedical Question Answering System using Deep Learning (BQA-DL): BQA-DL is a biomedical question answering system that uses deep learning techniques to analyze biomedical texts and identify relevant answers. It has been shown to be effective in answering a wide range of biomedical questions, including those related to disease diagnosis, treatment, and prevention.\nThese are just a few examples of the many biomedical question answering systems that are available. Each system has its own strengths and limitations, and the choice of which system to use will depend on the specific needs and goals of the user.",
    "llama-2-7b-chat-hf_fact_raw": "1. PubMedQA is a biomedical question answering system that is designed to extract answers from the PubMed database using NLP techniques.\n2. BioASQ is a biomedical question answering system that answers questions across various domains such as gene expression and drug discovery through NLP and machine learning.\n3. Biomedical Information Retrieval and Question Answering System (BIRQA) uses NLP and machine learning techniques to answer biomedical questions.\n4. Medical Information Retrieval and Question Answering System (MIRQA) uses NLP and machine learning to retrieve and rank relevant answers from biomedical literature.\n5. Biomedical Question Answering System using Deep Learning (BQA-DL) applies deep learning techniques to analyze biomedical texts for answering questions.",
    "llama-2-7b-chat-hf_fact": [
      "PubMedQA is a biomedical question answering system that is designed to extract answers from the PubMed database using NLP techniques.",
      "BioASQ is a biomedical question answering system that answers questions across various domains such as gene expression and drug discovery through NLP and machine learning.",
      "Biomedical Information Retrieval and Question Answering System (BIRQA) uses NLP and machine learning techniques to answer biomedical questions.",
      "Medical Information Retrieval and Question Answering System (MIRQA) uses NLP and machine learning to retrieve and rank relevant answers from biomedical literature.",
      "Biomedical Question Answering System using Deep Learning (BQA-DL) applies deep learning techniques to analyze biomedical texts for answering questions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: PubMedQA is a dataset, not a question answering system. It is designed for developing biomedical question answering systems using the PubMed abstracts.\n2. TRUE\n3. UNKNOWN: There is no widely recognized system or project by the name \"Biomedical Information Retrieval and Question Answering System (BIRQA),\" so its existence and use of NLP and machine learning techniques cannot be confirmed without additional context.\n4. UNKNOWN: Similarly, there is no widespread recognition of a \"Medical Information Retrieval and Question Answering System (MIRQA).\" Without further information, it is not possible to confirm the existence or describe the use of NLP and machine learning in such a system.\n5. UNKNOWN: Without specific details regarding a system named \"Biomedical Question Answering System using Deep Learning (BQA-DL),\" it is not possible to confirm its use of deep learning techniques. However, it should be noted that deep learning techniques are commonly applied in biomedical text analysis for question answering.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the trancription factor that activates the betalain pathway is beta-arrestin. The document states that the biased agonist (D-Trp(12),Tyr(34))-PTH(7-34) (PTH-betaarr) selectively activates the beta-arrestin pathway, but not the classic G protein signaling pathway, in mice. This suggests that beta-arrestin plays a role in activating the betalain pathway.",
    "llama-2-7b-chat-hf_fact_raw": "1. The transcription factor beta-arrestin activates the betalain pathway.\n2. The biased agonist (D-Trp(12),Tyr(34))-PTH(7-34) selectively activates the beta-arrestin pathway, not the classic G protein signaling pathway, in mice.",
    "llama-2-7b-chat-hf_fact": [
      "The transcription factor beta-arrestin activates the betalain pathway.",
      "The biased agonist (D-Trp(12),Tyr(34))-PTH(7-34) selectively activates the beta-arrestin pathway, not the classic G protein signaling pathway, in mice."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Beta-arrestin is not a transcription factor; it is a regulatory protein involved in G protein-coupled receptor (GPCR) signaling. The betalain biosynthetic pathway is instead regulated by specific transcription factors, not beta-arrestin.\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true"
    ]
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the preferred technologies for enrichment of phosphorylated peptides for global quantitative phosphoproteomic analyses are:\n1. TiO(2) phosphopeptide pre-enrichment step: This step provides high specificity and reduces sample preparation workload due to the adsorption of phosphorylated peptides onto TiO(2) beads.\n2. SIMAC (sequential elution from IMAC): This method separates multi- and mono-phosphorylated peptides based on their charge and hydrophobicity, allowing for the enrichment of specific phosphorylation sites.\n3. HILIC (hydrophilic interaction liquid chromatography): This method is used to separate mono-phosphorylated peptides based on their hydrophilicity, providing a high enrichment specificity.\nThese technologies are combined in a multi-dimensional strategy (TiSH) that enables the quantitative investigation of early interferon- signaling in low quantities of insulinoma cells, with an enrichment specificity of >94%. This strategy shows great potential for interrogating signaling networks from low amounts of sample with high sensitivity and specificity.",
    "llama-2-7b-chat-hf_fact_raw": "1. TiO(2) phosphopeptide pre-enrichment provides high specificity for phosphorylated peptides.\n2. SIMAC separates multi- and mono-phosphorylated peptides based on their charge and hydrophobicity.\n3. HILIC is used to separate mono-phosphorylated peptides based on their hydrophilicity.\n4. The combination of these technologies forms a multi-dimensional strategy known as TiSH.\n5. The TiSH strategy enables the quantitative investigation of early interferon signaling in low quantities of insulinoma cells with an enrichment specificity of over 94%.",
    "llama-2-7b-chat-hf_fact": [
      "TiO(2) phosphopeptide pre-enrichment provides high specificity for phosphorylated peptides.",
      "SIMAC separates multi- and mono-phosphorylated peptides based on their charge and hydrophobicity.",
      "HILIC is used to separate mono-phosphorylated peptides based on their hydrophilicity.",
      "The combination of these technologies forms a multi-dimensional strategy known as TiSH.",
      "The TiSH strategy enables the quantitative investigation of early interferon signaling in low quantities of insulinoma cells with an enrichment specificity of over 94%."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The multi-dimensional strategy combining metal oxide affinity chromatography (like TiO2), IMAC or SIMAC, and hydrophilic interaction liquid chromatography (HILIC) for the enrichment and separation of phosphopeptides is known as the TiSH (TiO2-SIMAC-HILIC) strategy.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the disorder that is rated by Palmini classification is X-linked intellectual disability with spastic paraplegia and palmo-plantar hyperkeratosis.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, there is evidence to suggest that viruses may be involved in the etiology of human subacute thyroiditis. The document reports the isolation of viruses from patients with subacute thyroiditis de Quervain, and describes their characteristic morphological, cytological, some physico-chemical and biological features. While the isolated viruses remain unclassified, the document suggests that they may play a role in human and animal health disorders. Therefore, it is possible that viruses contribute to the development of subacute thyroiditis, a condition characterized by inflammation of the thyroid gland.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viruses may be involved in the etiology of human subacute thyroiditis.\n2. Document-0 reports the isolation of viruses from patients with subacute thyroiditis de Quervain.\n3. The document describes the isolated viruses' morphological, cytological, some physico-chemical, and biological features.\n4. The isolated viruses related to subacute thyroiditis remain unclassified.\n5. Subacute thyroiditis is a condition characterized by inflammation of the thyroid gland.",
    "llama-2-7b-chat-hf_fact": [
      "Viruses may be involved in the etiology of human subacute thyroiditis.",
      "Document-0 reports the isolation of viruses from patients with subacute thyroiditis de Quervain.",
      "The document describes the isolated viruses' morphological, cytological, some physico-chemical, and biological features.",
      "The isolated viruses related to subacute thyroiditis remain unclassified.",
      "Subacute thyroiditis is a condition characterized by inflammation of the thyroid gland."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, it appears that STAT3 is involved in the suppression of autophagy through its interaction with the eIF2 kinase 2 (EIF2AK2), also known as protein kinase R (PKR). The study found that inhibition of STAT3 stimulates the autophagic flux, while overexpression of STAT3 variants inhibits starvation-induced autophagy. The interaction between the SH2 domain of STAT3 and the catalytic domain of PKR was found to be involved in this process. Specifically, pharmacological and genetic inhibition of STAT3 led to the activating phosphorylation of PKR and subsequent eIF2 hyperphosphorylation, which facilitates autophagy induction. Additionally, the study found that the disruption of inhibitory STAT3-PKR interactions by chemical STAT3 inhibitors or free fatty acids like palmitate leads to PKR-dependent eIF2 phosphorylation and autophagy induction. Therefore, based on the information provided in Document-0, the answer to the user's question is yes, STAT3 is involved in the suppression of autophagy through its interaction with PKR.",
    "llama-2-7b-chat-hf_fact_raw": "1. STAT3 interacts with eIF2 kinase 2 (EIF2AK2) also referred to as protein kinase R (PKR).\n2. Inhibition of STAT3 stimulates autophagic flux.\n3. Overexpression of STAT3 variants inhibits starvation-induced autophagy.\n4. Pharmacological and genetic inhibition of STAT3 leads to activating phosphorylation of PKR and subsequent eIF2 hyperphosphorylation, inducing autophagy.\n5. Disruption of inhibitory STAT3-PKR interactions by chemical STAT3 inhibitors or free fatty acids like palmitate leads to PKR-dependent eIF2 phosphorylation and autophagy induction.",
    "llama-2-7b-chat-hf_fact": [
      "STAT3 interacts with eIF2 kinase 2 (EIF2AK2) also referred to as protein kinase R (PKR).",
      "Inhibition of STAT3 stimulates autophagic flux.",
      "Overexpression of STAT3 variants inhibits starvation-induced autophagy.",
      "Pharmacological and genetic inhibition of STAT3 leads to activating phosphorylation of PKR and subsequent eIF2 hyperphosphorylation, inducing autophagy.",
      "Disruption of inhibitory STAT3-PKR interactions by chemical STAT3 inhibitors or free fatty acids like palmitate leads to PKR-dependent eIF2 phosphorylation and autophagy induction."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - STAT3 is known to interact with various other proteins, including kinases such as EIF2AK2 (PKR), which is consistent with current biological understanding.\n2. TRUE - The inhibition of STAT3 has been shown to stimulate autophagy, which is a process for cellular degradation and recycling.\n3. TRUE - Overexpression of STAT3 can lead to the inhibition of autophagy, including that induced by starvation, which aligns with its role in cellular signaling pathways.\n4. TRUE - Inhibiting STAT3 can lead to the phosphorylation of PKR, and hyperphosphorylation of eIF2 can indeed induce autophagy through the unfolded protein response and other stress-related pathways.\n5. TRUE - Disruption of the interaction between STAT3 and PKR through pharmacological agents or specific lipids like palmitate can result in PKR activation and subsequent phosphorylation of eIF2, leading to autophagy induction. This is supported by research showing how free fatty acids and certain inhibitors can impact these pathways.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-2-7b-chat-hf_response": "Theatre is a web-based software tool designed for comparative genomic analysis, particularly in the context of gene regulation. It allows users to analyze and compare genomic sequences from different organisms, identifying patterns and features that may not be immediately apparent through other methods.\nTheatre uses a variety of tools and databases to determine or predict the positions of coding regions, repetitive sequences, and transcription factor binding sites in aligned genomic sequences. This information is displayed in a user-friendly format, making it easier to understand and interpret the results. Additionally, Theatre can produce publication-quality color hardcopies of the predicted features in aligned genomic sequences.\nOne of the key features of Theatre is its ability to compare the genomic sequences of different organisms, including mammals and non-mammalian species such as fish. For example, a case study using the p53 promoter region of four mammalian species and two fish species demonstrated the differences in the p53 promoter region between mammals and fish. This type of analysis can reveal important insights into the evolution of gene regulation and the adaptation of organisms to different environments.\nOverall, Theatre is a powerful tool for comparative genomic analysis, providing a user-friendly interface for researchers to explore and understand the complex patterns and features of genomic sequences. It can be accessed at <http://www.hgmp.mrc.ac.uk/Registered/Webapp/theatre/>.",
    "llama-2-7b-chat-hf_fact_raw": "1. Theatre is a web-based software tool used for comparative genomic analysis.\n2. Theatre allows for the analysis and comparison of genomic sequences from different organisms.\n3. The software can identify coding regions, repetitive sequences, and transcription factor binding sites in aligned genomic sequences.\n4. Theatre provides a user-friendly format for displaying genomic information.\n5. Theatre can produce publication-quality color hardcopies of the predicted features in aligned genomic sequences.",
    "llama-2-7b-chat-hf_fact": [
      "Theatre is a web-based software tool used for comparative genomic analysis.",
      "Theatre allows for the analysis and comparison of genomic sequences from different organisms.",
      "The software can identify coding regions, repetitive sequences, and transcription factor binding sites in aligned genomic sequences.",
      "Theatre provides a user-friendly format for displaying genomic information.",
      "Theatre can produce publication-quality color hardcopies of the predicted features in aligned genomic sequences."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout more specific information or context, it is not possible to evaluate the truthfulness of these statements regarding \"Theatre\" as a web-based software tool for genomic analysis. The name \"Theatre\" is not widely recognized in the context of genomic software, which might either be a fictional software, a new tool that is not well-known, or possibly a typographical error for a tool such as \"UCSC Genome Browser\" or \"Ensembl Genome Browser\". Without further context or information, no accurate assessment can be made.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences is approximately 21.4 GCUPS (Giga-Cells Per Second).",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, FLVCR1 is a member of the SLC22 family. Specifically, it is a member of the subfamily 2 (OAT) of the SLC22 family, which is responsible for the uptake of a wide range of organic anions and cations, including numerous endo- and xenobiotics. The document provides a detailed analysis of the expression patterns of SLC22 genes in various tissues of zebrafish, including the liver, kidney, intestine, gills, brain, skeletal muscle, eye, heart, and gonads. The study found that FLVCR1 is highly expressed in the kidney, especially in females, and has low expression in gills and moderate expression in heart and skeletal muscle. The study also observed differences in tissue expression patterns of SLC22 genes in comparison to human orthologs, suggesting that zebrafish Slc22 members may have partially conserved functions and potentially compensatory roles, while some orthologs may have more diverse and specific roles in zebrafish.",
    "llama-2-7b-chat-hf_fact_raw": "1. FLVCR1 is a member of the SLC22 family.\n2. FLVCR1 specifically belongs to the subfamily 2 (OAT) of the SLC22 family.\n3. The study indicated that FLVCR1 is highly expressed in the kidney, especially in females.\n4. FLVCR1 has low expression in gills and moderate expression in heart and skeletal muscle according to the study.\n5. The study suggests that zebrafish Slc22 members may have partially conserved functions compared to human orthologs.",
    "llama-2-7b-chat-hf_fact": [
      "FLVCR1 is a member of the SLC22 family.",
      "FLVCR1 specifically belongs to the subfamily 2 (OAT) of the SLC22 family.",
      "The study indicated that FLVCR1 is highly expressed in the kidney, especially in females.",
      "FLVCR1 has low expression in gills and moderate expression in heart and skeletal muscle according to the study.",
      "The study suggests that zebrafish Slc22 members may have partially conserved functions compared to human orthologs."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: FLVCR1 is not a member of the SLC22 family; it is part of the SLC49 family.\n2. FALSE [correction]: Since FLVCR1 specifically does not belong to the SLC22 family, it cannot belong to subfamily 2 (OAT) of the SLC22 family.\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the interacting partners of GATA-1 that were discovered through the biotinylation tagging approach are:\n1. Streptavidin: The direct binding of biotinylated GATA-1 to streptavidin in nuclear extracts resulted in the single-step capture of the tagged factor and associated proteins, which were eluted and identified by mass spectrometry.\n2. Other transcription factors: The characterization of several distinct GATA-1 complexes with other transcription factors and chromatin remodeling cofactors, which are involved in activation and repression of gene targets.\n3. Chromatin remodeling cofactors: The characterization of several distinct GATA-1 complexes with other transcription factors and chromatin remodeling cofactors, which are involved in activation and repression of gene targets.\nThese interacting partners were identified through the use of the biotinylation tagging approach, which involves the efficient purification of protein complexes using the very high affinity of the biotin/(strept)avidin system. By fusing a short peptide tag to the N-terminus of GATA-1 and using the BirA biotin ligase to biotinylate the tag, the tagged GATA-1 can be captured and isolated using streptavidin, allowing for the identification of its interacting partners by mass spectrometry.",
    "llama-2-7b-chat-hf_fact_raw": "1. Streptavidin binds directly to biotinylated GATA-1 in nuclear extracts.\n2. Biotinylation tagging approach is used to identify interacting partners of GATA-1 by capturing the tagged factor and associated proteins for mass spectrometry analysis.\n3. GATA-1 forms complexes with other transcription factors as an outcome of this approach.\n4. GATA-1 also forms complexes with chromatin remodeling cofactors, as determined by the biotinylation tagging method.\n5. The biotinylation tagging method involves fusing a peptide tag to GATA-1 and using BirA biotin ligase for biotinylation, followed by capture with streptavidin.",
    "llama-2-7b-chat-hf_fact": [
      "Streptavidin binds directly to biotinylated GATA-1 in nuclear extracts.",
      "Biotinylation tagging approach is used to identify interacting partners of GATA-1 by capturing the tagged factor and associated proteins for mass spectrometry analysis.",
      "GATA-1 forms complexes with other transcription factors as an outcome of this approach.",
      "GATA-1 also forms complexes with chromatin remodeling cofactors, as determined by the biotinylation tagging method.",
      "The biotinylation tagging method involves fusing a peptide tag to GATA-1 and using BirA biotin ligase for biotinylation, followed by capture with streptavidin."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Streptavidin is known for its strong affinity to biotin and is commonly used in various biological applications to capture biotinylated proteins, including transcription factors like GATA-1.\n\n2. TRUE: A biotinylation tagging approach does indeed involve tagging a protein of interest (such as GATA-1) with biotin and then using mass spectrometry to identify interacting proteins that bind to the biotinylated protein.\n\n3. TRUE: One of the outcomes of the biotinylation tagging approach is the identification of complexes that GATA-1 forms with other transcription factors, as it can capture not only the protein of interest but also other proteins that are bound to it.\n\n4. TRUE: GATA-1 is known to interact with various proteins, including chromatin remodeling cofactors. The biotinylation tagging method can be used to determine these interactions, as it captures the protein of interest along with its associated proteins.\n\n5. TRUE: The biotinylation tagging method involves genetically engineering a protein such as GATA-1 to contain a biotin acceptor peptide. BirA biotin ligase will enzymatically biotinylate this peptide tag in vivo. The biotinylated protein can then be captured using streptavidin affinity purification, which is commonly used for subsequent analysis, including mass spectrometry.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, TAF10 interacting with the GATA1 transcription factor leads to a differentiation block accompanied by deregulated GATA1 target genes, including Gata1 itself. This suggests that there is a functional cross talk between GATA1 and TAF10, and that TAF10 plays a role in regulating the expression of genes controlled by GATA1 during erythropoiesis. Additionally, the document shows that TAF10 interacts directly with GATA1 and is enriched on the GATA1 locus in human fetal erythroid cells, further supporting the idea that TAF10 plays a role in regulating GATA1-controlled genes during erythropoiesis.",
    "llama-2-7b-chat-hf_fact_raw": "1. TAF10 interaction with the GATA1 transcription factor results in a differentiation block.\n2. The interaction between TAF10 and GATA1 leads to deregulated GATA1 target genes, including Gata1 itself.\n3. There is a functional cross talk between GATA1 and TAF10.\n4. TAF10 is involved in regulating the expression of genes controlled by GATA1 during erythropoiesis.\n5. TAF10 is enriched on the GATA1 locus in human fetal erythroid cells.",
    "llama-2-7b-chat-hf_fact": [
      "TAF10 interaction with the GATA1 transcription factor results in a differentiation block.",
      "The interaction between TAF10 and GATA1 leads to deregulated GATA1 target genes, including Gata1 itself.",
      "There is a functional cross talk between GATA1 and TAF10.",
      "TAF10 is involved in regulating the expression of genes controlled by GATA1 during erythropoiesis.",
      "TAF10 is enriched on the GATA1 locus in human fetal erythroid cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe statements pertain to specific molecular biology interactions that would require supporting scientific evidence for a true or false determination. While statements 3 and 4 are consistent with plausible scientific mechanisms where transcription factors and cofactors interact, without specific research data or context, the true or false status of statements 1, 2, and 5 can't be accurately determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "llama-2-7b-chat-hf_response": "Yes, there are decision support systems available for chronic pain management. The study you provided information on demonstrates the effectiveness of a computer-based decision support system (CBDS) in enhancing the ability of primary care physicians (PCPs) to manage chronic pain.\nIn the study, a pain specialist used a decision support system to determine appropriate pain therapy for 50 chronic pain patients referred by PCPs to a pain clinic. The system provided structured summaries of the patients' information and recommended new or adjusted therapies. Five board-certified PCPs then used the CBDS system to \"treat\" the 50 cases, and the outcomes were evaluated by two pain specialists.\nThe results showed that the PCPs \"prescribed\" additional pain therapy in 85% of the evaluations, with a medical appropriateness score of 5.5 +/- 0.1. Only 25% of the chronic pain patients were subsequently re-referred to the pain clinic within one year. These findings suggest that the use of a CBDS system may improve the ability of PCPs to manage chronic pain and facilitate screening of consults to optimize specialist utilization.\nThere are several other decision support systems available for chronic pain management, including:\n1. The Chronic Pain Management Decision Support System (CPM-DSS): This system provides evidence-based recommendations for managing chronic pain, including assessment and diagnosis, pharmacological and non-pharmacological interventions, and ongoing management.\n2. The Pain Management Collaborative (PMC): This is a web-based platform that provides a structured approach to chronic pain management, including assessment, diagnosis, and treatment planning.\n3. The American Academy of Pain Medicine (AAPM) Decision Support System (DSS): This system provides evidence-based recommendations for managing chronic pain, including assessment and diagnosis, pharmacological and non-pharmacological interventions, and ongoing management.\n4. The Chronic Pain Center (CPC): This is a comprehensive decision support system that provides evidence-based recommendations for managing chronic pain, including assessment and diagnosis, pharmacological and non",
    "llama-2-7b-chat-hf_fact_raw": "1. A computer-based decision support system (CBDS) has been used to enhance the primary care physicians' ability to manage chronic pain.\n2. In a study, 50 chronic pain patients were referred by PCPs to a pain clinic, where a pain specialist used a decision support system to determine appropriate therapy.\n3. After using the CBDS system, the PCPs prescribed additional pain therapy in 85% of the evaluations.\n4. Only 25% of the chronic pain patients who were part of the study were re-referred to the pain clinic within one year after the initial use of the CBDS system.\n5. The Pain Management Collaborative (PMC) is a web-based platform that provides structured approaches to chronic pain management.",
    "llama-2-7b-chat-hf_fact": [
      "A computer-based decision support system (CBDS) has been used to enhance the primary care physicians' ability to manage chronic pain.",
      "In a study, 50 chronic pain patients were referred by PCPs to a pain clinic, where a pain specialist used a decision support system to determine appropriate therapy.",
      "After using the CBDS system, the PCPs prescribed additional pain therapy in 85% of the evaluations.",
      "Only 25% of the chronic pain patients who were part of the study were re-referred to the pain clinic within one year after the initial use of the CBDS system.",
      "The Pain Management Collaborative (PMC) is a web-based platform that provides structured approaches to chronic pain management."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE (Assuming there are studies or evidence that a computer-based decision support system has been employed for such purposes)\n2. UNKNOWN (The statement is specific, and without the exact evidence or study, it's difficult to determine its truthfulness)\n3. UNKNOWN (The specific percentage provided is not verifiable without relevant data or the results of the study referred to)\n4. UNKNOWN (Similarly, the percentage of re-referral would need to be substantiated by the specific study's findings)\n5. UNKNOWN (This statement about the Pain Management Collaborative being a web-based platform is specific and without additional context or a source, its truthfulness cannot be determined)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the subcellular localization of the protein angiogenin is primarily in the cytoplasm, with some evidence of internalization and processing within the perinuclear region. The document mentions that the internalized native protein is localized in the perinuclear region at 30 min and then disperses throughout the cytoplasm, and also shows that the molecule has a half-life of around 12 hours in chase experiments. Additionally, the document mentions that in cell extracts, three fragments with molecular masses of 10.5, 8.7, and 6.1 kDa are detected at 48 hours, suggesting that angiogenin is processed into smaller fragments within the cells. Therefore, based on the information provided in the document, the subcellular localization of angiogenin is primarily in the cytoplasm, with some evidence of internalization and processing within the perinuclear region.",
    "llama-2-7b-chat-hf_fact_raw": "1. The subcellular localization of the protein angiogenin is primarily in the cytoplasm.\n2. Angiogenin is internalized and processed within the perinuclear region.\n3. Internalized native angiogenin is localized in the perinuclear region at 30 minutes post-internalization.\n4. Angiogenin disperses throughout the cytoplasm after being localized in the perinuclear region.\n5. Angiogenin has a molecular half-life of around 12 hours in chase experiments.",
    "llama-2-7b-chat-hf_fact": [
      "The subcellular localization of the protein angiogenin is primarily in the cytoplasm.",
      "Angiogenin is internalized and processed within the perinuclear region.",
      "Internalized native angiogenin is localized in the perinuclear region at 30 minutes post-internalization.",
      "Angiogenin disperses throughout the cytoplasm after being localized in the perinuclear region.",
      "Angiogenin has a molecular half-life of around 12 hours in chase experiments."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Angiogenin is primarily localized in the cytoplasm.\n2. TRUE: Angiogenin can indeed be internalized and processed within the perinuclear region of a cell.\n3. TRUE: It is consistent with the behavior of internalized proteins like angiogenin to be localized in the perinuclear region at a specific time post-internalization; however, experimental data would be needed for an exact time verification such as 30 minutes.\n4. UNKNOWN: Without specific scientific evidence mentioned in the statement, it is unclear whether angiogenin disperses throughout the cytoplasm after initially being localized in the perinuclear region.\n5. UNKNOWN: The exact molecular half-life of angiogenin would vary depending on several factors and would require an empirical source to confirm the statement of it being around 12 hours in chase experiments.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, ranolazine (RAN) appears to affect kinase signaling activation in the heart by increasing the levels of phosphorylated protein kinase B (Akt) and mammalian target of rapamycin (mTOR) in both nondiabetic and diabetic infarcted hearts. These kinases play a crucial role in regulating cell survival, proliferation, and metabolism, and their activation has been shown to promote cardiac function recovery after myocardial infarction (MI).\nIn diabetic hearts, RAN also resulted in a significant increase in the ratio of sarcoplasmic Ca(2+)-ATPase/phospholamban, which is a target of Akt signaling. Additionally, RAN increased levels of phosphorylated calcium-regulated adenosine monophosphate-activated protein kinase (AMPK) in diabetic hearts. AMPK is a key regulator of energy metabolism and is activated downstream of LKB1, which is a kinase that is activated by Ca(2+) and ATP.\nThe activation of Akt/mTOR and AMPK by RAN may contribute to the greater effect of RAN on the recovery of cardiac function in diabetic rats compared to nondiabetic rats. These findings provide a plausible explanation for the results of the TERISA trial, which showed a greater antianginal effect of RAN in patients with coronary artery disease and diabetes.\nIn summary, ranolazine appears to enhance kinase signaling activation in the heart by increasing the levels of phosphorylated Akt and mTOR, and by activating AMPK in diabetic hearts. These effects may contribute to the greater effect of RAN on cardiac function recovery in diabetic rats compared to nondiabetic rats.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ranolazine increases the levels of phosphorylated protein kinase B (Akt) and mammalian target of rapamycin (mTOR) in both nondiabetic and diabetic infarcted hearts.\n2. The kinases Akt and mTOR regulate cell survival, proliferation, and metabolism, and their activation is associated with promoting cardiac function recovery after myocardial infarction.\n3. In diabetic hearts, ranolazine significantly increases the ratio of sarcoplasmic Ca(2+)-ATPase/phospholamban, a target of Akt signaling.\n4. Ranolazine increases levels of phosphorylated AMP-activated protein kinase (AMPK) in diabetic hearts.\n5. The TERISA trial showed a greater antianginal effect of ranolazine in patients with coronary artery disease and diabetes.",
    "llama-2-7b-chat-hf_fact": [
      "Ranolazine increases the levels of phosphorylated protein kinase B (Akt) and mammalian target of rapamycin (mTOR) in both nondiabetic and diabetic infarcted hearts.",
      "The kinases Akt and mTOR regulate cell survival, proliferation, and metabolism, and their activation is associated with promoting cardiac function recovery after myocardial infarction.",
      "In diabetic hearts, ranolazine significantly increases the ratio of sarcoplasmic Ca(2+)-ATPase/phospholamban, a target of Akt signaling.",
      "Ranolazine increases levels of phosphorylated AMP-activated protein kinase (AMPK) in diabetic hearts.",
      "The TERISA trial showed a greater antianginal effect of ranolazine in patients with coronary artery disease and diabetes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nStatements 1, 3, and 4 are specific assertions regarding the effects of ranolazine on cellular and molecular processes within the heart. Without access to the specific research studies or clinical trial results that support these statements, it is difficult to verify their accuracy. An expert in cardiovascular pharmacology or a lookup of the specific research the statements are based on would be required to validate these claims.\n\nStatement 2 is a true statement as both Akt and mTOR are well-known for their roles in regulating cell survival, proliferation, and metabolism. Their activation is indeed often associated with recovery after myocardial infarction.\n\nStatement 5 is about the results of the TERISA (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina) trial, which was a study demonstrating that ranolazine was more effective for treating angina in patients with both coronary artery disease and diabetes than in those without diabetes. Assuming this representation of the trial's findings is accurate, the statement is true. However, without direct access to the trial results, it would usually be difficult to confirm.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that the regulation of Vsr endonuclease is not independent of the growth phase of bacteria. According to the document, overexpression of Vsr does increase the stationary-phase reversion of a Lac-frameshift allele, but the absence of Vsr has no effect. This suggests that Vsr plays a role in stationary-phase mutation, and that its regulation is linked to the growth phase of the bacteria. Therefore, the answer to the user's question is yes, the regulation of Vsr endonuclease is dependent on the growth phase of bacteria.",
    "llama-2-7b-chat-hf_fact_raw": "1. The regulation of Vsr endonuclease is not independent of the growth phase of bacteria.\n2. Overexpression of Vsr increases the stationary-phase reversion of a Lac-frameshift allele.\n3. The absence of Vsr endonuclease has no effect on the stationary-phase reversion of a Lac-frameshift allele.\n4. Vsr endonuclease plays a role in stationary-phase mutation in bacteria.",
    "llama-2-7b-chat-hf_fact": [
      "The regulation of Vsr endonuclease is not independent of the growth phase of bacteria.",
      "Overexpression of Vsr increases the stationary-phase reversion of a Lac-frameshift allele.",
      "The absence of Vsr endonuclease has no effect on the stationary-phase reversion of a Lac-frameshift allele.",
      "Vsr endonuclease plays a role in stationary-phase mutation in bacteria."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The absence of Vsr endonuclease reduces the stationary-phase reversion of a Lac-frameshift allele.\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are several computational tools that can be used for the prediction of beta-barrel transmembrane proteins:\n1. transFold: This is a novel method that uses pairwise interstrand residue statistical potentials derived from globular (non-outer membrane) proteins to predict the supersecondary structure of transmembrane beta-barrel proteins. The algorithm employs a generalized hidden Markov model (i.e., multitape S-attribute grammar) to describe potential beta-barrel supersecondary structures and then computes the minimum free energy beta-barrel structure using dynamic programming.\n2. Pairwise Interstrand Residue Potentials (PIR): This method uses a set of potentials that describe the interactions between adjacent residues in a transmembrane beta-barrel protein. The potentials are derived from the analysis of globular proteins and are used to predict the secondary structure of the protein.\n3. Machine Learning (ML) methods: These methods use traditional machine learning techniques, such as support vector machines (SVMs) or neural networks, to predict the structure of transmembrane beta-barrel proteins. These methods typically require a training phase on known TMB structures to learn the patterns and relationships between the sequence and structure of the proteins.\n4. Hybrid methods: These methods combine different computational tools and techniques to predict the structure of transmembrane beta-barrel proteins. For example, a hybrid method might use a machine learning algorithm to predict the overall structure of the protein, and then use a structural alignment method to refine the predictions.\nIt is important to note that the accuracy of these methods can vary depending on the length and complexity of the protein sequence, as well as the quality of the experimental data used to train the models. Therefore, it is recommended to use multiple methods and compare their predictions to obtain the most accurate results.",
    "llama-2-7b-chat-hf_fact_raw": "1. transFold is a method that predicts the supersecondary structure of transmembrane beta-barrel proteins using pairwise interstrand residue statistical potentials.\n2. Pairwise Interstrand Residue Potentials (PIR) describe interactions between adjacent residues in transmembrane beta-barrel proteins to predict their secondary structure.\n3. Machine Learning methods, including support vector machines and neural networks, are used to predict the structure of transmembrane beta-barrel proteins after a training phase on known TMB structures.\n4. Hybrid methods for predicting transmembrane beta-barrel protein structures combine various computational tools and techniques, such as machine learning algorithms and structural alignment methods.\n5. The accuracy of computational prediction methods for transmembrane beta-barrel proteins can be influenced by factors including protein sequence length, complexity, and the quality of experimental data used in model training.",
    "llama-2-7b-chat-hf_fact": [
      "transFold is a method that predicts the supersecondary structure of transmembrane beta-barrel proteins using pairwise interstrand residue statistical potentials.",
      "Pairwise Interstrand Residue Potentials (PIR) describe interactions between adjacent residues in transmembrane beta-barrel proteins to predict their secondary structure.",
      "Machine Learning methods, including support vector machines and neural networks, are used to predict the structure of transmembrane beta-barrel proteins after a training phase on known TMB structures.",
      "Hybrid methods for predicting transmembrane beta-barrel protein structures combine various computational tools and techniques, such as machine learning algorithms and structural alignment methods.",
      "The accuracy of computational prediction methods for transmembrane beta-barrel proteins can be influenced by factors including protein sequence length, complexity, and the quality of experimental data used in model training."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Pairwise interstrand residue potentials (PIR) describe interactions between beta-strands, not necessarily between adjacent residues, to help in the prediction of the tertiary structure of transmembrane beta-barrel proteins.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, Galassi classification is used for bipolar affective disorder.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the article, the common features of Shapiro syndrome are:\n1. Recurrent spontaneous hypothermia: The patient experiences episodes of hypothermia without any obvious cause.\n2. Hyperhidrosis: The patient has excessive sweating, which is a characteristic feature of Shapiro syndrome.\n3. Agenesis of the corpus callosum: The patient has a missing corpus callosum, which is a hallmark of Shapiro syndrome.\n4. Electroencephalographic (EEG) abnormalities: The patient's EEG shows rhythmic low- to medium-voltage theta waves without clear epileptiform activity.\n5. Neuroimaging abnormalities: The patient's brain MRI is normal.\n6. Impaired consciousness: The patient experiences impaired consciousness during episodes, which can be a result of the underlying neurological disorder.\n7. Hypotonia: The patient has decreased muscle tone, which can contribute to the impaired consciousness and other neurological symptoms.\n8. Early onset: The patient's symptoms began before the age of one, which is earlier than the typical age of onset of Shapiro syndrome.\nIt is important to note that Shapiro syndrome is a rare disorder, and the features may vary in different cases. However, the combination of recurrent spontaneous hypothermia, hyperhidrosis, agenesis of the corpus callosum, and EEG abnormalities are highly suggestive of Shapiro syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Recurrent spontaneous hypothermia without any obvious cause is a common feature of Shapiro syndrome.\n2. Patients with Shapiro syndrome commonly experience excessive sweating, known as hyperhidrosis.\n3. Agenesis of the corpus callosum is a hallmark of Shapiro syndrome.\n4. EEG abnormalities in patients with Shapiro syndrome often show rhythmic low- to medium-voltage theta waves without clear epileptiform activity.\n5. Neuroimaging such as brain MRI is typically normal in patients with Shapiro syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Recurrent spontaneous hypothermia without any obvious cause is a common feature of Shapiro syndrome.",
      "Patients with Shapiro syndrome commonly experience excessive sweating, known as hyperhidrosis.",
      "Agenesis of the corpus callosum is a hallmark of Shapiro syndrome.",
      "EEG abnormalities in patients with Shapiro syndrome often show rhythmic low- to medium-voltage theta waves without clear epileptiform activity.",
      "Neuroimaging such as brain MRI is typically normal in patients with Shapiro syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Patients with Shapiro syndrome commonly experience a lack of sweating, known as hypohidrosis, rather than hyperhidrosis.\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: Neuroimaging such as brain MRI in patients with Shapiro syndrome may show agenesis of the corpus callosum, which is not a normal finding.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the disease linked to mutations within BRAG1 is Congenital Central Hypoventilation Syndrome (CCHS). The report mentions that the infant in question had a mutation in the PHOX2B gene, which is associated with CCHS, and also found a further mutation in the BRAF oncogene. The association between these mutations and the shared qualities of tumorigenesis between BRAF and PHOX2B suggests that the mutations in BRAG1 may play a role in the development of CCHS.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations within the BRAG1 gene are linked to Congenital Central Hypoventilation Syndrome (CCHS).\n2. The PHOX2B gene mutation is associated with Congenital Central Hypoventilation Syndrome (CCHS).\n3. The infant mentioned had a mutation in the PHOX2B gene.\n4. A mutation was found in the BRAF oncogene in the context provided.\n5. The mutations in BRAG1 may contribute to the development of Congenital Central Hypoventilation Syndrome (CCHS).",
    "llama-2-7b-chat-hf_fact": [
      "Mutations within the BRAG1 gene are linked to Congenital Central Hypoventilation Syndrome (CCHS).",
      "The PHOX2B gene mutation is associated with Congenital Central Hypoventilation Syndrome (CCHS).",
      "The infant mentioned had a mutation in the PHOX2B gene.",
      "A mutation was found in the BRAF oncogene in the context provided.",
      "The mutations in BRAG1 may contribute to the development of Congenital Central Hypoventilation Syndrome (CCHS)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Mutations within the PHOX2B gene are linked to Congenital Central Hypoventilation Syndrome (CCHS).\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: It is mutations in the PHOX2B gene, not BRAG1, that may contribute to the development of Congenital Central Hypoventilation Syndrome (CCHS).",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the main inhibitor of protein phosphatase 1 (PP1) is protein phosphatase inhibitor-1 (PPI-1).",
    "llama-2-7b-chat-hf_fact_raw": "1. Protein phosphatase inhibitor-1 (PPI-1) is the main inhibitor of protein phosphatase 1 (PP1).",
    "llama-2-7b-chat-hf_fact": [
      "Protein phosphatase inhibitor-1 (PPI-1) is the main inhibitor of protein phosphatase 1 (PP1)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n\nProtein phosphatase inhibitor-1 (PPI-1), also known as inhibitor-1, is indeed known as an inhibitor of protein phosphatase 1 (PP1). PPI-1 regulates PP1 activity in a variety of cellular processes.",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the mechanisms that underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis are:\n1. Regulation by comA and comK genes: The study showed that adaptive mutagenesis in B. subtilis is subject to regulation by at least two genes involved in the regulation of post-exponential phase prokaryotic differentiation, specifically comA and comK.\n2. Lack of functional RecA protein requirement: The results indicated that a functional RecA protein is not required for adaptive mutagenesis in B. subtilis, suggesting that other mechanisms may be involved in this process.\n3. Hypermutability of a small subpopulation: The study found that a small subpopulation of the culture is involved in adaptive mutagenesis and is hypermutable, meaning that it has an increased ability to accumulate mutations.\nOverall, these mechanisms suggest that adaptive mutagenesis in B. subtilis involves a complex interplay of genetic and environmental factors, including the regulation of gene expression, the presence of a hypermutable subpopulation, and the lack of a functional RecA protein.",
    "llama-2-7b-chat-hf_fact_raw": "1. comA and comK genes are involved in the regulation of adaptive mutagenesis in Bacillus subtilis.\n2. A functional RecA protein is not required for adaptive mutagenesis in Bacillus subtilis.\n3. A hypermutable subpopulation exists within the culture of Bacillus subtilis that is involved in adaptive mutagenesis.\n4. Adaptive mutagenesis in Bacillus subtilis is influenced by regulation of post-exponential phase prokaryotic differentiation.",
    "llama-2-7b-chat-hf_fact": [
      "comA and comK genes are involved in the regulation of adaptive mutagenesis in Bacillus subtilis.",
      "A functional RecA protein is not required for adaptive mutagenesis in Bacillus subtilis.",
      "A hypermutable subpopulation exists within the culture of Bacillus subtilis that is involved in adaptive mutagenesis.",
      "Adaptive mutagenesis in Bacillus subtilis is influenced by regulation of post-exponential phase prokaryotic differentiation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The comA and comK genes are known to be involved in competence development in Bacillus subtilis and can also be linked to the regulation of adaptive mutagenesis, as competence development and mutagenesis are related processes in this bacterium.\n2. FALSE [correction]: A functional RecA protein is typically required for adaptive mutagenesis in Bacillus subtilis, as RecA is involved in the DNA repair and homologous recombination processes that can give rise to mutations.\n3. TRUE: Studies have suggested that within a culture of Bacillus subtilis, there can be a subpopulation that has a higher mutation rate, which contributes to adaptive mutagenesis.\n4. TRUE: Adaptive mutagenesis in Bacillus subtilis is influenced by a variety of factors, including those related to the regulatory networks that control cell differentiation and stress responses during the post-exponential (stationary) phase of growth.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, erucism is caused by the venom-containing spines of the gum leaf skeletoniser (Uraba lugens). The spines of this insect can cause a stinging sensation, followed by itching and the formation of wheals in humans. Therefore, exposure to U. lugens should be considered by medical practitioners in the differential diagnosis of contact dermatitis in the Auckland region.",
    "llama-2-7b-chat-hf_fact_raw": "1. Erucism is caused by the venom-containing spines of the gum leaf skeletoniser (Uraba lugens).\n2. The spines of the gum leaf skeletoniser can cause a stinging sensation in humans.\n3. Contact with the gum leaf skeletoniser can result in itching and the formation of wheals.\n4. Medical practitioners should consider exposure to Uraba lugens in the differential diagnosis of contact dermatitis in the Auckland region.",
    "llama-2-7b-chat-hf_fact": [
      "Erucism is caused by the venom-containing spines of the gum leaf skeletoniser (Uraba lugens).",
      "The spines of the gum leaf skeletoniser can cause a stinging sensation in humans.",
      "Contact with the gum leaf skeletoniser can result in itching and the formation of wheals.",
      "Medical practitioners should consider exposure to Uraba lugens in the differential diagnosis of contact dermatitis in the Auckland region."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nEach of these statements is consistent with what is known about the gum leaf skeletoniser (Uraba lugens) and the condition erucism, which is a skin irritation caused by contact with the hairs or spines of certain caterpillar larvae, including those of the gum leaf skeletoniser. The symptoms described, such as a stinging sensation, itching, and formation of wheals, are typical reactions to the caterpillar's spines. Lastly, the mention of the Auckland region suggests that the statements are given a specific geographical context where the gum leaf skeletoniser is found and may potentially cause skin irritations that could be misdiagnosed as contact dermatitis. Therefore, it would be reasonable for medical practitioners in that area to consider exposure to Uraba lugens when diagnosing such skin conditions.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the indications for hydrochlorothiazide (HCTZ) are:\n1. Hypertension: HCTZ is a diuretic that is used to treat hypertension, or high blood pressure.\n2. Class IV of the Biopharmaceutics Classification System: HCTZ belongs to class IV of the Biopharmaceutics Classification System, which means it is a drug that is primarily metabolized by the liver.\n3. No requirement for dissolution and dissolution profile testing: There is no requirement for dissolution and dissolution profile testing for the commercialization of compounded drugs, such as Lab 5 and Lab 6, which contain HCTZ.\n4. Incompatibility with lactose and mannitol: HCTZ is incompatible with lactose and mannitol, which may explain the lack of equivalence of the generic pharmaceutical product.\nIt is important to note that the information provided is based on the document provided and may not be comprehensive or up-to-date. If you have any further questions or concerns, please let me know.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hydrochlorothiazide (HCTZ) is used to treat hypertension, or high blood pressure.\n2. HCTZ is classified under class IV of the Biopharmaceutics Classification System.\n3. There is no requirement for dissolution and dissolution profile testing for the commercialization of compounded drugs containing HCTZ.\n4. HCTZ is incompatible with lactose and mannitol.",
    "llama-2-7b-chat-hf_fact": [
      "Hydrochlorothiazide (HCTZ) is used to treat hypertension, or high blood pressure.",
      "HCTZ is classified under class IV of the Biopharmaceutics Classification System.",
      "There is no requirement for dissolution and dissolution profile testing for the commercialization of compounded drugs containing HCTZ.",
      "HCTZ is incompatible with lactose and mannitol."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Hydrochlorothiazide (HCTZ) is classified under class III (high solubility, low permeability) of the Biopharmaceutics Classification System (BCS), not class IV.\n3. FALSE [correction]: While the specific requirements for compounded drugs can vary, typically there is a requirement for dissolution or dissolution profile testing for the commercialization of compounded drugs containing any active pharmaceutical ingredient, including HCTZ, to ensure their quality and performance.\n4. FALSE [correction]: HCTZ is typically compatible with both lactose and mannitol, which are commonly used as pharmaceutical excipients. Compatibility is drug-specific and can depend on many factors, but there is no widely recognized incompatibility of HCTZ with these substances.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "llama-2-7b-chat-hf_response": "Yes, silicon has been used in the treatment of incontinence after radical prostatectomy (RP). In a study published in the Journal of Urology, six patients with severe post-operative incontinence after RP were treated with transurethral submucosal injection therapy using polydimethylsiloxane (PDS) particles. The results showed that after a mean follow-up of 15.5 months, five patients were dry, with no incontinence during the day or night, while one patient improved significantly but still required two pads during the day. The side-effects of therapy were minimal, with dysuria and urinary retention being the most common complications. The study concluded that transurethral injection therapy using silicone particles is a justifiable procedure for treating incontinence after RP.",
    "llama-2-7b-chat-hf_fact_raw": "1. Silicon has been used in the treatment of incontinence after radical prostatectomy (RP).\n2. In a study published in the Journal of Urology, six patients were treated with polydimethylsiloxane (PDS) particles for post-operative incontinence after RP.\n3. After a mean follow-up of 15.5 months, five of the treated patients experienced no incontinence during day or night.\n4. One patient from the study showed significant improvement but still required two pads during the day.\n5. Dysuria and urinary retention were noted as the most common side-effects of the silicone particle therapy.",
    "llama-2-7b-chat-hf_fact": [
      "Silicon has been used in the treatment of incontinence after radical prostatectomy (RP).",
      "In a study published in the Journal of Urology, six patients were treated with polydimethylsiloxane (PDS) particles for post-operative incontinence after RP.",
      "After a mean follow-up of 15.5 months, five of the treated patients experienced no incontinence during day or night.",
      "One patient from the study showed significant improvement but still required two pads during the day.",
      "Dysuria and urinary retention were noted as the most common side-effects of the silicone particle therapy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout having access to the specific study referenced and details in the statements, I cannot confirm the correctness of statements 2 through 5. They are specific claims that require verification from the original source.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is an association between the moon cycle and the risk of rupture of intracranial aneurysms. The study found that the incidence of aneurysm rupture peaked during the new moon phase, which was statistically significant. This suggests that there may be a link between the lunar cycle and the risk of aneurysm rupture. However, it is important to note that the study only observed an association and did not establish a causal relationship between the moon cycle and aneurysm rupture. Further research is needed to confirm these findings and to determine the underlying mechanisms.",
    "llama-2-7b-chat-hf_fact_raw": "1. A study found an association between the moon cycle and the risk of rupture of intracranial aneurysms.\n2. The incidence of aneurysm rupture peaked during the new moon phase, according to the study.\n3. The association observed in the study was statistically significant.\n4. The study did not establish a causal relationship between the moon cycle and aneurysm rupture.\n5. Further research is needed to confirm the findings and determine the underlying mechanisms.",
    "llama-2-7b-chat-hf_fact": [
      "A study found an association between the moon cycle and the risk of rupture of intracranial aneurysms.",
      "The incidence of aneurysm rupture peaked during the new moon phase, according to the study.",
      "The association observed in the study was statistically significant.",
      "The study did not establish a causal relationship between the moon cycle and aneurysm rupture.",
      "Further research is needed to confirm the findings and determine the underlying mechanisms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "llama-2-7b-chat-hf_response": "Yes, the HuR protein does regulate the splicing process. According to the provided information, the HuR protein modulates mRNA splicing, trafficking, translation, and stability. The report mentions that HuR interacts with thousands of cellular transcripts, including non-coding RNAs such as natural antisense transcripts from stress responsive loci. The study also found that secondary structures of 66-75 nucleotides enhance HuR's recognition of its specific RNA targets composed of short primary sequence patterns. These findings suggest that HuR plays a role in regulating the splicing process by interacting with RNAs and modulating their stability and translation.",
    "llama-2-7b-chat-hf_fact_raw": "1. The HuR protein regulates the splicing process.\n2. HuR modulates mRNA splicing, trafficking, translation, and stability.\n3. HuR interacts with thousands of cellular transcripts, including non-coding RNAs.\n4. Natural antisense transcripts from stress responsive loci are among the RNAs that HuR interacts with.\n5. Secondary structures of 66-75 nucleotides enhance HuR's recognition of its specific RNA targets.",
    "llama-2-7b-chat-hf_fact": [
      "The HuR protein regulates the splicing process.",
      "HuR modulates mRNA splicing, trafficking, translation, and stability.",
      "HuR interacts with thousands of cellular transcripts, including non-coding RNAs.",
      "Natural antisense transcripts from stress responsive loci are among the RNAs that HuR interacts with.",
      "Secondary structures of 66-75 nucleotides enhance HuR's recognition of its specific RNA targets."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The HuR protein does not regulate the splicing process; it primarily regulates mRNA stability and translation.\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: While HuR does recognize and bind to specific RNA targets often through secondary structures, the exact number of nucleotides required for the optimal secondary structure for HuR binding is not specified as \"66-75 nucleotides\" universally. The length and structure for optimal binding can vary based on the RNA transcript in question.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the known functions of the prothymosin alpha c-terminal peptide are:\n1. Nuclear localization: Prothymosin alpha has been shown to localize to the nucleus in COS cells transfected with the human prothymosin alpha gene, as well as in constructs where the prothymosin alpha nucleic acid sequences were fused in-frame with either the amino or carboxyl terminus of the beta-galactosidase gene in COS cells.\n2. Nuclear targeting signal: The basic cluster of amino acids at the carboxyl terminus of prothymosin alpha, TKKQKT, has been identified as part of the nuclear targeting signal, which enables the protein to localize to the nucleus.\n3. Lack of amino-terminal signal peptide: Prothymosin alpha lacks an amino-terminal signal peptide, which was once thought to be a precursor for thymosin alpha 1, a putative peptide hormone secreted by the thymus.\nIn summary, the prothymosin alpha c-terminal peptide is primarily involved in nuclear localization and targeting, and does not appear to have any direct role in the production of thymosin alpha 1.",
    "llama-2-7b-chat-hf_fact_raw": "1. Prothymosin alpha localizes to the nucleus in COS cells transfected with the human prothymosin alpha gene.\n2. Constructs with prothymosin alpha nucleic acid sequences fused in-frame with beta-galactosidase gene also localize to the nucleus in COS cells.\n3. The amino acid sequence TKKQKT at the carboxyl terminus of prothymosin alpha is part of the nuclear targeting signal.\n4. Prothymosin alpha lacks an amino-terminal signal peptide.\n5. Prothymosin alpha, as suggested, does not play a direct role in the production of thymosin alpha 1.",
    "llama-2-7b-chat-hf_fact": [
      "Prothymosin alpha localizes to the nucleus in COS cells transfected with the human prothymosin alpha gene.",
      "Constructs with prothymosin alpha nucleic acid sequences fused in-frame with beta-galactosidase gene also localize to the nucleus in COS cells.",
      "The amino acid sequence TKKQKT at the carboxyl terminus of prothymosin alpha is part of the nuclear targeting signal.",
      "Prothymosin alpha lacks an amino-terminal signal peptide.",
      "Prothymosin alpha, as suggested, does not play a direct role in the production of thymosin alpha 1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: If the statement comes from a reliable source confirming an experiment, it is likely that prothymosin alpha does localize to the nucleus in COS cells transfected with the human prothymosin alpha gene.\n2. TRUE: This statement appears to be a factual representation of experimental results, in which constructs with prothymosin alpha nucleic acid sequences fused in-frame with beta-galactosidase also localize to the nucleus in COS cells.\n3. UNKNOWN: The detail regarding the amino acid sequence TKKQKT being part of the nuclear targeting signal is very specific and would require biochemical knowledge or research data to confirm or deny.\n4. UNKNOWN: The presence or absence of an amino-terminal signal peptide in prothymosin alpha is a specific biochemical detail that would need to be verified by scientific literature.\n5. UNKNOWN: Whether prothymosin alpha plays a direct role in the production of thymosin alpha 1 is something that would need to be confirmed with scientific studies. Without the context from specific research or literature, we cannot determine the truthfulness of this statement.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the peptide that plays a pivotal role in human cystatin C (HCC) fibrillization is (47)LQVVR(51). This peptide was identified as \"aggregation-prone\" using an algorithm developed in the lab, and was synthesized and self-assembled into amyloid-like fibrils in vitro. The results of electron microscopy, X-ray fiber diffraction, Attenuated Total Reflectance Fourier-Transform Spectroscopy, and Congo red staining studies confirm the importance of this peptide in HCC fibrillization. Therefore, the answer to the user's question is (47)LQVVR(51).",
    "llama-2-7b-chat-hf_fact_raw": "1. The peptide identified as pivotal in human cystatin C (HCC) fibrillization is (47)LQVVR(51).\n2. The peptide (47)LQVVR(51) was identified as \"aggregation-prone\" using an algorithm.\n3. The peptide (47)LQVVR(51) was synthesized and self-assembled into amyloid-like fibrils in vitro.\n4. Electron microscopy, X-ray fiber diffraction, Attenuated Total Reflectance Fourier-Transform Spectroscopy, and Congo red staining studies were used to confirm the importance of the peptide in HCC fibrillization.",
    "llama-2-7b-chat-hf_fact": [
      "The peptide identified as pivotal in human cystatin C (HCC) fibrillization is (47)LQVVR(51).",
      "The peptide (47)LQVVR(51) was identified as \"aggregation-prone\" using an algorithm.",
      "The peptide (47)LQVVR(51) was synthesized and self-assembled into amyloid-like fibrils in vitro.",
      "Electron microscopy, X-ray fiber diffraction, Attenuated Total Reflectance Fourier-Transform Spectroscopy, and Congo red staining studies were used to confirm the importance of the peptide in HCC fibrillization."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nThe available context does not provide enough specific information to confirm or correct the statements regarding the peptide (47)LQVVR(51) in human cystatin C (HCC) fibrillization. Without access to the relevant scientific literature or research findings, the veracity of these highly specialized statements remains unknown.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the answer to the user's question is: Yes, the concentration of protein HIF-1α does increase after the administration of the cytoprotective prodrug amifostine (ethyol).\nThe document states that amifostine (ethyol) induces HIF1 alpha accumulation in normal tissues, both in vitro and in vivo. In the in vitro experiments, incubation of cell lines with amifostine resulted in HIF1 alpha induction. Similarly, in vivo experiments with Wistar rats showed that administration of amifostine resulted in increased HIF1 alpha accumulation in normal tissues.\nTherefore, based on the information provided in the document, it can be concluded that the concentration of protein HIF-1α does increase after the administration of amifostine (ethyol), which suggests that this cytoprotective prodrug has additional cytoprotective pathways involving intracellular hypoxia and the activation of the HIF pathway.",
    "llama-2-7b-chat-hf_fact_raw": "1. The concentration of protein HIF-1α increases after administering the cytoprotective prodrug amifostine (ethyol).\n2. Amifostine (ethyol) induces HIF1 alpha accumulation in normal tissues both in vitro and in vivo.\n3. Incubation of cell lines with amifostine results in HIF1 alpha induction, as shown in in vitro experiments.\n4. In vivo experiments with Wistar rats demonstrated increased HIF1 alpha accumulation in normal tissues after administering amifostine.\n5. The increase in HIF-1α concentration suggests that amifostine has cytoprotective pathways involving intracellular hypoxia and the activation of the HIF pathway.",
    "llama-2-7b-chat-hf_fact": [
      "The concentration of protein HIF-1α increases after administering the cytoprotective prodrug amifostine (ethyol).",
      "Amifostine (ethyol) induces HIF1 alpha accumulation in normal tissues both in vitro and in vivo.",
      "Incubation of cell lines with amifostine results in HIF1 alpha induction, as shown in in vitro experiments.",
      "In vivo experiments with Wistar rats demonstrated increased HIF1 alpha accumulation in normal tissues after administering amifostine.",
      "The increase in HIF-1α concentration suggests that amifostine has cytoprotective pathways involving intracellular hypoxia and the activation of the HIF pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The increase in the concentration of protein HIF-1α after administering amifostine is a specific scientific claim that requires supporting research data to confirm. Without access to the relevant research studies or results, the truth of this statement cannot be determined.\n\n2. UNKNOWN: Similarly, the statement that amifostine induces HIF1 alpha accumulation in normal tissues both in vitro and in vivo is specific to scientific experimental outcomes. It would require access to particular study results to verify the truth of this claim.\n\n3. UNKNOWN: The induction of HIF1 alpha in cell lines with amifostine is another specific scientific outcome that relies on experimental data. Without evidence from the in vitro experiments, it's not possible to verify this claim.\n\n4. UNKNOWN: This statement regarding the results of in vivo experiments with Wistar rats is also specific and would require the relevant experimental data to confirm its truthfulness.\n\n5. UNKNOWN: The assertion about the linkage between the increase in HIF-1α concentration and amifostine’s cytoprotective pathways involves understanding complex biological mechanisms. Determining the truth of this statement requires in-depth knowledge of the specific scientific research findings, which are not available in the context provided.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, Set7 deposits histone H4 Lys 20 methylation, which is a mark of constitutive and facultative heterochromatin.",
    "llama-2-7b-chat-hf_fact_raw": "1. Set7 is responsible for depositing histone H4 Lys 20 methylation.\n2. Histone H4 Lys 20 methylation is a mark of constitutive heterochromatin.\n3. Histone H4 Lys 20 methylation is also a mark of facultative heterochromatin.",
    "llama-2-7b-chat-hf_fact": [
      "Set7 is responsible for depositing histone H4 Lys 20 methylation.",
      "Histone H4 Lys 20 methylation is a mark of constitutive heterochromatin.",
      "Histone H4 Lys 20 methylation is also a mark of facultative heterochromatin."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: SETD8 (also known as SET8/PR-Set7) is responsible for depositing histone H4 Lys 20 methylation.\n2. TRUE\n3. FALSE [correction]: Histone H4 Lys 20 methylation is generally associated with the repression of gene expression and has been linked to both constitutive and facultative heterochromatin; however, it is more commonly known as a hallmark for constitutive heterochromatin. Tri-methylation at this residue (H4K20me3) is particularly associated with constitutive heterochromatin, while mono-methylation (H4K20me1) has been linked to both euchromatin and heterochromatin, and the association with facultative heterochromatin is less well-established.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the protein hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein hepcidin has 4 disulfide bridges.",
    "llama-2-7b-chat-hf_fact": [
      "The protein hepcidin has 4 disulfide bridges."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The protein hepcidin typically has 8 cysteine residues that form 4 disulfide bridges.",
    "llama-2-7b-chat-hf_judge": [
      "false"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the localization of the protein encoded by the gene DNAJC11 (also known as DNAJC12 in the document) is primarily cytoplasmic. The document states that the recombinant DNAJC12 protein is diffusely distributed in the cytoplasm of LNCaP prostate cancer cells, and immunofluorescence studies showed that the protein is present throughout the cytoplasm. Additionally, the document mentions that DNAJC12 interacts with Hsc70, a cognate Hsp70 chaperone, in unstressed cells, and that in stressed cells, the ER chaperone BiP is frequently associated with DNAJC12. These findings suggest that DNAJC12 is primarily localized in the cytoplasm, where it may play a role in regulating the function of Hsp70 and other nucleotide-binding proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein encoded by the gene DNAJC11 is primarily cytoplasmic in localization.\n2. Recombinant DNAJC12 protein is distributed throughout the cytoplasm in LNCaP prostate cancer cells.\n3. Immunofluorescence studies have shown the presence of DNAJC12 protein throughout the cytoplasm.\n4. DNAJC12 is known to interact with the chaperone Hsc70 in unstressed cells.\n5. During cellular stress, the ER chaperone BiP is often associated with DNAJC12.",
    "llama-2-7b-chat-hf_fact": [
      "The protein encoded by the gene DNAJC11 is primarily cytoplasmic in localization.",
      "Recombinant DNAJC12 protein is distributed throughout the cytoplasm in LNCaP prostate cancer cells.",
      "Immunofluorescence studies have shown the presence of DNAJC12 protein throughout the cytoplasm.",
      "DNAJC12 is known to interact with the chaperone Hsc70 in unstressed cells.",
      "During cellular stress, the ER chaperone BiP is often associated with DNAJC12."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided require specific scientific knowledge and data that was not given in the context of the statements. Without access to the relevant scientific studies or literature, it is not possible to verify the accuracy of these statements about the DNAJC11 and DNAJC12 proteins, their localization, or their interactions with other proteins like Hsc70 or BiP.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the answer to the user's question is: Yes, ultraconserved elements are depleted among copy number variants (CNVs).\nThe document states that ultraconserved elements are strongly depleted from segmental duplications and copy number variations in the human genome, suggesting that deletion or duplication of a UCE can be deleterious to the mammalian cell. Additionally, the document finds that even newly formed de novo CNVs are significantly depleted for UCEs, indicating that the depletion of UCEs is not limited to CNVs that have passed through meiosis.\nHowever, the document also notes that CNVs arising specifically in cancer cells are not depleted for UCEs and can even become significantly enriched, which raises the possibility that CNVs that arise somatically and are relatively newly formed are less likely to have established a CNV profile that is depleted for UCEs. Alternatively, the lack of depletion for UCEs from cancer CNVs may reflect the diseased state.\nOverall, the document provides evidence that ultraconserved elements are depleted among copy number variants in the human genome, although the mechanisms underlying this depletion may vary depending on the context in which the CNVs arise.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ultraconserved elements are strongly depleted from segmental duplications and copy number variations in the human genome.\n2. Deletion or duplication of an ultraconserved element can be deleterious to the mammalian cell.\n3. Newly formed de novo copy number variants are significantly depleted for ultraconserved elements.\n4. Copy number variants arising in cancer cells are not depleted for ultraconserved elements.\n5. CNVs that arise somatically may be less likely to show depletion of ultraconserved elements.",
    "llama-2-7b-chat-hf_fact": [
      "Ultraconserved elements are strongly depleted from segmental duplications and copy number variations in the human genome.",
      "Deletion or duplication of an ultraconserved element can be deleterious to the mammalian cell.",
      "Newly formed de novo copy number variants are significantly depleted for ultraconserved elements.",
      "Copy number variants arising in cancer cells are not depleted for ultraconserved elements.",
      "CNVs that arise somatically may be less likely to show depletion of ultraconserved elements."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE - Ultraconserved elements are regions of the genome that are highly conserved across different species and are typically depleted from segmental duplications and copy number variations, as having such elements altered can be detrimental to the organism.\n2. TRUE - Given the high level of conservation, it implies that there is strong evolutionary pressure to maintain these sequences, suggesting that their deletion or duplication could be harmful.\n3. TRUE - It is consistent with the notion that de novo copy number variants, which occur new in an individual without being inherited, are also selected against if they affect these ultraconserved elements.\n4. FALSE [correction]: Copy number variants arising in cancer cells may indeed show depletion for ultraconserved elements, as sustaining such mutations without significant consequences may contribute to the abnormal growth characteristics of cancer.\n5. TRUE - Somatic CNVs, which occur in non-germline cells and are not passed on to offspring, may not be under the same evolutionary pressures as inherited CNVs, and hence they may be less likely to show depletion of ultraconserved elements.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the substrate of the Haspin kinase during mitosis is histone H3. The document mentions that Haspin phosphorylates the Thr3 residue of histone H3, indicating that histone H3 is the substrate of Haspin during mitosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. The substrate of the Haspin kinase during mitosis is histone H3.\n2. Haspin kinase phosphorylates the Thr3 residue of histone H3.",
    "llama-2-7b-chat-hf_fact": [
      "The substrate of the Haspin kinase during mitosis is histone H3.",
      "Haspin kinase phosphorylates the Thr3 residue of histone H3."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the mechanism of viroid replication is through a rolling circle mechanism that is exclusively RNA-dependent. This means that viroids replicate by circularizing their RNA molecules and then using the circularized molecule as a template for new RNA synthesis. The replication initiation sites of viroids, such as the A50/C51 site in peach latent mosaic viroid (PLMVd), are identified through the use of in vitro selection procedures and the analysis of conserved sequence elements. In the case of PLMVd, a highly conserved CAGACG box is found in the vicinity of the initiation sites, which contributes to delineating the initiation site and provides an explanation for the presence of a specific universal initiation site on the PLMVd molecule.",
    "llama-2-7b-chat-hf_fact_raw": "1. Viroid replication occurs through a rolling circle mechanism that is RNA-dependent.\n2. Viroids replicate by circularizing their RNA molecules and using them as templates for new RNA synthesis.\n3. Replication initiation sites of viroids can be identified through in vitro selection procedures and the analysis of conserved sequence elements.\n4. The A50/C51 site in peach latent mosaic viroid (PLMVd) is an example of a replication initiation site.\n5. A highly conserved CAGACG box is found in the vicinity of replication initiation sites in PLMVd.",
    "llama-2-7b-chat-hf_fact": [
      "Viroid replication occurs through a rolling circle mechanism that is RNA-dependent.",
      "Viroids replicate by circularizing their RNA molecules and using them as templates for new RNA synthesis.",
      "Replication initiation sites of viroids can be identified through in vitro selection procedures and the analysis of conserved sequence elements.",
      "The A50/C51 site in peach latent mosaic viroid (PLMVd) is an example of a replication initiation site.",
      "A highly conserved CAGACG box is found in the vicinity of replication initiation sites in PLMVd."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The A50/G51 site, not the A50/C51 site, in peach latent mosaic viroid (PLMVd) is an example of a replication initiation site.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, fibronectin does constitute a serum biomarker for Duchenne muscular dystrophy (DMD). The study found a significant increase in fibronectin levels in DMD patients compared to age-matched controls, and a progressive elevation in fibronectin levels was observed in longitudinal samples from 22 DMD patients followed up for a period of 6 months up to 4 years. These findings suggest that fibronectin may be a useful biomarker to monitor disease progression in DMD patients.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fibronectin is considered a serum biomarker for Duchenne muscular dystrophy (DMD).\n2. A study found increased levels of fibronectin in DMD patients compared to age-matched controls.\n3. A progressive elevation in fibronectin levels was observed in longitudinal samples from DMD patients.\n4. The longitudinal study on DMD patients was conducted over a period of 6 months to 4 years.",
    "llama-2-7b-chat-hf_fact": [
      "Fibronectin is considered a serum biomarker for Duchenne muscular dystrophy (DMD).",
      "A study found increased levels of fibronectin in DMD patients compared to age-matched controls.",
      "A progressive elevation in fibronectin levels was observed in longitudinal samples from DMD patients.",
      "The longitudinal study on DMD patients was conducted over a period of 6 months to 4 years."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the passage, the DeepBlue epigenomic data server contains data from the following four major epigenome projects:\n1. ENCODE (Encyclopedia of DNA Elements)\n2. ROADMAP (Roadmap Epigenomics Consortium)\n3. BLUEPRINT (Blueprint Epigenomics Project)\n4. DEEP (Deep Epigenomics Project)\nTherefore, the answer to the user's question is: The DeepBlue epigenomic data server contains data from four major epigenome projects, namely ENCODE, ROADMAP, BLUEPRINT, and DEEP.",
    "llama-2-7b-chat-hf_fact_raw": "1. The DeepBlue epigenomic data server contains data from the ENCODE project.\n2. The ROADMAP project data is included in the DeepBlue epigenomic data server.\n3. The BLUEPRINT project is one of the major epigenome projects whose data is stored in the DeepBlue epigenomic data server.\n4. Data from the DEEP project can be found within the DeepBlue epigenomic data server.\n5. There are data from four major epigenome projects contained in the DeepBlue epigenomic data server.",
    "llama-2-7b-chat-hf_fact": [
      "The DeepBlue epigenomic data server contains data from the ENCODE project.",
      "The ROADMAP project data is included in the DeepBlue epigenomic data server.",
      "The BLUEPRINT project is one of the major epigenome projects whose data is stored in the DeepBlue epigenomic data server.",
      "Data from the DEEP project can be found within the DeepBlue epigenomic data server.",
      "There are data from four major epigenome projects contained in the DeepBlue epigenomic data server."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN (Without the specific names of all four major epigenome projects, it is not possible to verify the statement as true or false)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the tool that employs self-organizing maps for analyzing synonymous codon usage is the \"Charif04\" tool available through the Pole Bioinformatique Lyonnais (PBIL) Web server. The tool uses within-group correspondence analysis to cope with the problem of variability in amino acid composition between proteins when analyzing synonymous codon usage variability. The tool is user-friendly and available for genomic studies, and the underlying software is distributed under a GPL licence.",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"Charif04\" tool uses self-organizing maps for analyzing synonymous codon usage.\n2. The \"Charif04\" tool is available through the Pole Bioinformatique Lyonnais (PBIL) Web server.\n3. The tool employs within-group correspondence analysis to address variability in amino acid composition between proteins.\n4. The \"Charif04\" tool is designed for use in genomic studies.\n5. The underlying software of the \"Charif04\" tool is distributed under a GPL licence.",
    "llama-2-7b-chat-hf_fact": [
      "The \"Charif04\" tool uses self-organizing maps for analyzing synonymous codon usage.",
      "The \"Charif04\" tool is available through the Pole Bioinformatique Lyonnais (PBIL) Web server.",
      "The tool employs within-group correspondence analysis to address variability in amino acid composition between proteins.",
      "The \"Charif04\" tool is designed for use in genomic studies.",
      "The underlying software of the \"Charif04\" tool is distributed under a GPL licence."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE - Based on the context that \"Charif04\" is a tool related to codon usage, it can be inferred that it is likely designed for use in genomic studies, as synonymous codon usage analysis is relevant in this field.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, MINDY-1 appears to be a gene that plays a crucial role in regulating energy metabolism and mitochondrial function in mammals. The document mentions that the knockout mouse model of the mammalian Indy (mIndy) homolog, SLC13A5, reduces hepatocellular ATP/ADP ratio, activates hepatic AMPK, induces PGC-1, inhibits ACC-2, and reduces SREBP-1c levels. These changes in cellular signaling promote hepatic mitochondrial biogenesis, lipid oxidation, and energy expenditure, and attenuate hepatic de novo lipogenesis. The document suggests that these traits protect mINDY(-/-) mice from the adiposity and insulin resistance that evolve with high-fat feeding and aging, and implies that mIndy may be a therapeutic target for the treatment of obesity and type 2 diabetes. Therefore, MINDY-1 can be inferred to be a gene that plays a critical role in regulating energy metabolism and mitochondrial function in mammals, and may have potential as a therapeutic target for metabolic disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. MINDY-1 is a gene associated with the regulation of energy metabolism and mitochondrial function in mammals.\n2. Knockout of the SLC13A5 gene (mIndy homolog) in mice leads to reduced hepatocellular ATP/ADP ratio.\n3. Knockout of the SLC13A5 gene results in activation of hepatic AMPK and induction of PGC-1 in mice.\n4. Knockout of the SLC13A5 gene inhibits ACC-2 and reduces SREBP-1c levels in mice.\n5. MINDY-1 may serve as a therapeutic target for the treatment of obesity and type 2 diabetes.",
    "llama-2-7b-chat-hf_fact": [
      "MINDY-1 is a gene associated with the regulation of energy metabolism and mitochondrial function in mammals.",
      "Knockout of the SLC13A5 gene (mIndy homolog) in mice leads to reduced hepatocellular ATP/ADP ratio.",
      "Knockout of the SLC13A5 gene results in activation of hepatic AMPK and induction of PGC-1 in mice.",
      "Knockout of the SLC13A5 gene inhibits ACC-2 and reduces SREBP-1c levels in mice.",
      "MINDY-1 may serve as a therapeutic target for the treatment of obesity and type 2 diabetes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nPlease note that while these statements all appear to relate to scientific findings that are feasible, as an AI, I cannot access the latest literature to confirm the current state of research on the gene mentioned. The answers provided are based on common scientific knowledge up until my last update. For the most accurate and up-to-date information, please refer to the latest scientific research on this gene and its effects.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the software package available for the analysis of conserved genomic loci is Mega. Mega is a sophisticated software package that contains many tools and methods for phylogenomics and phylomedicine, including the ability to analyze tens of thousands of sequences, build timetrees, and predict gene duplication events in gene family trees. The software is available in two interfaces: a graphical user interface (GUI) for Windows, Mac OS X, and Linux, and a command line interface for high-throughput and scripted analysis. Both versions are available for free download from the Mega software website.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mega is a software package used for the analysis of conserved genomic loci.\n2. Mega contains tools and methods for phylogenomics and phylomedicine.\n3. The software can analyze tens of thousands of sequences and build timetrees.\n4. Mega provides a graphical user interface (GUI) for Windows, Mac OS X, and Linux.\n5. The software has a command line interface available for high-throughput and scripted analysis.",
    "llama-2-7b-chat-hf_fact": [
      "Mega is a software package used for the analysis of conserved genomic loci.",
      "Mega contains tools and methods for phylogenomics and phylomedicine.",
      "The software can analyze tens of thousands of sequences and build timetrees.",
      "Mega provides a graphical user interface (GUI) for Windows, Mac OS X, and Linux.",
      "The software has a command line interface available for high-throughput and scripted analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MEGA (Molecular Evolutionary Genetics Analysis) is a software package used for the analysis of molecular evolutionary genetics data, not specifically for conserved genomic loci.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: MEGA provides a graphical user interface (GUI) primarily for Windows. There is no native GUI for Mac OS X or Linux, although it can be run on these systems using compatibility layers or virtual machines.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the three diseases associated with the PIEZO2 gene are:\n1. Dominant distal arthrogryposis 3 (DA3)\n2. Dominant distal arthrogryposis 5 (DA5)\n3. Marden-Walker syndrome (MWKS)\nThese diseases are caused by mutations in the PIEZO2 gene, which leads to nonsense-mediated transcript decay and lack of PIEZO2 protein. Heterozygous gain-of-function missense mutations in the C terminus of the gene can cause these diseases, which are characterized by contractures of hands and feet, scoliosis, ophthalmoplegia, and ptosis. The PIEZO2 gene encodes a mechanosensitive ion channel that plays a major role in light-touch mechanosensation and has been identified as the principal mechanotransduction channel for proprioception.",
    "llama-2-7b-chat-hf_fact_raw": "1. Dominant distal arthrogryposis 3 (DA3) is a disease associated with the PIEZO2 gene.\n2. Dominant distal arthrogryposis 5 (DA5) is a disease associated with the PIEZO2 gene.\n3. Marden-Walker syndrome (MWKS) is a disease associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_fact": [
      "Dominant distal arthrogryposis 3 (DA3) is a disease associated with the PIEZO2 gene.",
      "Dominant distal arthrogryposis 5 (DA5) is a disease associated with the PIEZO2 gene.",
      "Marden-Walker syndrome (MWKS) is a disease associated with the PIEZO2 gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Dominant distal arthrogryposis 5 (DA5) is associated with the ECEL1 gene, not the PIEZO2 gene.\n3. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, ERAP1-ERAP2 dimerization promotes the production of mature epitopes presented by MHC class I molecules. The study found that stabilized ERAP1-ERAP2 heterodimers produced several mature epitopes more efficiently than a mix of the two enzymes unable to dimerize. This suggests that the physical interaction between ERAP1 and ERAP2 changes basic enzymatic parameters of ERAP1, improving its substrate-binding affinity, and creating complexes with superior peptide-trimming efficacy. These complexes are likely to enhance Ag presentation by cells displaying coordinated expression of the two enzymes.",
    "llama-2-7b-chat-hf_fact_raw": "1. ERAP1-ERAP2 dimerization promotes the production of mature epitopes presented by MHC class I molecules.\n2. Stabilized ERAP1-ERAP2 heterodimers produce mature epitopes more efficiently than a mix of the two enzymes that cannot dimerize.\n3. The physical interaction between ERAP1 and ERAP2 improves the substrate-binding affinity of ERAP1.\n4. ERAP1-ERAP2 complexes have superior peptide-trimming efficacy.\n5. Cells displaying coordinated expression of ERAP1 and ERAP2 are likely to enhance antigen (Ag) presentation.",
    "llama-2-7b-chat-hf_fact": [
      "ERAP1-ERAP2 dimerization promotes the production of mature epitopes presented by MHC class I molecules.",
      "Stabilized ERAP1-ERAP2 heterodimers produce mature epitopes more efficiently than a mix of the two enzymes that cannot dimerize.",
      "The physical interaction between ERAP1 and ERAP2 improves the substrate-binding affinity of ERAP1.",
      "ERAP1-ERAP2 complexes have superior peptide-trimming efficacy.",
      "Cells displaying coordinated expression of ERAP1 and ERAP2 are likely to enhance antigen (Ag) presentation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided pertain to specific biochemical interactions and processes involving ERAP1 and ERAP2 – enzymes that are important in antigen processing for presentation by MHC class I molecules. They refer to the potential effects of dimerization and interaction between ERAP1 and ERAP2 on the production of epitopes for immune recognition. These are specialized knowledge statements that require expertise in immunology or a review of scientific literature for verification. Without access to the relevant and specific scientific research or data, the truth value of these statements cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, R-spondin 1 and noggin are likely involved in the regulation of gallbladder mucus release in non-damaged gallbladders. The study suggests that glycoproteins, including R-spondin 1 and noggin, play a role in the pathogenesis of gallstone formation by regulating the release of mucus from the gallbladder epithelium.\nProstaglandin E2 (PGE2) was found to reduce the relative volume of glycoprotein granules in the principal cells of the mouse gallbladder epithelium within 20 minutes of injection into the gallbladder lumen. This suggests that PGE2 may be involved in the regulation of mucus release from the gallbladder epithelium, and that R-spondin 1 and noggin may play a role in this process.\nIt is worth noting that the study did not directly investigate the function of R-spondin 1 and noggin in gallbladder mucus release, but rather demonstrated that PGE2 regulates this process. However, given the role of R-spondin 1 and noggin in the regulation of cellular processes, including cell adhesion and signaling, it is likely that they play a role in the regulation of gallbladder mucus release as well.\nIn summary, based on the information provided, R-spondin 1 and noggin are likely involved in the regulation of gallbladder mucus release in non-damaged gallbladders, and may play a role in the pathogenesis of gallstone formation by regulating the release of mucus from the gallbladder epithelium.",
    "llama-2-7b-chat-hf_fact_raw": "1. R-spondin 1 and noggin are likely involved in the regulation of gallbladder mucus release in non-damaged gallbladders.\n2. R-spondin 1 and noggin may play a role in the pathogenesis of gallstone formation.\n3. Prostaglandin E2 (PGE2) was found to reduce the relative volume of glycoprotein granules in the principal cells of the mouse gallbladder epithelium within 20 minutes of injection.\n4. PGE2 is suggested to be involved in the regulation of mucus release from the gallbladder epithelium.\n5. The study indicated a possibility that R-spondin 1 and noggin contribute to the regulation of gallbladder mucus release despite not directly investigating their function in this process.",
    "llama-2-7b-chat-hf_fact": [
      "R-spondin 1 and noggin are likely involved in the regulation of gallbladder mucus release in non-damaged gallbladders.",
      "R-spondin 1 and noggin may play a role in the pathogenesis of gallstone formation.",
      "Prostaglandin E2 (PGE2) was found to reduce the relative volume of glycoprotein granules in the principal cells of the mouse gallbladder epithelium within 20 minutes of injection.",
      "PGE2 is suggested to be involved in the regulation of mucus release from the gallbladder epithelium.",
      "The study indicated a possibility that R-spondin 1 and noggin contribute to the regulation of gallbladder mucus release despite not directly investigating their function in this process."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without direct evidence or a specific passage stating the roles of R-spondin 1 and noggin in the regulation of gallbladder mucus release, it's difficult to determine the truth value of this statement.\n2. UNKNOWN: Similar to statement 1, the role of R-spondin 1 and noggin in the pathogenesis of gallstone formation would require specific evidence or studies, which are not provided.\n3. UNKNOWN: The effect of Prostaglandin E2 (PGE2) on the relative volume of glycoprotein granules in the mouse gallbladder epithelium would need to be supported by a specific study or experimental results, which are not mentioned here.\n4. UNKNOWN: The involvement of PGE2 in the regulation of mucus release from the gallbladder epithelium is another statement that would need specific scientific evidence or a citation to confirm its veracity.\n5. UNKNOWN: While this statement suggests a possibility, without the actual study or further context, it is not possible to verify the accuracy of the claim that R-spondin 1 and noggin may contribute to the regulation of gallbladder mucus release. \n\nNote: The context given does not provide enough information to confidently assess the true or false nature of these biological claims. Typically, such assertions would need to be checked against scientific literature or experimental findings.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it appears that NADPH oxidase 5 does require a subunit for its function. The document mentions the presence of a large subunit (beta) of cytochrome b558, which is identified as the subunit that is involved in the NADPH dehydrogenase function of the neutrophil oxidase complex. The document also shows that the photolabeled protein band of 80-100 kDa, which corresponds to the large subunit (beta) of cytochrome b558, is fully inactivated upon photolabeling, indicating that this subunit is essential for the enzyme's function.\nTherefore, the answer to the user's question is yes, NADPH oxidase 5 does require a subunit for its function.",
    "llama-2-7b-chat-hf_fact_raw": "1. NADPH oxidase 5 requires a subunit for its function.\n2. The large subunit (beta) of cytochrome b558 is involved in the NADPH dehydrogenase function of the neutrophil oxidase complex.\n3. Cytochrome b558's large subunit is essential for the enzyme's function.\n4. The photolabeled protein band of 80-100 kDa corresponds to the large subunit (beta) of cytochrome b558.\n5. Photolabeling fully inactivates the 80-100 kDa protein band, indicating its necessity for the enzyme's activity.",
    "llama-2-7b-chat-hf_fact": [
      "NADPH oxidase 5 requires a subunit for its function.",
      "The large subunit (beta) of cytochrome b558 is involved in the NADPH dehydrogenase function of the neutrophil oxidase complex.",
      "Cytochrome b558's large subunit is essential for the enzyme's function.",
      "The photolabeled protein band of 80-100 kDa corresponds to the large subunit (beta) of cytochrome b558.",
      "Photolabeling fully inactivates the 80-100 kDa protein band, indicating its necessity for the enzyme's activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nThe first three statements deal with well-established knowledge about NADPH oxidase and cytochrome b558, components of the neutrophil oxidase complex. However, the last two statements about the photolabeled protein band and its relationship to inactivation require specific experimental data that is not provided, therefore their veracity cannot be determined without additional context.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there is a clear connection between furin and hepcidin. Hepcidin is an 84 amino acid prepropeptide that contains a typical N-terminal endoplasmic reticulum targeting signal sequence and a 35 amino acid proregion (pro) with a consensus furin cleavage site. The document states that the hepatic prohormone convertase furin mediates the posttranslational processing of hepcidin, specifically the proteolytic cleavage of prohepcidin to hepcidin.\nIn the absence of furin inhibitors or furin siRNA, hepcidin is found to be processed in less than 1 hour and secreted as a 3 kDa form reactive with anti-mature but not anti-pro antibody. However, in the presence of furin inhibitors or furin siRNA, a 6 kDa form reactive with both anti-pro and anti-mature antibody is rapidly secreted into the medium. This suggests that furin plays a crucial role in the processing of hepcidin and that its activity is necessary for the proper secretion of the hormone.\nFurthermore, the document states that the proteolytic cleavage of prohepcidin to hepcidin is not regulated by iron-transferrin or the HIF pathway. This suggests that the processing of hepcidin by furin is independent of other factors and is a unique process.\nIn conclusion, the information provided suggests that furin plays a crucial role in the posttranslational processing of hepcidin, and that its activity is necessary for the proper secretion of the hormone.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hepcidin is an 84 amino acid prepropeptide.\n2. Hepcidin contains a consensus furin cleavage site within its 35 amino acid proregion.\n3. The hepatic prohormone convertase furin mediates the proteolytic cleavage of prohepcidin to hepcidin.\n4. In the absence of furin inhibitors or furin siRNA, hepcidin is processed in less than 1 hour and secreted as a 3 kDa form.\n5. In the presence of furin inhibitors or furin siRNA, a 6 kDa form of hepcidin is secreted into the medium.",
    "llama-2-7b-chat-hf_fact": [
      "Hepcidin is an 84 amino acid prepropeptide.",
      "Hepcidin contains a consensus furin cleavage site within its 35 amino acid proregion.",
      "The hepatic prohormone convertase furin mediates the proteolytic cleavage of prohepcidin to hepcidin.",
      "In the absence of furin inhibitors or furin siRNA, hepcidin is processed in less than 1 hour and secreted as a 3 kDa form.",
      "In the presence of furin inhibitors or furin siRNA, a 6 kDa form of hepcidin is secreted into the medium."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Hepcidin is typically described as a peptide hormone consisting of 25 amino acids, not 84. The 84 amino acid sequence is the prepropeptide form, which includes the signal sequence and propeptide that are cleaved to produce the active form of hepcidin.\n2. TRUE\n3. TRUE: Furin is known to cleave proproteins at specific sites, including the conversion of prohepcidin to hepcidin.\n4. UNKNOWN: The time required for hepcidin processing and the exact size of the secreted form after cleavage can vary based on experimental conditions and measurement techniques. The statement provides specific details that would require experimental data to validate.\n5. UNKNOWN: It is known that furin inhibitors or RNA interference can affect the processing of proproteins like hepcidin, resulting in larger, unprocessed forms. However, the exact size of the secreted hepcidin in the presence of these inhibitors would require specific data from experimental results to confirm.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the largest metabolic gene cluster in yeast is the GAL (Glycolysis and Gluconeogenesis) gene cluster.",
    "llama-2-7b-chat-hf_fact_raw": "1. The largest metabolic gene cluster in yeast is known as the GAL gene cluster.\n2. The GAL gene cluster is associated with Glycolysis and Gluconeogenesis.",
    "llama-2-7b-chat-hf_fact": [
      "The largest metabolic gene cluster in yeast is known as the GAL gene cluster.",
      "The GAL gene cluster is associated with Glycolysis and Gluconeogenesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The GAL gene cluster is associated with the uptake and metabolism of galactose, not directly with Glycolysis and Gluconeogenesis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the role of the lncRNA LIMT (LncRNA Inhibiting Metastasis) is to inhibit extracellular matrix invasion of mammary cells in vitro and tumor metastasis in vivo. The study found that LIMT is downregulated in basal-like and HER2-positive tumors, and low expression of LIMT predicts poor patient prognosis. Additionally, the study found that EGF (Epidermal Growth Factor) rapidly downregulates LIMT expression by enhancing histone deacetylation at the respective promoter. These findings suggest that LIMT plays a role in regulating the aggressiveness of basal-like tumors and may serve as a prognostic biomarker for cancer progression.",
    "llama-2-7b-chat-hf_fact_raw": "1. LncRNA LIMT (LncRNA Inhibiting Metastasis) inhibits extracellular matrix invasion of mammary cells in vitro.\n2. LIMT lncRNA inhibits tumor metastasis in vivo.\n3. LIMT is downregulated in basal-like and HER2-positive tumors.\n4. Low expression of LIMT predicts poor patient prognosis.\n5. EGF (Epidermal Growth Factor) downregulates LIMT expression by enhancing histone deacetylation at the respective promoter.",
    "llama-2-7b-chat-hf_fact": [
      "LncRNA LIMT (LncRNA Inhibiting Metastasis) inhibits extracellular matrix invasion of mammary cells in vitro.",
      "LIMT lncRNA inhibits tumor metastasis in vivo.",
      "LIMT is downregulated in basal-like and HER2-positive tumors.",
      "Low expression of LIMT predicts poor patient prognosis.",
      "EGF (Epidermal Growth Factor) downregulates LIMT expression by enhancing histone deacetylation at the respective promoter."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: EGF (Epidermal Growth Factor) upregulates LIMT expression by enhancing histone acetylation at the respective promoter.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the R/Bioconductor package used for performing SNP enrichment analysis is TEQC.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the key players in radial glial specification to ependymal cells are:\n1. Radial glial cells: These are neurogenic precursors that are acutely stimulated by stroke to proliferate and differentiate into ependymal cells.\n2. Adult ependymal cells: These are postmitotic and highly differentiated cells that are stimulated to proliferate after stroke.\n3. Neural progenitors: These are cells that are found in the subventricular zone (SVZ) and are increased in number after stroke.\n4. Neurons: These are the cells that are generated from the radial glial cells after stroke, and they migrate towards the ischemic boundary region.\nIn summary, the key players in radial glial specification to ependymal cells are the cells that are involved in the process of proliferation, differentiation, and migration after stroke. These cells include radial glial cells, adult ependymal cells, neural progenitors, and neurons.",
    "llama-2-7b-chat-hf_fact_raw": "1. Radial glial cells can proliferate and differentiate into ependymal cells after a stroke.\n2. Adult ependymal cells can be stimulated to proliferate following a stroke.\n3. After a stroke, the number of neural progenitors in the subventricular zone (SVZ) increases.\n4. Neurons generated from radial glial cells migrate towards the ischemic boundary region after a stroke.",
    "llama-2-7b-chat-hf_fact": [
      "Radial glial cells can proliferate and differentiate into ependymal cells after a stroke.",
      "Adult ependymal cells can be stimulated to proliferate following a stroke.",
      "After a stroke, the number of neural progenitors in the subventricular zone (SVZ) increases.",
      "Neurons generated from radial glial cells migrate towards the ischemic boundary region after a stroke."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Radial glial cells have the ability to proliferate and differentiate into various types of cells, including ependymal cells, especially during brain development or after injury such as a stroke.\n2. TRUE: Adult ependymal cells can be stimulated to proliferate following injury to the central nervous system, including a stroke.\n3. TRUE: After a stroke, the subventricular zone (SVZ) is known to increase the production of neural progenitor cells, which can lead to an increased number of these cells.\n4. TRUE: In response to a stroke, neurons generated from radial glial cells or other neural progenitors in the SVZ can migrate towards the ischemic boundary region to attempt to replace lost or damaged neurons.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the article, triple negative gliomas are characterized by the following features on DCE MR images:\n1. Higher ADC (apparent diffusion coefficient) values: Triple negative gliomas have higher ADC values compared to other types of breast cancer, indicating a more rapid diffusion of contrast agent.\n2. Lower T1 and T2 values: Triple negative gliomas have lower T1 and T2 values, indicating a higher signal intensity on T1- and T2-weighted images.\n3. Higher lesion contrast: Triple negative gliomas have higher lesion contrast on DCE MR images, indicating a more prominent enhancement pattern.\n4. Irregular shape: Triple negative gliomas often have irregular shapes, which can make them difficult to distinguish from benign fibroadenomas.\nThese features can be used to differentiate triple negative gliomas from other types of breast cancer and benign lesions using a computer-aided diagnosis (CAD) system. The article reports an area under the receiver operating characteristic curve (Az) of 0.73 for the classification of triple-negative cancer versus all non-triple-negative lesions, indicating moderate accuracy in the classification.",
    "llama-2-7b-chat-hf_fact_raw": "1. Triple negative gliomas have higher apparent diffusion coefficient (ADC) values compared to other types of breast cancer.\n2. Triple negative gliomas have lower T1 and T2 values than other types.\n3. Triple negative gliomas have higher lesion contrast on DCE MR images.\n4. Triple negative gliomas often have an irregular shape.\n5. An area under the receiver operating characteristic curve (Az) of 0.73 was reported for the classification of triple-negative cancer versus all non-triple-negative lesions, indicating moderate accuracy.",
    "llama-2-7b-chat-hf_fact": [
      "Triple negative gliomas have higher apparent diffusion coefficient (ADC) values compared to other types of breast cancer.",
      "Triple negative gliomas have lower T1 and T2 values than other types.",
      "Triple negative gliomas have higher lesion contrast on DCE MR images.",
      "Triple negative gliomas often have an irregular shape.",
      "An area under the receiver operating characteristic curve (Az) of 0.73 was reported for the classification of triple-negative cancer versus all non-triple-negative lesions, indicating moderate accuracy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gliomas are a type of brain cancer, not breast cancer. Therefore, the statement is false as it incorrectly refers to breast cancer. \n2. UNKNOWN: Without specific data or context, it's difficult to confirm the accuracy of this statement regarding T1 and T2 values for triple negative gliomas compared to other types.\n3. UNKNOWN: Whether triple negative gliomas have higher lesion contrast on DCE MR images requires specific medical imaging data which is not provided.\n4. TRUE: Gliomas, including triple negative ones, can often present with irregular shapes on imaging modalities.\n5. UNKNOWN: Without access to the study or data that reported this, the specificity of the information provided makes it difficult to validate the accuracy of the AUC (area under the curve) for classifying triple-negative cancer.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, TOPAZ1 appears to be a device or unit designed for cleaning immunological plates. The technical parameters of the unit are stated in Document-0, which includes information on the cleaning device, discharge block, cleaning solution vessel, and wasted liquid collector. It is likely that TOPAZ1 is a specialized tool used in laboratory settings for cleaning and maintaining immunological plates.",
    "llama-2-7b-chat-hf_fact_raw": "1. TOPAZ1 is a device or unit designed for cleaning immunological plates.\n2. Technical parameters of TOPAZ1 are detailed in Document-0.\n3. The device includes a cleaning device, discharge block, cleaning solution vessel, and wasted liquid collector.\n4. TOPAZ1 is likely used in laboratory settings.",
    "llama-2-7b-chat-hf_fact": [
      "TOPAZ1 is a device or unit designed for cleaning immunological plates.",
      "Technical parameters of TOPAZ1 are detailed in Document-0.",
      "The device includes a cleaning device, discharge block, cleaning solution vessel, and wasted liquid collector.",
      "TOPAZ1 is likely used in laboratory settings."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the gene that controls the expression of GATA-1 isoforms is FOG-1. The document states that FOG-1 physically interacts with GATA-1 and regulates its activity, but the mechanisms by which FOG-1 regulates GATA-1 function are unknown. The document also shows that a conditional form of GATA-1 (GATA-1-ER) strongly induces histone acetylation at the beta-major globin promoter in vivo, while a mutant form of GATA-1 (GATA-1(V205M)-ER) fails to do so. Additionally, the document finds that the interaction with FOG-1 is required for GATA-1 occupancy at select sites, such as HS2, but is dispensable at others, including the FOG-1-independent GATA-1 target gene EKLF. These findings suggest that FOG-1 plays a crucial role in regulating the expression of GATA-1 isoforms.",
    "llama-2-7b-chat-hf_fact_raw": "1. The gene FOG-1 controls the expression of GATA-1 isoforms.\n2. FOG-1 physically interacts with GATA-1 and regulates its activity.\n3. The mechanisms by which FOG-1 regulates GATA-1 function are unknown.\n4. A conditional form of GATA-1 (GATA-1-ER) induces histone acetylation at the beta-major globin promoter in vivo.\n5. The interaction with FOG-1 is necessary for GATA-1 occupancy at certain sites, including HS2.",
    "llama-2-7b-chat-hf_fact": [
      "The gene FOG-1 controls the expression of GATA-1 isoforms.",
      "FOG-1 physically interacts with GATA-1 and regulates its activity.",
      "The mechanisms by which FOG-1 regulates GATA-1 function are unknown.",
      "A conditional form of GATA-1 (GATA-1-ER) induces histone acetylation at the beta-major globin promoter in vivo.",
      "The interaction with FOG-1 is necessary for GATA-1 occupancy at certain sites, including HS2."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The gene FOG-1 (Friend of GATA-1) is known to control the expression of GATA-1 isoforms.\n2. TRUE: FOG-1 does physically interact with GATA-1 and regulates its activity. This is a well-described relationship in molecular biology.\n3. FALSE [correction]: While the mechanisms are complex and research is ongoing, it is not true that the mechanisms by which FOG-1 regulates GATA-1 function are completely unknown. There has been considerable research detailing the interactions between FOG-1 and GATA-1 and their roles in hematopoiesis.\n4. UNKNOWN: The statement about GATA-1-ER (a fusion protein of GATA-1 with the estrogen receptor ligand-binding domain) inducing histone acetylation at the beta-major globin promoter in vivo is specific and would require a reference to experimental evidence for validation.\n5. TRUE: The interaction with FOG-1 has been shown to be necessary for GATA-1 occupancy at certain sites, including the HS2 enhancer, which is important for the regulation of the beta-globin gene cluster.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, MIRA-seq appears to be a medical information, retrieval, and archives system developed and implemented at the University Hospital Freiburg. The system integrates the Minimum Basic Data Set into the hospital's patient administration system and other parts of the hospital information system, providing physicians and other users with access to basic medical data of all patients treated in the hospital since 1986.\nMIRA-seq offers privacy-controlled access to the central patient data bases, which contain records of approximately 450,000 patients, through 610 online PCs and dialog terminals. The system is designed to be user-friendly, with many easy-to-use standard functions and special extensions for different clinical departments, making it one of the best-accepted electronic patient data systems (edp systems) among physicians, nurses, and administrators.\nIn summary, MIRA-seq is a comprehensive medical information system that provides access to patient data and other medical information for various purposes, including readmission and scientific and managerial purposes.",
    "llama-2-7b-chat-hf_fact_raw": "1. MIRA-seq was developed and implemented at the University Hospital Freiburg.\n2. The system has integrated the Minimum Basic Data Set with the hospital's patient administration system.\n3. MIRA-seq provides access to basic medical data of all patients treated at the hospital since 1986.\n4. Approximately 450,000 patient records are contained in MIRA-seq's central patient databases.\n5. The system is accessible through 610 online PCs and dialog terminals.",
    "llama-2-7b-chat-hf_fact": [
      "MIRA-seq was developed and implemented at the University Hospital Freiburg.",
      "The system has integrated the Minimum Basic Data Set with the hospital's patient administration system.",
      "MIRA-seq provides access to basic medical data of all patients treated at the hospital since 1986.",
      "Approximately 450,000 patient records are contained in MIRA-seq's central patient databases.",
      "The system is accessible through 610 online PCs and dialog terminals."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific context or a referenced passage providing details about MIRA-seq, it is not possible to verify the accuracy of these statements. MIRA-seq appears to be a specific system with details that are not universally known or easily verifiable. Therefore, the truthfulness of the given statements cannot be determined with the information provided.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the indication of ARCALYST is that it is a novel type of Ca(2+) channel that is specifically activated by low concentrations of agonists, such as carbachol, in arachidonate-regulated manner. These channels provide the predominant pathway for Ca(2+) entry at low agonist concentrations, where oscillatory [Ca(2+)](i) signals are typically produced. Uncoupling the receptor-mediated activation of cytosolic phospholipase A(2) (cPLA(2)) with isotetrandrine reduces the activation of the ARC channels and markedly inhibits the [Ca(2+)](i) signals induced by low agonist concentrations, while the signals seen at high agonist concentrations are essentially unaffected. Additionally, the indication is that the ARC channels are present in both parotid and pancreatic acinar cells, and that the activation of these channels by cholecystokinin induces a current that is only approximately 60% of that seen with carbachol.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the human acrocentric chromosomes involved in Robertsonian translocations are:\n* Chromosome 21 (21q)\nRobertsonian translocations between acrocentric chromosomes are the most common structural chromosomal rearrangements in humans and other organisms, and they typically involve the exchange of genetic material between two acrocentric chromosomes. In the case of the translocation 21q;21q, the two 21q arms of the rearranged chromosome have a biparental origin, meaning that one 21q arm is paternal and the other is maternal. This suggests that the formation of the Robertsonian translocation occurs in the zygote or in the first few postzygotic mitotic divisions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Human acrocentric chromosomes can be involved in Robertsonian translocations.\n2. Chromosome 21 is one of the acrocentric chromosomes that can be involved in Robertsonian translocations.\n3. Robertsonian translocations are the most common structural chromosomal rearrangements in humans.\n4. Robertsonian translocations typically involve the exchange of genetic material between two acrocentric chromosomes.\n5. In the translocation 21q;21q, one 21q arm is of paternal origin and the other is of maternal origin.",
    "llama-2-7b-chat-hf_fact": [
      "Human acrocentric chromosomes can be involved in Robertsonian translocations.",
      "Chromosome 21 is one of the acrocentric chromosomes that can be involved in Robertsonian translocations.",
      "Robertsonian translocations are the most common structural chromosomal rearrangements in humans.",
      "Robertsonian translocations typically involve the exchange of genetic material between two acrocentric chromosomes.",
      "In the translocation 21q;21q, one 21q arm is of paternal origin and the other is of maternal origin."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: In the translocation 21q;21q, this type of Robertsonian translocation involves both long arms of chromosome 21, but it typically results in a formation of a single chromosome with two long arms from the same origin (either both maternal or both paternal), not one from each parent. This arrangement leads to a form of Down syndrome if the translocated chromosome is present alongside two normal copies of chromosome 21.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the R package that could be used for the identification of pediatric brain tumors is likely to be \"nmrMRS\". This package provides functions for analyzing and interpreting proton magnetic resonance spectroscopy (MRS) data, including the analysis of metabolites such as N-acetylaspartate (NAA), choline containing-compounds (Cho), creatine and phosphocreatine (Cr), and lactate (Lac). The package also includes functions for visualizing and interpreting MRS data, which could be useful for identifying patterns and correlations in the data that could aid in the diagnosis of pediatric brain tumors.\nSpecifically, the \"nmrMRS\" package includes functions for:\n1. Data import and export: The package provides functions for importing and exporting MRS data in various formats, including NMR Spectral Data (NSD) and MRS Data (MRS).\n2. Data preprocessing: The package includes functions for preprocessing MRS data, such as filtering, normalization, and peak picking.\n3. Metabolite analysis: The package provides functions for analyzing metabolites in MRS data, including peak picking, integration, and quantification.\n4. Visualization: The package includes functions for visualizing MRS data, such as creating spectra and maps, and performing statistical analysis.\n5. Interpretation: The package provides functions for interpreting MRS data in the context of pediatric brain tumors, including identifying patterns and correlations that could aid in the diagnosis of these tumors.\nOverall, the \"nmrMRS\" package appears to be a suitable choice for analyzing and interpreting proton MRS data in the context of pediatric brain tumors, based on the information provided in the document.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R package \"nmrMRS\" could be used for the identification of pediatric brain tumors.\n2. \"nmrMRS\" provides functions for analyzing and interpreting proton magnetic resonance spectroscopy (MRS) data.\n3. The package includes functions for metabolite analysis such as N-acetylaspartate (NAA), choline containing-compounds (Cho), creatine and phosphocreatine (Cr), and lactate (Lac).\n4. \"nmrMRS\" offers functions for visualizing MRS data, including creating spectra and maps.\n5. The package helps in interpreting MRS data for diagnosing pediatric brain tumors through pattern and correlation analysis.",
    "llama-2-7b-chat-hf_fact": [
      "The R package \"nmrMRS\" could be used for the identification of pediatric brain tumors.",
      "\"nmrMRS\" provides functions for analyzing and interpreting proton magnetic resonance spectroscopy (MRS) data.",
      "The package includes functions for metabolite analysis such as N-acetylaspartate (NAA), choline containing-compounds (Cho), creatine and phosphocreatine (Cr), and lactate (Lac).",
      "\"nmrMRS\" offers functions for visualizing MRS data, including creating spectra and maps.",
      "The package helps in interpreting MRS data for diagnosing pediatric brain tumors through pattern and correlation analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: \"nmrMRS\" could indeed be used for the identification of pediatric brain tumors, as MRS is a technique for that purpose and the package is designed for analyzing MRS data.\n2. TRUE: \"nmrMRS\" is likely to provide functions for analyzing and interpreting proton magnetic resonance spectroscopy (MRS) data, as that is the primary purpose of a specialized package in this field.\n3. TRUE: It is common for MRS data analysis packages to include functions for metabolite analysis, and N-acetylaspartate (NAA), choline-containing compounds (Cho), creatine and phosphocreatine (Cr), and lactate (Lac) are key metabolites routinely quantified in MRS.\n4. TRUE: Visualization, including creating spectra and maps, is a standard feature in MRS data analysis tools, and \"nmrMRS\" would reasonably provide such functionality.\n5. TRUE: Interpreting MRS data for diagnosing brain tumors, including pediatric ones, would generally involve pattern recognition and correlation analysis, likely features of an MRS analysis package like \"nmrMRS\".",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, NEMO is indeed a zinc finger protein. The document reports that the zinc finger (ZF) motif located in the regulatory C-terminal half of NEMO forms a specific complex with ubiquitin. The study uses various biochemical and biophysical techniques, including NMR, fluorescence, and mutagenesis, to investigate the NEMO ZF-ubiquitin interaction and propose a structural model of the complex. The findings indicate that the ZF residues involved in ubiquitin binding are functionally important and required for NF-κB signaling in response to tumor necrosis factor-alpha. Therefore, based on the information provided in the document, NEMO can be classified as a zinc finger protein.",
    "llama-2-7b-chat-hf_fact_raw": "1. NEMO is classified as a zinc finger protein.\n2. The zinc finger motif in NEMO is located in the regulatory C-terminal half of the protein.\n3. NEMO forms a specific complex with ubiquitin.\n4. Studies have used NMR, fluorescence, and mutagenesis techniques to investigate the NEMO ZF-ubiquitin interaction.\n5. The zinc finger residues involved in ubiquitin binding in NEMO are important for NF-κB signaling in response to tumor necrosis factor-alpha.",
    "llama-2-7b-chat-hf_fact": [
      "NEMO is classified as a zinc finger protein.",
      "The zinc finger motif in NEMO is located in the regulatory C-terminal half of the protein.",
      "NEMO forms a specific complex with ubiquitin.",
      "Studies have used NMR, fluorescence, and mutagenesis techniques to investigate the NEMO ZF-ubiquitin interaction.",
      "The zinc finger residues involved in ubiquitin binding in NEMO are important for NF-κB signaling in response to tumor necrosis factor-alpha."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nBased on the specificity of these statements, they seem to be accurate details that one would find in a scientific description of the protein NEMO (NF-kappaB essential modulator). The zinc finger motif is indeed a structural motif that can contribute to protein function, including interactions with other molecules, like ubiquitin. The importance of specific residues in signaling pathways such as NF-κB in response to cytokines like tumor necrosis factor-alpha (TNFα) is a common area of study, often involving techniques like NMR, fluorescence, and mutagenesis. However, without the specific reference to the scientific literature or passage that these statements came from, it is assumed they are accurate based on the context provided.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it appears that TFIIS does affect nucleosome positioning. The study found that the lack of TFIIS leads to general increases in nucleosomal fuzziness and more restricted changes in nucleosome occupancy, which concentrates in some gene categories. Specifically, the study found that TATA-containing genes were preferentially associated with decreased occupancy in gene bodies, while TATA-like genes showed increased fuzziness. These changes in nucleosome positioning were found to correlate with functional defects in nascent transcription, as revealed by genomic run-on experiments.\nTherefore, based on the information provided in the document, the answer to the user's question is yes, TFIIS does affect nucleosome positioning.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFIIS affects nucleosome positioning according to the study referenced.\n2. A lack of TFIIS leads to general increases in nucleosomal fuzziness.\n3. A lack of TFIIS leads to more restricted changes in nucleosome occupancy.\n4. TATA-containing genes are associated with decreased occupancy in gene bodies when TFIIS is lacking.\n5. TATA-like genes showed increased fuzziness as a result of TFIIS absence.",
    "llama-2-7b-chat-hf_fact": [
      "TFIIS affects nucleosome positioning according to the study referenced.",
      "A lack of TFIIS leads to general increases in nucleosomal fuzziness.",
      "A lack of TFIIS leads to more restricted changes in nucleosome occupancy.",
      "TATA-containing genes are associated with decreased occupancy in gene bodies when TFIIS is lacking.",
      "TATA-like genes showed increased fuzziness as a result of TFIIS absence."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout the specific study being referenced and the actual data or conclusions it presented, I cannot accurately confirm or correct these statements. They are specific claims that require evidence provided by the mentioned study to verify their validity.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it appears that origins of replication close to yeast centromeres tend to fire late in S phase. The document mentions that previous studies in budding yeast suggested that most DNA replication origins fire early in S phase, but that cis-acting sequences can force origins to fire later. The document also reports the identification of a specific stretch of DNA (200 bp) that is sufficient to compel nearby origins to fire late, regardless of their location in the genome. This stretch contains a cluster of three close matches to a G-rich, 10-bp late consensus sequence (LCS), which cooperate with other sequences within the stretch to enforce late replication. Finally, the document notes that all of the origins that fire in very late S phase in fission yeast are located close to a cluster of LCS elements. Based on these findings, it is likely that origins of replication close to yeast centromeres tend to fire late in S phase.",
    "llama-2-7b-chat-hf_fact_raw": "1. Origins of replication close to yeast centromeres tend to fire late in S phase.\n2. Previous studies in budding yeast suggested that most DNA replication origins fire early in S phase.\n3. A specific stretch of DNA (200 bp) that contains a cluster of three close matches to a late consensus sequence (LCS) can force origins to fire late, regardless of their location in the genome.\n4. The 10-bp late consensus sequence (LCS) cooperates with other sequences to enforce late replication.\n5. All of the origins that fire in very late S phase in fission yeast are located close to a cluster of LCS elements.",
    "llama-2-7b-chat-hf_fact": [
      "Origins of replication close to yeast centromeres tend to fire late in S phase.",
      "Previous studies in budding yeast suggested that most DNA replication origins fire early in S phase.",
      "A specific stretch of DNA (200 bp) that contains a cluster of three close matches to a late consensus sequence (LCS) can force origins to fire late, regardless of their location in the genome.",
      "The 10-bp late consensus sequence (LCS) cooperates with other sequences to enforce late replication.",
      "All of the origins that fire in very late S phase in fission yeast are located close to a cluster of LCS elements."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: In yeast, origins of replication that are close to centromeres do tend to fire late in the S phase of the cell cycle.\n2. TRUE: It has been observed in studies of budding yeast that a significant number of DNA replication origins tend to fire early in S phase.\n3. UNKNOWN: The statement may be referencing specific scientific findings, but without a specific study or evidence, the effect of a stretch of DNA with three matches to an LCS on the timing of origin firing cannot be confirmed.\n4. UNKNOWN: Without specific scientific evidence or a reference to actual research findings, the function and cooperation of the 10-bp LCS with other sequences are not able to be confirmed.\n5. UNKNOWN: The statement regarding the location of very late-firing origins in fission yeast and their relation to clusters of LCS elements is very specific and would require specific scientific evidence to confirm or deny.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the article, the properties of mammalian GA-sequences are:\n1. They are longer than 50 bases and consist exclusively of G's and A's.\n2. They are found ubiquitously along the chromosomes of human, chimpanzee, dog, cat, rat, and mouse, with a species-dependent density.\n3. They are unique individuals, containing repeated short GA-containing motifs.\n4. They share a common hexa-nucleotide spectrum.\n5. They are not coding for proteins, as only a small number of them are transcribed into mRNAs.\n6. They contain fewer point mutations than one would expect from the genome at large.\n7. There are approximately as many pure GA-sequences as pure TC-sequences, but fewer pure AC-, TA, and TG-sequences.\n8. There are practically no pure GC-sequences.\n9. The functions of pure GA-sequences are speculated to be related to genomic sign posting and spatial linkage, possibly helping guide polymerases and transcription factors to their proper targets, and/or contributing to the 3-dimensional organization of chromatin.\nIn summary, mammalian GA-sequences are characterized by their exclusive composition of G's and A's, their ubiquitous distribution along the chromosomes of various mammalian species, their unique nature, and their potential functions related to genomic organization and navigation.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mammalian GA-sequences are longer than 50 bases and consist exclusively of G's and A's.\n2. These sequences are found ubiquitously along the chromosomes of human, chimpanzee, dog, cat, rat, and mouse, with varying densities depending on the species.\n3. Mammalian GA-sequences contain repeated short GA-containing motifs and are unique to individuals.\n4. A small number of mammalian GA-sequences are transcribed into mRNAs and they are not coding for proteins.\n5. There are approximately equal numbers of pure GA-sequences and pure TC-sequences in the genome.",
    "llama-2-7b-chat-hf_fact": [
      "Mammalian GA-sequences are longer than 50 bases and consist exclusively of G's and A's.",
      "These sequences are found ubiquitously along the chromosomes of human, chimpanzee, dog, cat, rat, and mouse, with varying densities depending on the species.",
      "Mammalian GA-sequences contain repeated short GA-containing motifs and are unique to individuals.",
      "A small number of mammalian GA-sequences are transcribed into mRNAs and they are not coding for proteins.",
      "There are approximately equal numbers of pure GA-sequences and pure TC-sequences in the genome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: While GA-sequences (or GAGA motifs) in mammals are rich in guanine (G) and adenine (A), the statement that they are exclusively longer than 50 bases and consist only of G's and A's is not universally accurate. GA-sequences can vary in length, and while they are characterized by a high frequency of G's and A's, they may not be exclusively so.\n2. TRUE: These sequences, typically referred to as GA-rich sequences or GAGA motifs, are indeed found throughout the genomes of various species, including humans, chimpanzees, dogs, cats, rats, and mice, although their densities and distributions can vary between species.\n3. FALSE [correction]: While mammalian GA-sequences do contain GA-rich motifs, the statement that they are unique to individuals is too broad and not necessarily accurate. They can be variable among individuals but saying they are unique to individuals implicitly suggests a level of uniqueness akin to fingerprints, which is not demonstrated for these sequences.\n4. TRUE: Some GA-sequences are indeed transcribed into non-coding RNAs, which means they are not translated into proteins. This is the case with many sequences in the genome that are transcribed into RNA but do not serve as templates for protein synthesis.\n5. UNKNOWN: Without specific genomic data, it is difficult to confirm whether there are equal numbers of pure GA-sequences and pure TC-sequences (complementary to GA) in the genome. The distribution of such sequences can vary widely across different organisms and within different regions of the genome.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are at least four Groucho-related genes (Grg) contained in the mouse genome. These genes are Grg1, Grg2, Grg3, and Grg4. The document mentions that these genes are involved in a signalling pathway downstream of Notch, and that Grg4 is expressed in proliferating epithelial tissues undergoing mesenchymal induction, as well as in the central nervous system and somites. However, it does not provide the exact number of Grg genes present in the mouse genome.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are at least four Groucho-related genes (Grg) in the mouse genome.\n2. The Groucho-related genes in the mouse genome include Grg1, Grg2, Grg3, and Grg4.\n3. These genes are involved in a signalling pathway downstream of Notch.\n4. Grg4 is expressed in proliferating epithelial tissues undergoing mesenchymal induction.\n5. Grg4 is also expressed in the central nervous system and somites.",
    "llama-2-7b-chat-hf_fact": [
      "There are at least four Groucho-related genes (Grg) in the mouse genome.",
      "The Groucho-related genes in the mouse genome include Grg1, Grg2, Grg3, and Grg4.",
      "These genes are involved in a signalling pathway downstream of Notch.",
      "Grg4 is expressed in proliferating epithelial tissues undergoing mesenchymal induction.",
      "Grg4 is also expressed in the central nervous system and somites."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The Groucho-related genes in the mouse genome include Grg1, Grg2, Grg3, and Grg5. There are also alternative namings like TLE1, TLE2, TLE3, and TLE4 for human homologs.\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the RNA polymerase II subunit that carries RNA cleavage activity is the largest subunit's C-terminal domain (CTD). The study found that the CTD is responsible for the pre-mRNA polyadenylation cleavage reaction in vitro, and that the heptads in the vicinity of 30 to 37 in the CTD contribute modestly more than other sections to the cleavage activity. Additionally, the study found that the nonconsensus CTD heptads are responsible for only 20% of the wild-type cleavage activity, while the remaining 80% directly correlates with CTD length, with significant activity requiring approximately 26 or more repeats. Therefore, the answer to the user's question is that the RNA polymerase II subunit that carries RNA cleavage activity is the C-terminal domain of the largest subunit.",
    "llama-2-7b-chat-hf_fact_raw": "1. The RNA polymerase II subunit that carries RNA cleavage activity is the largest subunit's C-terminal domain (CTD).\n2. The CTD is responsible for the pre-mRNA polyadenylation cleavage reaction in vitro.\n3. The heptads in the vicinity of 30 to 37 in the CTD contribute more to the cleavage activity than other sections.\n4. Nonconsensus CTD heptads are responsible for 20% of the wild-type cleavage activity.\n5. Significant RNA cleavage activity requires approximately 26 or more repeats of the CTD.",
    "llama-2-7b-chat-hf_fact": [
      "The RNA polymerase II subunit that carries RNA cleavage activity is the largest subunit's C-terminal domain (CTD).",
      "The CTD is responsible for the pre-mRNA polyadenylation cleavage reaction in vitro.",
      "The heptads in the vicinity of 30 to 37 in the CTD contribute more to the cleavage activity than other sections.",
      "Nonconsensus CTD heptads are responsible for 20% of the wild-type cleavage activity.",
      "Significant RNA cleavage activity requires approximately 26 or more repeats of the CTD."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The RNA polymerase II subunit does not carry the RNA cleavage activity in its C-terminal domain (CTD). The CTD is involved in the process of transcription regulation and RNA processing, but RNA cleavage activity during pre-mRNA processing is typically carried out by other proteins or complexes, such as the cleavage and polyadenylation specificity factor (CPSF).\n\n2. FALSE [correction]: The CTD is not directly responsible for the pre-mRNA polyadenylation cleavage reaction in vitro. Instead, it provides a binding site for RNA processing factors, which include the cleavage and polyadenylation machinery. The actual cleavage reaction is carried out by other components of the pre-mRNA processing complex.\n\n3. UNKNOWN: Without specific literature or context, it is difficult to evaluate the exact contribution of heptads at positions 30 to 37 in the CTD to cleavage activity. This level of detail requires specific empirical evidence from scientific studies.\n\n4. UNKNOWN: The information about nonconsensus CTD heptads being responsible for 20% of the wild-type cleavage activity is too specific and requires a supporting reference to determine its veracity.\n\n5. UNKNOWN: The statement about requiring approximately 26 or more repeats of the CTD for significant RNA cleavage activity is specific and depends on empirical data that is not provided. Therefore, without reference to relevant scientific literature, the truth of this statement cannot be ascertained.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the genetic basis of Ohdo syndrome is not explicitly stated. However, the document does mention that Ohdo syndrome is a multiple malformation syndrome caused by a genetic mutation. The mutation is believed to occur sporadically, as all cases with the severe phenotype have been sporadic. Additionally, the document mentions that telomeric FISH studies of all chromosome arms on the two cases showed no abnormality.\nBased on these findings, it is likely that the genetic basis of Ohdo syndrome is a mutation in a gene or genes that are involved in the development of the facial features, hearing impairment, and intellectual disability associated with the syndrome. However, the specific genetic mechanism underlying Ohdo syndrome has not been identified in the provided document. Further research and studies are needed to determine the genetic basis of this syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ohdo syndrome is a multiple malformation syndrome caused by a genetic mutation.\n2. The mutation responsible for Ohdo syndrome occurs sporadically.\n3. Severe phenotype cases of Ohdo syndrome have been sporadic.\n4. Telomeric FISH studies showed no abnormality in the chromosome arms of the two cases studied.\n5. The specific genetic mechanism underlying Ohdo syndrome has not been identified in the provided document.",
    "llama-2-7b-chat-hf_fact": [
      "Ohdo syndrome is a multiple malformation syndrome caused by a genetic mutation.",
      "The mutation responsible for Ohdo syndrome occurs sporadically.",
      "Severe phenotype cases of Ohdo syndrome have been sporadic.",
      "Telomeric FISH studies showed no abnormality in the chromosome arms of the two cases studied.",
      "The specific genetic mechanism underlying Ohdo syndrome has not been identified in the provided document."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the R/Bioconductor package that has been developed for the analysis of psychiatric disease genes is CTDquerier. The package provides functions for integrating data from the Comparative Toxicogenomics Database (CTD) into R/Bioconductor analysis pipelines, allowing researchers to perform enrichment analyses at the chemicals-genes or chemicals-diseases levels. The package also includes visualization tools and example code for analyzing asthma-related genes. Therefore, CTDquerier is a helpful tool for researchers interested in studying the relationships between chemicals and psychiatric diseases using R/Bioconductor.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R/Bioconductor package developed for the analysis of psychiatric disease genes is called CTDquerier.\n2. CTDquerier provides functions for integrating data from the Comparative Toxicogenomics Database into R/Bioconductor analysis pipelines.\n3. CTDquerier allows for enrichment analyses at the chemicals-genes or chemicals-diseases levels.\n4. The package includes visualization tools and example code for analyzing asthma-related genes.",
    "llama-2-7b-chat-hf_fact": [
      "The R/Bioconductor package developed for the analysis of psychiatric disease genes is called CTDquerier.",
      "CTDquerier provides functions for integrating data from the Comparative Toxicogenomics Database into R/Bioconductor analysis pipelines.",
      "CTDquerier allows for enrichment analyses at the chemicals-genes or chemicals-diseases levels.",
      "The package includes visualization tools and example code for analyzing asthma-related genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The R/Bioconductor package developed specifically for the analysis of psychiatric disease genes is not named CTDquerier. CTDquerier is a tool to retrieve data from the Comparative Toxicogenomics Database, but it is not specifically focused on psychiatric disease genes.\n2. TRUE\n3. FALSE [correction]: While CTDquerier does allow for integration of data from the Comparative Toxicogenomics Database, it is not explicitly stated whether it allows for enrichment analyses at the chemicals-genes or chemicals-diseases levels. It is a tool for querying the database, but whether it performs enrichment analysis requires additional information.\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_response": "Thank you for asking! Based on the information provided in Document-0, the swirl sign in intracerebral hemorrhage refers to a specific radiological sign that can be observed on a non-contrast CT scan. This sign consists of two components: hyperacute and acute.\nThe hyperacute component represents an ongoing active intracranial bleed, which is a sign of a recent and potentially life-threatening injury. The acute component, on the other hand, consists of surrounding hyperattenuated clotted blood, which can indicate the presence of an expanding extradural hematoma.\nThe importance of identifying the swirl sign early on is highlighted in two clinical scenarios provided in Document-0. In both scenarios, the prompt identification of the swirl sign by surgeons led to aggressive surgical management, which may have a bearing on the prognosis and survival of the patients.\nIn summary, the swirl sign in intracerebral hemorrhage is a radiological sign that can be observed on a non-contrast CT scan, and its identification is crucial for early surgical management to improve patient outcomes.",
    "llama-2-7b-chat-hf_fact_raw": "1. The swirl sign in intracerebral hemorrhage is a radiological sign visible on a non-contrast CT scan.\n2. The swirl sign consists of two components: hyperacute and acute.\n3. The hyperacute component represents an ongoing active intracranial bleed.\n4. The acute component of the swirl sign consists of surrounding hyperattenuated clotted blood.\n5. Prompt identification of the swirl sign can lead to aggressive surgical management that may improve the prognosis and survival of patients with intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_fact": [
      "The swirl sign in intracerebral hemorrhage is a radiological sign visible on a non-contrast CT scan.",
      "The swirl sign consists of two components: hyperacute and acute.",
      "The hyperacute component represents an ongoing active intracranial bleed.",
      "The acute component of the swirl sign consists of surrounding hyperattenuated clotted blood.",
      "Prompt identification of the swirl sign can lead to aggressive surgical management that may improve the prognosis and survival of patients with intracerebral hemorrhage."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The swirl sign consists of a combination of hypoattenuating and hyperattenuating areas within a hematoma.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, Arabidopsis ROF1 expression is induced by heat stress. The study shows that ROF1 binds heat shock proteins HSP90.1 via its tetratricopeptide repeat domain and localizes in the cytoplasm under normal conditions. However, exposure to heat stress induces nuclear localization of the ROF1-HSP90.1 complex, which is dependent on the presence of the transcription factor HsfA2. The study also shows that ROF1 knockout plants exhibit collapse when exposed to high temperatures, while transgenic ROF1 over-expressors show better survival in response to high temperatures. Additionally, the study found that the level of expression of small HSPs regulated by HsfA2 is dramatically reduced in rof1 knockout mutants after exposure to high temperatures, which correlates well with the mutant phenotype. Based on these findings, it can be concluded that ROF1 plays a role in prolonging thermotolerance by sustaining the levels of small HSPs that are essential for survival at high temperatures.",
    "llama-2-7b-chat-hf_fact_raw": "1. Arabidopsis ROF1 expression is induced by heat stress.\n2. ROF1 binds heat shock proteins HSP90.1 via its tetratricopeptide repeat domain.\n3. Exposure to heat stress induces nuclear localization of the ROF1-HSP90.1 complex.\n4. ROF1 knockout plants collapse when exposed to high temperatures.\n5. Transgenic ROF1 over-expressors show better survival in response to high temperatures compared to ROF1 knockout plants.",
    "llama-2-7b-chat-hf_fact": [
      "Arabidopsis ROF1 expression is induced by heat stress.",
      "ROF1 binds heat shock proteins HSP90.1 via its tetratricopeptide repeat domain.",
      "Exposure to heat stress induces nuclear localization of the ROF1-HSP90.1 complex.",
      "ROF1 knockout plants collapse when exposed to high temperatures.",
      "Transgenic ROF1 over-expressors show better survival in response to high temperatures compared to ROF1 knockout plants."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the most common cause of hereditary renal amyloidosis is the fibrinogen alpha-chain gene. The document states that three members of a family died with renal amyloidosis and were found to share a single nucleotide substitution in the fibrinogen alpha-chain gene, specifically the Arg554Leu mutation. This mutation was proven by amino acid sequence analysis of amyloid fibril protein isolated from postmortem kidney of an affected individual. Additionally, direct genomic DNA sequencing and restriction fragment length polymorphism analysis demonstrated that all three affected individuals had the guanine to thymine 4993 transversion, which is a variant of the fibrinogen alpha-chain gene. Therefore, the fibrinogen alpha-chain gene is the most common cause of hereditary renal amyloidosis based on the information provided.",
    "llama-2-7b-chat-hf_fact_raw": "1. The fibrinogen alpha-chain gene is the most common cause of hereditary renal amyloidosis.\n2. Three family members who died with renal amyloidosis shared a single nucleotide substitution in the fibrinogen alpha-chain gene.\n3. The Arg554Leu mutation in the fibrinogen alpha-chain gene was validated through amino acid sequence analysis of amyloid fibril protein from a postmortem kidney of an affected individual.\n4. Direct genomic DNA sequencing indicated a guanine to thymine 4993 transversion in all three affected family members.\n5. Restriction fragment length polymorphism analysis was used to demonstrate the presence of the 4993 transversion in the fibrinogen alpha-chain gene in affected individuals.",
    "llama-2-7b-chat-hf_fact": [
      "The fibrinogen alpha-chain gene is the most common cause of hereditary renal amyloidosis.",
      "Three family members who died with renal amyloidosis shared a single nucleotide substitution in the fibrinogen alpha-chain gene.",
      "The Arg554Leu mutation in the fibrinogen alpha-chain gene was validated through amino acid sequence analysis of amyloid fibril protein from a postmortem kidney of an affected individual.",
      "Direct genomic DNA sequencing indicated a guanine to thymine 4993 transversion in all three affected family members.",
      "Restriction fragment length polymorphism analysis was used to demonstrate the presence of the 4993 transversion in the fibrinogen alpha-chain gene in affected individuals."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The most common cause of hereditary renal amyloidosis is related to the transthyretin gene, not the fibrinogen alpha-chain gene. However, mutations in the fibrinogen alpha-chain gene can cause a type of hereditary renal amyloidosis known as fibrinogen A alpha-chain amyloidosis.\n2. UNKNOWN: Without more context or knowledge of a specific study, it is not possible to validate the truthfulness of the statement regarding the shared single nucleotide substitution in the fibrinogen alpha-chain gene within a specific family.\n3. UNKNOWN: The specific validation of the Arg554Leu mutation in the fibrinogen alpha-chain gene through amino acid sequence analysis would require detailed information from a scientific study or report.\n4. UNKNOWN: The statement about the genomic DNA sequencing showing a guanine to thymine transversion at a specific position (4993) requires a specific scientific reference to be verified.\n5. UNKNOWN: The method (restriction fragment length polymorphism analysis) to demonstrate the presence of a transversion in the gene is plausible, as it is one of the techniques used for such analysis, but the specific instance of its use to demonstrate the 4993 transversion in the fibrinogen alpha-chain gene in affected individuals cannot be verified without additional information.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "llama-2-7b-chat-hf_response": "Yes, the proteome of the mouse hippocampus has been analyzed using proteomics technologies. A study published in the document you provided used 2-DE coupled to MS (MALDI-TOF/TOF) to construct a comprehensive reference database of proteins expressed in the mouse hippocampus. The study analyzed the hippocampal proteomes of five different mouse strains and identified 469 individual proteins, represented by 1156 spots displaying various functional states of the respective gene products. This study provides a valuable resource for understanding the characteristics of proteins serving the highly sophisticated function of neuronal information processing and storage in the hippocampus.",
    "llama-2-7b-chat-hf_fact_raw": "1. Proteomics technologies have been used to analyze the proteome of the mouse hippocampus.\n2. A study used 2-DE coupled to MS (MALDI-TOF/TOF) to create a reference database of proteins expressed in the mouse hippocampus.\n3. The study analyzed hippocampal proteomes from five different mouse strains.\n4. In the study, 469 individual proteins were identified.\n5. The database includes 1156 spots representing various functional states of protein gene products.",
    "llama-2-7b-chat-hf_fact": [
      "Proteomics technologies have been used to analyze the proteome of the mouse hippocampus.",
      "A study used 2-DE coupled to MS (MALDI-TOF/TOF) to create a reference database of proteins expressed in the mouse hippocampus.",
      "The study analyzed hippocampal proteomes from five different mouse strains.",
      "In the study, 469 individual proteins were identified.",
      "The database includes 1156 spots representing various functional states of protein gene products."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, mouse chromosomes are not acrocentric. According to the document, chromosomes 19 and the sex chromosomes are the only acrocentric chromosomes in mice. All the other chromosomes, including chromosomes 1 to 18, are metacentric. Therefore, the answer to the user's question is \"No, mouse chromosomes are not acrocentric.\"",
    "llama-2-7b-chat-hf_fact_raw": "1. Mouse chromosomes 19 and the sex chromosomes are the only acrocentric chromosomes in mice.\n2. Chromosomes 1 to 18 in mice are metacentric.\n3. Not all mouse chromosomes are acrocentric.",
    "llama-2-7b-chat-hf_fact": [
      "Mouse chromosomes 19 and the sex chromosomes are the only acrocentric chromosomes in mice.",
      "Chromosomes 1 to 18 in mice are metacentric.",
      "Not all mouse chromosomes are acrocentric."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: In mice, chromosomes 10 to 19 are acrocentric, not just chromosome 19 and the sex chromosomes.\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the siRNA-based drug that is in clinical trials for the treatment of pancreatic cancer is k-ras siRNA. The study found that treating tumor cell cultures with k-ras siRNA resulted in significant inhibition of k-ras endogenous expression and cell proliferation, and combining k-ras siRNA with gemcitabine resulted in strong growth inhibition of orthotopic pancreatic tumors in mice. These findings suggest that targeting mutant k-ras through specific siRNA might be effective for k-ras oncogene silencing and tumor growth inhibition, and that this strategy might be used therapeutically against human pancreatic cancer to potentiate the effects of conventional therapy.",
    "llama-2-7b-chat-hf_fact_raw": "1. The siRNA-based drug in clinical trials for the treatment of pancreatic cancer is k-ras siRNA.\n2. Treatment of tumor cell cultures with k-ras siRNA resulted in significant inhibition of k-ras endogenous expression and cell proliferation.\n3. Combining k-ras siRNA with gemcitabine led to strong growth inhibition of orthotopic pancreatic tumors in mice.\n4. Targeting mutant k-ras through specific siRNA could be effective for k-ras oncogene silencing and tumor growth inhibition.\n5. The strategy of using k-ras siRNA might be used therapeutically against human pancreatic cancer to enhance the effects of conventional therapy.",
    "llama-2-7b-chat-hf_fact": [
      "The siRNA-based drug in clinical trials for the treatment of pancreatic cancer is k-ras siRNA.",
      "Treatment of tumor cell cultures with k-ras siRNA resulted in significant inhibition of k-ras endogenous expression and cell proliferation.",
      "Combining k-ras siRNA with gemcitabine led to strong growth inhibition of orthotopic pancreatic tumors in mice.",
      "Targeting mutant k-ras through specific siRNA could be effective for k-ras oncogene silencing and tumor growth inhibition.",
      "The strategy of using k-ras siRNA might be used therapeutically against human pancreatic cancer to enhance the effects of conventional therapy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific information on the current clinical trials for pancreatic cancer and the details about the drug being referred to, it is not possible to confirm or deny that the siRNA-based drug in clinical trials is indeed k-ras siRNA.\n\n2. TRUE: This statement is consistent with known principles of molecular biology and pharmacology related to siRNA. When siRNA is used to target a specific gene such as k-ras in tumor cell cultures, it often results in the inhibition of that gene's endogenous expression and can lead to reduced cell proliferation.\n\n3. TRUE: This is a plausible outcome based on the principles of cancer treatment research. However, without specific data or references it's assumed to be correct in the context of commonly accepted scientific knowledge.\n\n4. TRUE: Targeting mutant k-ras through specific siRNA for oncogene silencing and tumor growth inhibition is a strategy that is supported by molecular cancer therapy approaches. Mutations in k-ras are known to play a significant role in many cancers, including pancreatic cancer, so this approach could be effective.\n\n5. TRUE: This statement is also consistent with the therapeutic strategies employed in oncology, where combining targeted treatments like siRNA for gene silencing with conventional therapies, such as chemotherapy agents like gemcitabine, could enhance treatment effects. However, this assumes that clinical data supports the use of such strategies in human patients.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the HPG pore refers to the porosity of the matrix tablets produced using heterodisperse polysaccharides (HP). The document discusses the release-controlling action of swellable hydrophilic materials based on HP in relation to the initial pore structure of the formulations.\nThe study found that the pore structure of the tablets, as quantified by mercury porosimetry, had a significant impact on the release of a water-soluble model compound, benzamide, from swollen matrices. However, the study also showed that the release of the model compound was not affected by the total porosity or median pore diameter of the initial dry matrix.\nThe term \"HPG pore\" is likely used to refer to the pores present in the matrix tablets, which are created during the production process. These pores are thought to play a role in the release of the model compound from the swollen matrices.\nIn summary, the HPG pore is a measure of the porosity of the matrix tablets produced using HP, and it is an important factor in determining the release of the model compound from these tablets.",
    "llama-2-7b-chat-hf_fact_raw": "1. HPG pore refers to the porosity of matrix tablets produced using heterodisperse polysaccharides.\n2. The study found that the pore structure measured by mercury porosimetry affects the release of benzamide from swollen matrices.\n3. The release of benzamide, a water-soluble model compound, from the swollen matrices was not influenced by the total porosity or median pore diameter of the initial dry matrix.\n4. The pores within the matrix tablets are created during the production process.\n5. HPG pore is considered an important factor in determining the release of a model compound from matrix tablets.",
    "llama-2-7b-chat-hf_fact": [
      "HPG pore refers to the porosity of matrix tablets produced using heterodisperse polysaccharides.",
      "The study found that the pore structure measured by mercury porosimetry affects the release of benzamide from swollen matrices.",
      "The release of benzamide, a water-soluble model compound, from the swollen matrices was not influenced by the total porosity or median pore diameter of the initial dry matrix.",
      "The pores within the matrix tablets are created during the production process.",
      "HPG pore is considered an important factor in determining the release of a model compound from matrix tablets."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: HPG pore often stands for \"High Porous Graphite,\" and it does not refer to the porosity of matrix tablets produced using heterodisperse polysaccharides. Without additional context, the specific meaning of \"HPG pore\" in relation to matrix tablets is unknown.\n2. TRUE (Assuming the preceding statement is referring to a study involving matrix tablets and the measurement of pore structure)\n3. TRUE (This statement is specific and presents a finding from a study; thus, it's assumed to be true based on the context provided)\n4. TRUE (Pores within matrix tablets are indeed typically created during the production process, such as granulation or compression)\n5. TRUE (Assuming \"HPG pore\" is a typographical or contextual error, and the statement is intended to say that the pore structure is an important factor in determining the release of a model compound from matrix tablets)",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "llama-2-7b-chat-hf_response": "The 959 Nematode Genomes initiative is a community-curated semantic wiki that aims to coordinate the sequencing efforts of individual labs to collectively sequence 959 genomes spanning the phylum Nematoda. The main goal of the wiki is to track sequencing projects, both proposed and completed, and provide a way for users to query the status of their favorite worm using machine- and human-readable metadata. The wiki is based on the same platform as Wikipedia, with semantic extensions that allow for easy maintenance and updates of the underlying taxonomy and data storage models. The initiative has already fostered new international collaborations and attracted newcomers to the community of nematode genomicists, and has provided a way to track and share preliminary data that may not be polished enough to be submitted to official sequence repositories.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 959 Nematode Genomes initiative is a community-curated semantic wiki.\n2. It aims to coordinate the sequencing of 959 genomes from the phylum Nematoda.\n3. The wiki tracks both proposed and completed sequencing projects.\n4. The platform of the wiki is based on that of Wikipedia and includes semantic extensions.\n5. The initiative has resulted in new international collaborations among nematode genomicists.",
    "llama-2-7b-chat-hf_fact": [
      "The 959 Nematode Genomes initiative is a community-curated semantic wiki.",
      "It aims to coordinate the sequencing of 959 genomes from the phylum Nematoda.",
      "The wiki tracks both proposed and completed sequencing projects.",
      "The platform of the wiki is based on that of Wikipedia and includes semantic extensions.",
      "The initiative has resulted in new international collaborations among nematode genomicists."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The 959 Nematode Genomes initiative is not a wiki; it is a scientific project with the goal of sequencing 959 nematode genomes.\n2. TRUE\n3. UNKNOWN (Without specific details about the initiative's tracking methods for sequencing projects, it is not possible to determine the validity of this statement.)\n4. FALSE [correction]: The 959 Nematode Genomes initiative is not based on a wiki platform, so it does not use Wikipedia's platform or semantic extensions.\n5. TRUE (It is reasonable to assume that such a large-scale scientific initiative would result in new international collaborations among researchers in the field, though specific instances of these collaborations are not provided.)",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the R package developed for analyzing Non-invasive prenatal testing (NIPT) data is called \"NIPTmer\". The package is based on counting pre-defined per-chromosome sets of unique k-mers from raw sequencing data and applying linear regression model on the counts. Additionally, the filtering process used for k-mer list creation allows one to take into account the genetic variance in a specific sample, thus reducing the source of uncertainty. The processing time of one sample is less than 10 CPU-minutes on a high-end workstation. The package was validated on a cohort of 583 NIPT samples and correctly predicted 37 non-mosaic fetal aneuploidies. The software package is freely available for non-commercial users at <http://bioinfo.ut.ee/NIPTMer/>.",
    "llama-2-7b-chat-hf_fact_raw": "1. The R package developed for analyzing Non-invasive prenatal testing (NIPT) data is called \"NIPTmer\".\n2. \"NIPTmer\" uses a method that counts per-chromosome sets of unique k-mers from raw sequencing data.\n3. The software applies a linear regression model on the k-mer counts.\n4. The package \"NIPTmer\" was validated on a cohort of 583 NIPT samples, where it correctly predicted 37 non-mosaic fetal aneuploidies.\n5. The processing time for one sample using \"NIPTmer\" is less than 10 CPU-minutes on a high-end workstation.",
    "llama-2-7b-chat-hf_fact": [
      "The R package developed for analyzing Non-invasive prenatal testing (NIPT) data is called \"NIPTmer\".",
      "\"NIPTmer\" uses a method that counts per-chromosome sets of unique k-mers from raw sequencing data.",
      "The software applies a linear regression model on the k-mer counts.",
      "The package \"NIPTmer\" was validated on a cohort of 583 NIPT samples, where it correctly predicted 37 non-mosaic fetal aneuploidies.",
      "The processing time for one sample using \"NIPTmer\" is less than 10 CPU-minutes on a high-end workstation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The software applies a logistic regression model on the k-mer counts.\n4. UNKNOWN \n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbach’s syndrome.",
    "llama-2-7b-chat-hf_response": "Achenbach's syndrome is a rare medical condition characterized by the formation of spontaneous or mechanically induced hematomas (blood accumulations) on the volar aspects of fingers, typically associated with burning pain and swelling of the digits. The condition was first described by Achenbach in 1933 and has been reported in only a few cases since then.\nThe exact cause of Achenbach's syndrome is not well understood, but it is believed to be related to a combination of factors, including trauma, repetitive motion, and certain medical conditions. The condition typically affects the fingers, particularly the thumb and index finger, although it can occur on other digits as well.\nThe symptoms of Achenbach's syndrome can vary in severity and may include:\n* Spontaneous or mechanically induced swelling of the fingers, particularly the thumb and index finger\n* Burning pain in the affected fingers\n* Limited range of motion in the affected digits\n* Skin discoloration or bruising on the volar aspect of the fingers\nIn some cases, Achenbach's syndrome may be associated with other medical conditions, such as Raynaud's disease or carpal tunnel syndrome. A proper diagnosis of Achenbach's syndrome typically involves a combination of physical examination, medical history, and imaging studies, such as X-rays or MRI.\nTreatment for Achenbach's syndrome typically involves conservative measures, such as immobilization of the affected digits, pain management, and physical therapy to improve range of motion and strength. In some cases, surgical intervention may be necessary to drain the hematomas or repair any damaged tissue.\nOverall, Achenbach's syndrome is a rare and poorly understood condition that can cause significant discomfort and disability in affected individuals. While the exact cause of the condition is still unclear, early diagnosis and appropriate treatment can help to manage symptoms and improve quality of life.",
    "llama-2-7b-chat-hf_fact_raw": "1. Achenbach's syndrome is characterized by spontaneous or mechanically induced hematomas on the volar aspects of fingers.\n2. The condition was first described by Achenbach in 1933.\n3. Achenbach's syndrome typically affects the fingers, particularly the thumb and index finger.\n4. Symptoms of Achenbach's syndrome can include swelling, burning pain, limited range of motion, and skin discoloration or bruising on the volar aspect of the fingers.\n5. Treatment for Achenbach's syndrome may involve immobilization, pain management, physical therapy, and sometimes surgical intervention.",
    "llama-2-7b-chat-hf_fact": [
      "Achenbach's syndrome is characterized by spontaneous or mechanically induced hematomas on the volar aspects of fingers.",
      "The condition was first described by Achenbach in 1933.",
      "Achenbach's syndrome typically affects the fingers, particularly the thumb and index finger.",
      "Symptoms of Achenbach's syndrome can include swelling, burning pain, limited range of motion, and skin discoloration or bruising on the volar aspect of the fingers.",
      "Treatment for Achenbach's syndrome may involve immobilization, pain management, physical therapy, and sometimes surgical intervention."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Achenbach's syndrome was first described by Achenbach in 1958.\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nWhile the treatment of Achenbach's syndrome generally includes conservative measures such as rest and possibly pain management, the specifics of treatments like immobilization, physical therapy, and surgical intervention can vary and are not well-established due to the rarity of the condition. The statement as given is too vague to determine a definitive true or false without additional context about treatment protocols, which are not standardized.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the algorithm used for detection of long repeat expansions is the Repeat Expansion Detection (RED) method.",
    "llama-2-7b-chat-hf_fact_raw": "1. Repeat Expansion Detection (RED) method is used for the detection of long repeat expansions.",
    "llama-2-7b-chat-hf_fact": [
      "Repeat Expansion Detection (RED) method is used for the detection of long repeat expansions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, neuroligin-3 promotes medulloblastoma (MB) and glioblastoma (GBM). The study found that the drug CAT3, which is a prodrug of PF403, inhibited the growth of MB and GBM cells by interrupting the Hedgehog signaling pathway, which is hyperactivated in these tumors. Specifically, CAT3 was shown to inhibit the cell surface accumulation of the Smoothened (Smo) receptor, which is a key component of the Hh signaling pathway, and repress the transcription of Gli1, a transcription factor that is activated by the Hh pathway. These findings suggest that CAT3 may be a promising therapeutic agent for the treatment of Hh-driven MB and GBM.",
    "llama-2-7b-chat-hf_fact_raw": "1. Neuroligin-3 promotes medulloblastoma (MB) and glioblastoma (GBM).\n2. The drug CAT3 is a prodrug of PF403.\n3. CAT3 inhibits the growth of MB and GBM cells by interrupting the Hedgehog (Hh) signaling pathway.\n4. CAT3 inhibits the cell surface accumulation of the Smoothened (Smo) receptor.\n5. CAT3 represses the transcription of Gli1, a transcription factor activated by the Hh pathway.",
    "llama-2-7b-chat-hf_fact": [
      "Neuroligin-3 promotes medulloblastoma (MB) and glioblastoma (GBM).",
      "The drug CAT3 is a prodrug of PF403.",
      "CAT3 inhibits the growth of MB and GBM cells by interrupting the Hedgehog (Hh) signaling pathway.",
      "CAT3 inhibits the cell surface accumulation of the Smoothened (Smo) receptor.",
      "CAT3 represses the transcription of Gli1, a transcription factor activated by the Hh pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific scientific context or a specific study reference, the role of Neuroligin-3 in promoting medulloblastoma (MB) and glioblastoma (GBM) cannot be confirmed.\n2. UNKNOWN: Without additional information, it is not possible to verify whether CAT3 is a prodrug of PF403.\n3. UNKNOWN: Whether CAT3 inhibits the growth of MB and GBM cells by interrupting the Hedgehog (Hh) signaling pathway would require specific scientific evidence or a study reference.\n4. UNKNOWN: Without specific data, it cannot be confirmed if CAT3 inhibits the cell surface accumulation of the Smoothened (Smo) receptor.\n5. UNKNOWN: Similarly, without precise information or a study reference, it cannot be determined if CAT3 represses the transcription of Gli1, a transcription factor activated by the Hh pathway.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the approximate size of gas vesicles in Microcylus aquaticus cells is around 100 nanometers (nm) in diameter. This is evident from the observation that the vesicles begin to elongate and increase in size to a maximum diameter of 100 nm around 90 minutes after cell suspension, and the initiation of smaller vesicles that result in a doubling of the number of vesicles per cell during this time period.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gas vesicles in Microcylus aquaticus cells have an approximate diameter of 100 nanometers.\n2. The gas vesicles begin to elongate and increase in size around 90 minutes after cell suspension.",
    "llama-2-7b-chat-hf_fact": [
      "Gas vesicles in Microcylus aquaticus cells have an approximate diameter of 100 nanometers.",
      "The gas vesicles begin to elongate and increase in size around 90 minutes after cell suspension."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gas vesicles in microorganisms like Microcylus aquaticus, if indeed the organism is meant to be Microcystis aeruginosa (a common freshwater cyanobacterium known to form gas vesicles), typically have a diameter ranging from 45 to 200 nanometers, but not precisely 100 nanometers.\n2. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are some of the BET proteins:\n1. BRD2 (Bromodomain and Extra-Terminal Domain Protein 2)\n2. BRD3 (Bromodomain and Extra-Terminal Domain Protein 3)\n3. BRD4 (Bromodomain and Extra-Terminal Domain Protein 4)\n4. Testis-specific BRDT (Bromodomain and Extra-Terminal Domain Protein Testis-specific)\nThe document highlights the potential of BET proteins as therapeutic targets for cancer and other diseases, and introduces a new class of PROTAC (Proteolysis Targeting Chimera) BET degraders as a promising approach to degrade these proteins. One of the most promising compounds, 23, is shown to effectively degrade BRD4 protein in RS4;11 leukemia cells at concentrations as low as 30 pM, with an IC50 value of 51 pM in inhibition of cell growth and rapid tumor regression in vivo against RS4;11 xenograft tumors.",
    "llama-2-7b-chat-hf_fact_raw": "1. BRD2 is a Bromodomain and Extra-Terminal Domain Protein.\n2. BRD3 is a Bromodomain and Extra-Terminal Domain Protein.\n3. BRD4 is a Bromodomain and Extra-Terminal Domain Protein.\n4. There is a Bromodomain and Extra-Terminal Domain Protein that is testis-specific, known as BRDT.\n5. PROTAC BET degraders are a new class of compounds with the potential to degrade BET proteins.",
    "llama-2-7b-chat-hf_fact": [
      "BRD2 is a Bromodomain and Extra-Terminal Domain Protein.",
      "BRD3 is a Bromodomain and Extra-Terminal Domain Protein.",
      "BRD4 is a Bromodomain and Extra-Terminal Domain Protein.",
      "There is a Bromodomain and Extra-Terminal Domain Protein that is testis-specific, known as BRDT.",
      "PROTAC BET degraders are a new class of compounds with the potential to degrade BET proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the algorithm developed for prediction of protein subcellular localization using deep learning is the comprehensive system integrating protein sequence-derived data and text-based information. The system is tested on three large data sets and demonstrates better performance than previously reported results for a wide range of eukaryotic subcellular localizations.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, MULTOVL appears to be an application suite designed to detect and analyze multiple overlaps of genomic regions in a fast and efficient manner. The package supports the detection of multiple region intersections, unions, and what it refers to as \"solitary\" genomic regions. Additionally, the significance of actually observed overlaps is estimated by comparing them with empirical null distributions generated by random shuffling of the input regions.",
    "llama-2-7b-chat-hf_fact_raw": "1. MULTOVL is an application suite designed for the detection and analysis of multiple overlaps in genomic regions.\n2. MULTOVL can detect intersections and unions of genomic regions.\n3. The application identifies \"solitary\" genomic regions as part of its functionality.\n4. MULTOVL estimates the significance of observed overlaps by comparing them with empirical null distributions.\n5. The empirical null distributions in MULTOVL are generated by random shuffling of input genomic regions.",
    "llama-2-7b-chat-hf_fact": [
      "MULTOVL is an application suite designed for the detection and analysis of multiple overlaps in genomic regions.",
      "MULTOVL can detect intersections and unions of genomic regions.",
      "The application identifies \"solitary\" genomic regions as part of its functionality.",
      "MULTOVL estimates the significance of observed overlaps by comparing them with empirical null distributions.",
      "The empirical null distributions in MULTOVL are generated by random shuffling of input genomic regions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nExplanation: Without specific information about the MULTOVL application suite, I cannot verify most of the statements as they are very specific to its features and functionalities. The statement about detecting intersections and unions is in line with common features of genomic region analysis software; therefore, it seems plausible and is marked as true. The other details would require more information or access to documentation about MULTOVL to determine their accuracy.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it appears that GDF15 can be a biomarker for metformin treatment. The document states that in participants with diabetes, metformin treatment was associated with a 40% rise in GDF-15 levels, which was independent of other major factors and largely explained their elevated GDF-15 levels. This suggests that GDF15 levels may be a useful indicator of metformin treatment in individuals with diabetes. Additionally, the document notes that the relatively high GDF-15 bioavailability might partly explain the protective cardiovascular effects of metformin, further supporting the idea that GDF15 can be used as a biomarker for metformin treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. GDF15 levels can be a biomarker for metformin treatment.\n2. In participants with diabetes, metformin treatment was associated with a 40% rise in GDF-15 levels.\n3. The rise in GDF-15 levels was independent of other major factors.\n4. GDF-15 levels can serve as an indicator of metformin treatment in individuals with diabetes.\n5. High GDF-15 bioavailability might partly explain the protective cardiovascular effects of metformin.",
    "llama-2-7b-chat-hf_fact": [
      "GDF15 levels can be a biomarker for metformin treatment.",
      "In participants with diabetes, metformin treatment was associated with a 40% rise in GDF-15 levels.",
      "The rise in GDF-15 levels was independent of other major factors.",
      "GDF-15 levels can serve as an indicator of metformin treatment in individuals with diabetes.",
      "High GDF-15 bioavailability might partly explain the protective cardiovascular effects of metformin."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Growth Differentiation Factor 15 (GDF15) levels can serve as a biomarker for various conditions and treatments, including metformin treatment for diabetes.\n2. UNKNOWN: Without the specific study or source data, the exact percentage increase in GDF-15 levels in participants with diabetes due to metformin treatment cannot be verified.\n3. UNKNOWN: The independence of GDF-15 level changes from other major factors would need to be verified by specific study results, which are not provided here.\n4. TRUE: GDF-15 levels have the potential to serve as an indicator for various treatments and conditions, including metformin treatment in individuals with diabetes.\n5. UNKNOWN: While there is research suggesting that metformin has protective cardiovascular effects, without specific reference to a study that links high GDF-15 bioavailability to those effects, the accuracy of this statement cannot be verified.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, recursive splicing is more common in short introns. The document states that \"recursive splicing has been observed in a small subset of Drosophila melanogaster introns,\" and that \"hundreds of novel sites of recursive splicing\" were identified in nascent RNA sequencing data from Drosophila S2 cells. Additionally, the document notes that recursive sites tend to occur near the midpoints of introns and that fly introns with recursive sites are spliced more accurately than comparably sized non-recursive introns. These observations suggest that recursive splicing is more prevalent in shorter introns than in longer ones.",
    "llama-2-7b-chat-hf_fact_raw": "1. Recursive splicing is more common in short introns.\n2. Recursive splicing has been observed in a small subset of Drosophila melanogaster introns.\n3. Hundreds of novel sites of recursive splicing were identified in nascent RNA sequencing data from Drosophila S2 cells.\n4. Recursive sites tend to occur near the midpoints of introns.\n5. Fly introns with recursive sites are spliced more accurately than comparably sized non-recursive introns.",
    "llama-2-7b-chat-hf_fact": [
      "Recursive splicing is more common in short introns.",
      "Recursive splicing has been observed in a small subset of Drosophila melanogaster introns.",
      "Hundreds of novel sites of recursive splicing were identified in nascent RNA sequencing data from Drosophila S2 cells.",
      "Recursive sites tend to occur near the midpoints of introns.",
      "Fly introns with recursive sites are spliced more accurately than comparably sized non-recursive introns."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Recursive splicing is less common in short introns and is more commonly associated with longer introns.\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the TALE-iD method is used for genome editing and gene regulation applications. Specifically, TALEs (recombinant transcription activator-like effectors) can be tailored to target almost any user-defined DNA sequence, and the fairyTALE platform is capable of producing hundreds of expression-ready TALEs within a single day with high assembly efficiency and low material cost. As proof of concept, the document demonstrates the synthesis and testing of 90 TALEs, each recognizing a 27 bp DNA sequence, with 96% of them found to be functional.",
    "llama-2-7b-chat-hf_fact_raw": "1. The TALE-iD method is used for genome editing and gene regulation applications.\n2. TALEs can be tailored to target almost any user-defined DNA sequence.\n3. The fairyTALE platform can produce hundreds of expression-ready TALEs within a single day.\n4. The document demonstrated the synthesis and testing of 90 TALEs, each recognizing a 27 bp DNA sequence.\n5. 96% of the TALEs tested were found to be functional.",
    "llama-2-7b-chat-hf_fact": [
      "The TALE-iD method is used for genome editing and gene regulation applications.",
      "TALEs can be tailored to target almost any user-defined DNA sequence.",
      "The fairyTALE platform can produce hundreds of expression-ready TALEs within a single day.",
      "The document demonstrated the synthesis and testing of 90 TALEs, each recognizing a 27 bp DNA sequence.",
      "96% of the TALEs tested were found to be functional."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The TALE-iD method is indeed used for genome editing and gene regulation applications.\n2. TRUE: TALEs (Transcription Activator-Like Effectors) can be engineered to bind to virtually any desired DNA sequence, making them highly versatile for targeting specific genomic locations.\n3. UNKNOWN: Without additional context or a reference to the specific capabilities of the \"fairyTALE platform,\" it is not possible to confirm the accuracy of this statement.\n4. UNKNOWN: The statement's accuracy regarding the synthesis and testing of 90 TALEs, each recognizing a 27 base pair (bp) DNA sequence, depends on specific experimental data that is not provided.\n5. UNKNOWN: The functionality rate of the TALEs tested (96%) cannot be verified without access to the experimental results or data referenced in the document.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the Lisp framework that has been developed for image processing is FunImageJ. According to the document, FunImageJ is a Lisp framework for scientific image processing built upon the ImageJ software ecosystem, and it provides a natural functional-style for programming while accounting for the performance requirements necessary in big data processing commonly encountered in biological image analysis. It is freely available as a plugin to Fiji, and installation and use instructions are available at the ImageJ website. The contact person for more information is Dr. Kevin Harrington at kharrington@uidaho.edu.",
    "llama-2-7b-chat-hf_fact_raw": "1. FunImageJ is a Lisp framework developed for scientific image processing.\n2. FunImageJ is built upon the ImageJ software ecosystem.\n3. FunImageJ is designed with a functional programming style suitable for big data processing in biological image analysis.\n4. It is available as a plugin to Fiji.\n5. Installation and use instructions for FunImageJ can be found on the ImageJ website.",
    "llama-2-7b-chat-hf_fact": [
      "FunImageJ is a Lisp framework developed for scientific image processing.",
      "FunImageJ is built upon the ImageJ software ecosystem.",
      "FunImageJ is designed with a functional programming style suitable for big data processing in biological image analysis.",
      "It is available as a plugin to Fiji.",
      "Installation and use instructions for FunImageJ can be found on the ImageJ website."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it is estimated that approximately 85% of the genes that resulted from the ancient whole genome duplication in Saccharomyces cerevisiae were lost before the speciation event, while only 4-6% of the paralogous gene loss occurred after speciation. Therefore, the number of genes in S. cerevisiae that are the result of the ancient whole genome duplication is approximately 15-20%.",
    "llama-2-7b-chat-hf_fact_raw": "1. Approximately 85% of the genes from the ancient whole genome duplication in Saccharomyces cerevisiae were lost before the speciation event.\n2. Only 4-6% of the paralogous gene loss in Saccharomyces cerevisiae occurred after speciation.\n3. The number of genes in Saccharomyces cerevisiae that result from the ancient whole genome duplication is estimated at 15-20%.",
    "llama-2-7b-chat-hf_fact": [
      "Approximately 85% of the genes from the ancient whole genome duplication in Saccharomyces cerevisiae were lost before the speciation event.",
      "Only 4-6% of the paralogous gene loss in Saccharomyces cerevisiae occurred after speciation.",
      "The number of genes in Saccharomyces cerevisiae that result from the ancient whole genome duplication is estimated at 15-20%."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Approximately 90% of the genes from the ancient whole genome duplication in Saccharomyces cerevisiae were lost before the speciation event.\n2. FALSE [correction]: Only about 10% of the paralogous gene loss in Saccharomyces cerevisiae occurred after speciation.\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the complex that is bound by estrogen-related receptor β (Esrrb) is a novel estradiol-derived metal complex, estradiol-pyridine tetra acetate europium(III).",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, ZCCHC17 appears to be a protein that is involved in RNA quality control and degradation in humans, similar to its homologue ZCCHC9 in yeast. The ZCCHC17 protein contains four retroviral-type zinc knuckle motifs, which are likely to be involved in RNA binding and quality control. The NMR spectral assignment of the zinc knuckle region of ZCCHC17 will allow researchers to study the structure and RNA binding properties of the protein, which will help to elucidate its role in human RNA quality control.\nTherefore, based on the information provided, the role of ZCCHC17 is likely to be related to RNA quality control and degradation in humans, similar to its role in yeast. However, further research is needed to confirm this role and to fully understand the mechanisms by which ZCCHC17 functions in RNA quality control.",
    "llama-2-7b-chat-hf_fact_raw": "1. ZCCHC17 is a protein that is involved in RNA quality control and degradation in humans.\n2. ZCCHC17 contains four retroviral-type zinc knuckle motifs.\n3. The zinc knuckle motifs in ZCCHC17 are likely involved in RNA binding and quality control.\n4. NMR spectral assignment of the zinc knuckle region of ZCCHC17 will help study the structure and RNA binding properties of the protein.\n5. ZCCHC17 is homologous to the ZCCHC9 protein in yeast.",
    "llama-2-7b-chat-hf_fact": [
      "ZCCHC17 is a protein that is involved in RNA quality control and degradation in humans.",
      "ZCCHC17 contains four retroviral-type zinc knuckle motifs.",
      "The zinc knuckle motifs in ZCCHC17 are likely involved in RNA binding and quality control.",
      "NMR spectral assignment of the zinc knuckle region of ZCCHC17 will help study the structure and RNA binding properties of the protein.",
      "ZCCHC17 is homologous to the ZCCHC9 protein in yeast."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: ZCCHC17 contains two retroviral-type zinc knuckle motifs.\n3. TRUE\n4. TRUE\n5. FALSE [correction]: ZCCHC17 is not homologous to the ZCCHC9 protein in yeast; rather, it is homologous to the human protein which is ZCCHC8.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following proteins form the nuclear pore basket in human cells:\n1. Nucleoporins: These are the main proteins that make up the nuclear pore complex and create specialized channels for cargo transport between the cytoplasm and the nuclear interior. There are approximately 30 different nucleoporins present in the pore.\n2. Sentrin/SUMO-specific protease 1 (SENP1) and SENP2: These are two pore-associated small ubiquitin-like modifier (SUMO) proteases that play a role in nucleoporin homeostasis and proper configuration of the nuclear pore complex.\nIt is important to note that the exact composition of the nuclear pore basket may vary depending on the specific cell type and the stage of the cell cycle. However, the proteins listed above are some of the key components involved in the formation and function of the nuclear pore complex in human cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. Nucleoporins are proteins that make up the nuclear pore complex.\n2. There are approximately 30 different nucleoporins present in the nuclear pore complex.\n3. Sentrin/SUMO-specific protease 1 (SENP1) is associated with the nuclear pore complex.\n4. SENP2 is a pore-associated small ubiquitin-like modifier protease.\n5. The exact composition of the nuclear pore basket may vary depending on the cell type and stage of the cell cycle.",
    "llama-2-7b-chat-hf_fact": [
      "Nucleoporins are proteins that make up the nuclear pore complex.",
      "There are approximately 30 different nucleoporins present in the nuclear pore complex.",
      "Sentrin/SUMO-specific protease 1 (SENP1) is associated with the nuclear pore complex.",
      "SENP2 is a pore-associated small ubiquitin-like modifier protease.",
      "The exact composition of the nuclear pore basket may vary depending on the cell type and stage of the cell cycle."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There are approximately 30 different types of nucleoporins, but in total, the nuclear pore complex is made up of around 1,000 individual nucleoporin molecules.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, gepotidacin is a type IIA topoisomerase inhibitor.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gepotidacin is a type IIA topoisomerase inhibitor.",
    "llama-2-7b-chat-hf_fact": [
      "Gepotidacin is a type IIA topoisomerase inhibitor."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "llama-2-7b-chat-hf_response": "Canvas SPW is a tool developed by Illumina for identifying inherited and de novo copy number variants from pedigree sequencing data. It is designed to help researchers identify these variants in families with various pediatric and late-onset genetic diseases, where whole genome sequencing is becoming a diagnostic of choice.\nCanvas SPW addresses the challenge of joint variant calling in pedigrees, which can be complex due to the arbitrariness of consensus breakpoint alignment across samples within a pedigree structure. The tool supports a range of family structures and provides various scoring and filtering options to automate and streamline the identification of de novo variants.\nCanvas SPW is available for download from GitHub, and users can contact the authors for more information or support. Supplementary data are also available at Bioinformatics online.\nIn summary, Canvas SPW is a powerful tool for identifying inherited and de novo copy number variants from pedigree sequencing data, and it can help researchers in the field of genetics and genomics to identify genetic variations that may be associated with various diseases.",
    "llama-2-7b-chat-hf_fact_raw": "1. Canvas SPW is a tool developed by Illumina.\n2. Canvas SPW is used for identifying inherited and de novo copy number variants from pedigree sequencing data.\n3. The tool is designed to assist in researching familial pediatric and late-onset genetic diseases.\n4. Canvas SPW is capable of supporting various family structures during joint variant calling in pedigrees.\n5. The software is available for download on GitHub and supplementary data can be found at Bioinformatics online.",
    "llama-2-7b-chat-hf_fact": [
      "Canvas SPW is a tool developed by Illumina.",
      "Canvas SPW is used for identifying inherited and de novo copy number variants from pedigree sequencing data.",
      "The tool is designed to assist in researching familial pediatric and late-onset genetic diseases.",
      "Canvas SPW is capable of supporting various family structures during joint variant calling in pedigrees.",
      "The software is available for download on GitHub and supplementary data can be found at Bioinformatics online."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nBased on the context provided, all statements seem consistent with the description of a typical bioinformatics tool like Canvas SPW. However, without specific knowledge about the tool or access to confirming sources post-knowledge cut-off, the responses are assumed to be accurate. If any of the details provided in the statements are inaccurate in reality, then that information is beyond my current knowledge.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "llama-2-7b-chat-hf_response": "Based on the information provided, here are some STING agonists that may be relevant to the user's question:\n1. Echiichthys draco: As mentioned in the passage, great weever fishes (Echiichthys spp.) are the most venomous fishes in European waters and can cause severe sting reactions in humans.\n2. Other marine organisms: While the passage specifically mentions great weever fishes, other marine organisms such as jellyfish, corals, and sea anemones can also cause STING reactions.\n3. Plant extracts: Some plant extracts, such as those derived from the venom of the cone snail (Conus spp.), have been shown to act as STING agonists.\n4. Synthetic compounds: There are several synthetic compounds that have been identified as STING agonists, including the calcium channel blocker, verapamil, and the anti-inflammatory drug, dexamethasone.\nIt is important to note that the user's question did not specify the type of STING agonist they were looking for, so this list includes a variety of potential candidates. However, it is important to consult with a medical professional before using any of these substances as therapy, as they can have serious side effects and may interact with other medications.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "llama-2-7b-chat-hf_response": "Sure, I'd be happy to help! Based on the information provided in Document-0, here is a description of the SLIC-CAGE:\nThe SLIC-CAGE is a scanning liquid-filled ionization chamber (SLIC) electronic portal imaging device that has been investigated for its dosimetric characteristics. The device is capable of measuring the portal dose (transmission dose) to within 3% of the ionization chamber results for homogeneous attenuating phantom materials. For two-dimensional dosimetry applications, the SLIC-CAGE is calibrated with a 10 cm Perspex block used as beam flattening material on the detector cassette to correct for variations in individual ion chamber sensitivity and the effect of nonuniform beam profiles produced by the flattening filter.\nThe response of the SLIC-CAGE imaging system is dependent on incident radiation intensity and can be described to within 1% accuracy on central axis using a square root function. The system is capable of measuring open and wedged dose profiles, and the measurements agreed with ion chamber measured profiles to within 3.5% accuracy.\nOverall, the SLIC-CAGE is a reliable and accurate imaging device for measuring portal dose and two-dimensional dosimetry in radiation therapy. Its ability to correct for variations in individual ion chamber sensitivity and nonuniform beam profiles makes it a valuable tool for ensuring accurate dose delivery in radiation therapy treatments.",
    "llama-2-7b-chat-hf_fact_raw": "1. The SLIC-CAGE is an electronic portal imaging device used for dosimetric applications.\n2. It measures portal dose to within 3% accuracy compared with ionization chamber results for homogeneous attenuating phantom materials.\n3. For calibration, the SLIC-CAGE uses a 10 cm Perspex block placed on the detector cassette.\n4. The SLIC-CAGE's response to radiation intensity can be accurately described within 1% on central axis by a square root function.\n5. It is capable of measuring both open and wedged dose profiles with an agreement within 3.5% accuracy when compared to ion chamber measured profiles.",
    "llama-2-7b-chat-hf_fact": [
      "The SLIC-CAGE is an electronic portal imaging device used for dosimetric applications.",
      "It measures portal dose to within 3% accuracy compared with ionization chamber results for homogeneous attenuating phantom materials.",
      "For calibration, the SLIC-CAGE uses a 10 cm Perspex block placed on the detector cassette.",
      "The SLIC-CAGE's response to radiation intensity can be accurately described within 1% on central axis by a square root function.",
      "It is capable of measuring both open and wedged dose profiles with an agreement within 3.5% accuracy when compared to ion chamber measured profiles."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: For calibration, the SLIC-CAGE typically uses a reference dose or calibration factor that is obtained from a known dose, not necessarily a 10 cm Perspex block placed on the detector cassette. Calibration methods can vary and use different materials or setups.\n4. FALSE [correction]: The SLIC-CAGE's response to radiation intensity being accurately described within 1% on central axis by a square root function is very specific, and without context or a reference to a specific study, this cannot be validated. Response curves for electronic portal imaging devices are generally complex and may not fit a simple square root function within such a tight margin across all conditions.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the roles of LEM-3 (LEF-3) are:\n1. Nuclear localization: LEF-3 has a nuclear localization signal domain that allows it to enter the nucleus of infected cells.\n2. DNA replication: LEF-3 is essential for DNA replication in transient assays, and it performs other essential replication functions once inside the nucleus.\n3. Transport of P143: LEF-3 acts as a transporter to transport P143, a large DNA-binding protein, into the nucleus of infected cells.\nIn summary, LEM-3 has multiple roles during virus infection, including nuclear localization, DNA replication, and transport of other proteins into the nucleus.",
    "llama-2-7b-chat-hf_fact_raw": "1. LEF-3 has a nuclear localization signal domain that allows it to enter the nucleus of infected cells.\n2. LEF-3 is essential for DNA replication in transient assays.\n3. LEF-3 performs other essential replication functions once inside the nucleus.\n4. LEF-3 transports P143, a large DNA-binding protein, into the nucleus of infected cells.\n5. LEM-3 (LEF-3) has multiple roles during virus infection, including nuclear localization, DNA replication, and protein transport into the nucleus.",
    "llama-2-7b-chat-hf_fact": [
      "LEF-3 has a nuclear localization signal domain that allows it to enter the nucleus of infected cells.",
      "LEF-3 is essential for DNA replication in transient assays.",
      "LEF-3 performs other essential replication functions once inside the nucleus.",
      "LEF-3 transports P143, a large DNA-binding protein, into the nucleus of infected cells.",
      "LEM-3 (LEF-3) has multiple roles during virus infection, including nuclear localization, DNA replication, and protein transport into the nucleus."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The correct abbreviation is LEF-3 (Late Expression Factor-3), not LEM-3. LEF-3 has multiple roles during virus infection, including nuclear localization, DNA replication, and protein transport into the nucleus.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the releases of tmVar are as follows:\n1. Acetazolamide (AZ):\n\t* Unmodified matrices: 56 days (approximately 25% of the release period)\n\t* Matrices containing 5% PEG: 56 days (accelerated drug release)\n\t* Matrices with 1% PEG: 39 days (shortened drug release duration by one-third)\n2. Timolol maleate (TM):\n\t* Unmodified matrices: Not specified in the document\n\t* Matrices containing 5% PEG: Not specified in the document\n\t* Matrices with increased NVP content: Not specified in the document\nIt is important to note that these releases are based on the specific modifications made to the PPF/PNVP matrices and the drug loads used in the study. The releases may vary depending on the specific conditions and modifications used in different studies.",
    "llama-2-7b-chat-hf_fact_raw": "1. Acetazolamide (AZ) in unmodified matrices had a release period of approximately 56 days.\n2. Acetazolamide (AZ) in matrices containing 5% PEG also had a release period of approximately 56 days which is described as accelerated drug release.\n3. Acetazolamide (AZ) in matrices with 1% PEG had a shortened drug release duration of 39 days, which is about one-third less than the unmodified matrices.\n4. The release data for Timolol maleate (TM) in unmodified matrices and matrices with modifications were not specified in the document.\n5. The release durations for tmVar are influenced by modifications made to the PPF/PNVP matrices and the drug loads used in the study.",
    "llama-2-7b-chat-hf_fact": [
      "Acetazolamide (AZ) in unmodified matrices had a release period of approximately 56 days.",
      "Acetazolamide (AZ) in matrices containing 5% PEG also had a release period of approximately 56 days which is described as accelerated drug release.",
      "Acetazolamide (AZ) in matrices with 1% PEG had a shortened drug release duration of 39 days, which is about one-third less than the unmodified matrices.",
      "The release data for Timolol maleate (TM) in unmodified matrices and matrices with modifications were not specified in the document.",
      "The release durations for tmVar are influenced by modifications made to the PPF/PNVP matrices and the drug loads used in the study."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: Acetazolamide (AZ) in matrices with 1% PEG had a shortened drug release duration of 39 days, which is less than the unmodified matrices but not about one-third less; it is closer to one-quarter less (assuming the unmodified matrices release is 56 days).\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements about the specifics of drug release durations and effects of modifications to the matrices require access to the study or document containing these data to verify. Without the exact data, it is not possible to confirm whether the statements about the drug release periods and the influence of modifications on the release durations are true or false.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the database of somatic mutations in normal cells is the NIST reference material NA12878 genome. This genome has been well-characterized with publicly available high-confidence genotype calls, and it can be used to simulate tumors by introducing somatic small variants (SNVs and small indels) into homozygous reference or wildtype sites. The simulated tumors generated in this way can be used to benchmark somatic small variant callers and guide their improvement. The database contains a total of 135 simulated tumors from 5 pre-tumors/normals, each with its own unique sequencing and mapping error profiles, read length, number of sub-clones, VAF, mutation frequency across the genome, and genomic context. Additionally, the pure tumor/normal pairs can be mixed at desired ratios within each pair to simulate sample contamination.",
    "llama-2-7b-chat-hf_fact_raw": "1. The NIST reference material NA12878 genome is a database of somatic mutations in normal cells.\n2. The NA12878 genome has publicly available high-confidence genotype calls.\n3. The database of the NA12878 genome can be used to simulate tumors by introducing somatic small variants into reference sites.\n4. The NA12878 database contains a total of 135 simulated tumors from 5 pre-tumors/normals.\n5. The NA12878 database includes variables such as unique sequencing and mapping error profiles, read length, and number of sub-clones for the simulated tumors.",
    "llama-2-7b-chat-hf_fact": [
      "The NIST reference material NA12878 genome is a database of somatic mutations in normal cells.",
      "The NA12878 genome has publicly available high-confidence genotype calls.",
      "The database of the NA12878 genome can be used to simulate tumors by introducing somatic small variants into reference sites.",
      "The NA12878 database contains a total of 135 simulated tumors from 5 pre-tumors/normals.",
      "The NA12878 database includes variables such as unique sequencing and mapping error profiles, read length, and number of sub-clones for the simulated tumors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The NIST reference material NA12878 is a human cell line from a female donor that has been extensively sequenced to provide a high-confidence reference dataset, rather than a database of somatic mutations in normal cells.\n2. TRUE\n3. TRUE: While the NA12878 itself is a reference genome, researchers may use it as a baseline to simulate tumors by introducing somatic variants into it for research purposes.\n4. FALSE [correction]: The NA12878 database does not intrinsically contain simulated tumors. Any simulated tumors would be created in specific studies by researchers using the NA12878 data as a reference; the number 135 does not pertain to the NA12878 database itself.\n5. FALSE [correction]: The variables such as unique sequencing and mapping error profiles, read length, and number of sub-clones would be specific to simulation studies conducted by researchers and are not part of the NA12878 database itself.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "llama-2-7b-chat-hf_response": "Yes, there are graph kernel libraries available implemented in JAVA. One such library is GraphKernel, which is a Java implementation of graph kernel algorithms for graph similarity measurement. The library provides a set of baseline kernels, including label histogram based kernels, random walk based kernels, and the state-of-the-art Weisfeiler-Lehman graph kernel. The core of all graph kernels is implemented in C++ for efficiency.\nGraphKernel can be used to perform tasks such as classification, regression, and clustering on graph-structured samples. The library is available at <https://github.com/graphkernel/graphkernel>.\nAnother Java library for graph kernel computation is the GraphKernel library, which is a Java implementation of graph kernel algorithms for graph similarity measurement. The library provides a set of baseline kernels, including label histogram based kernels, random walk based kernels, and the state-of-the-art Weisfeiler-Lehman graph kernel. The core of all graph kernels is implemented in C++ for efficiency.\nIt's important to note that these libraries are not directly mentioned in the provided text, but they are related to graph kernel computation and are available in Java, which is the language mentioned in the question.",
    "llama-2-7b-chat-hf_fact_raw": "1. GraphKernel is a Java implementation of graph kernel algorithms.\n2. The GraphKernel library includes label histogram based kernels, random walk based kernels, and the Weisfeiler-Lehman graph kernel.\n3. The core of all graph kernels in the GraphKernel library is implemented in C++.\n4. GraphKernel can be used for classification, regression, and clustering on graph-structured samples.\n5. The GraphKernel library is available for download at <https://github.com/graphkernel/graphkernel>.",
    "llama-2-7b-chat-hf_fact": [
      "GraphKernel is a Java implementation of graph kernel algorithms.",
      "The GraphKernel library includes label histogram based kernels, random walk based kernels, and the Weisfeiler-Lehman graph kernel.",
      "The core of all graph kernels in the GraphKernel library is implemented in C++.",
      "GraphKernel can be used for classification, regression, and clustering on graph-structured samples.",
      "The GraphKernel library is available for download at <https://github.com/graphkernel/graphkernel>."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: The core of all graph kernels in the GraphKernel library is implemented in Java, as the statement asserts GraphKernel is a Java implementation of graph kernel algorithms.\n4. UNKNOWN\n5. UNKNOWN\n\nWithout additional context or the ability to verify the information on the provided GitHub URL (which appears to be a placeholder and not a valid URL), it's difficult to determine the truthfulness of statements 1, 2, 4, and 5. However, we can correct statement 3 based on the first statement, which indicates that the implementation is in Java, not C++.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the four advances integrated into the SHERLOCKv2 platform are:\n1. Four-channel single-reaction multiplexing with orthogonal CRISPR enzymes: SHERLOCKv2 allows for the simultaneous detection of four different nucleic acid targets in a single reaction, using orthogonal CRISPR enzymes that do not interfere with each other's activity.\n2. Quantitative measurement of input as low as 2 attomolar: SHERLOCKv2 can detect very low levels of nucleic acid inputs, down to 2 attomolar (a unit of measurement for concentrations of particles or molecules), making it a highly sensitive detection platform.\n3. 3.5-fold increase in signal sensitivity by combining Cas13 with Csm6, an auxiliary CRISPR-associated enzyme: By combining the Cas13 enzyme with Csm6, an auxiliary CRISPR-associated enzyme, SHERLOCKv2 achieves a significant increase in signal sensitivity, allowing for the detection of even smaller amounts of nucleic acids.\n4. Lateral-flow readout: SHERLOCKv2 uses a lateral-flow readout method, which involves the migration of nucleic acid targets through a microfluidic channel on a membrane, allowing for the detection of nucleic acids in a rapid and portable manner.\nOverall, these advances in SHERLOCKv2 make it a highly sensitive, multiplexable, and portable platform for the detection of nucleic acids, with potential applications in clinical diagnostics and biotechnology.",
    "llama-2-7b-chat-hf_fact_raw": "1. SHERLOCKv2 allows for simultaneous detection of four different nucleic acid targets in a single reaction due to four-channel single-reaction multiplexing with orthogonal CRISPR enzymes.\n2. The SHERLOCKv2 platform is capable of quantitative measurement of nucleic acid inputs as low as 2 attomolar.\n3. SHERLOCKv2 has achieved a 3.5-fold increase in signal sensitivity by combining Cas13 with Csm6, an auxiliary CRISPR-associated enzyme.\n4. SHERLOCKv2 utilizes a lateral-flow readout method for the detection of nucleic acids.",
    "llama-2-7b-chat-hf_fact": [
      "SHERLOCKv2 allows for simultaneous detection of four different nucleic acid targets in a single reaction due to four-channel single-reaction multiplexing with orthogonal CRISPR enzymes.",
      "The SHERLOCKv2 platform is capable of quantitative measurement of nucleic acid inputs as low as 2 attomolar.",
      "SHERLOCKv2 has achieved a 3.5-fold increase in signal sensitivity by combining Cas13 with Csm6, an auxiliary CRISPR-associated enzyme.",
      "SHERLOCKv2 utilizes a lateral-flow readout method for the detection of nucleic acids."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nNote: The responses are based on the most recent and credible scientific information available as of my knowledge cutoff date in early 2023. If there have been updates or changes to the SHERLOCKv2 platform after this date, I would not have the updated information to confirm the current accuracy of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "llama-2-7b-chat-hf_response": "The bartender algorithm is a novel approach to the cocktail party problem that utilizes a cortronic artificial neural network architecture to preprocess speech signals in advance of a pattern recognition system. The algorithm assumes and exploits detailed knowledge of the signals to be attended to in a cocktail party environment, and its goal is to provide preprocessing rather than explicit source separation. The neural network model used in the algorithm is more biologically feasible than other approaches to the problem. While the focus of the study is on the cocktail party problem, the method can be applied to other areas of information processing.",
    "llama-2-7b-chat-hf_fact_raw": "1. The bartender algorithm uses a cortronic artificial neural network architecture.\n2. It preprocesses speech signals before they are processed by a pattern recognition system.\n3. The bartender algorithm is specifically designed to address the cocktail party problem.\n4. The algorithm does not provide explicit source separation, but rather preprocessing.\n5. The neural network model in the bartender algorithm is considered more biologically feasible compared to other approaches.",
    "llama-2-7b-chat-hf_fact": [
      "The bartender algorithm uses a cortronic artificial neural network architecture.",
      "It preprocesses speech signals before they are processed by a pattern recognition system.",
      "The bartender algorithm is specifically designed to address the cocktail party problem.",
      "The algorithm does not provide explicit source separation, but rather preprocessing.",
      "The neural network model in the bartender algorithm is considered more biologically feasible compared to other approaches."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN\n\nThe provided statements lack specific context or a reliable source to verify some of the claims about the \"bartender algorithm,\" which doesn't seem to be a standard term in the field of artificial intelligence or neural networks as of my knowledge cutoff in 2023. Thus, the claims about cortical architecture, biological feasibility, and other specific details cannot be confirmed without additional context. However, the notion of preprocessing speech signals and addressing the cocktail party problem aligns with common objectives in the field of audio signal processing and neural network design.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, there are several web-based pedigree editors available, including:\n1. PedigreeJS: This is a freely available, lightweight, and easily configurable graphical pedigree editor written in JavaScript. It uses standard pedigree nomenclature and makes use of an open-source JavaScript library to define a hierarchical layout and produce images in scalable vector graphics (SVG) format that can be viewed and edited in web browsers.\n2. Pedigree Draw: This is a web-based pedigree editor that allows users to create and edit pedigrees using a simple and intuitive interface. It also provides features such as the ability to add notes and attachments to individuals, and to export pedigrees in various formats.\n3. Family Tree Builder: This is a web-based tool that allows users to create and edit family trees, including pedigrees. It provides a user-friendly interface and includes features such as the ability to add photos and stories to individuals, and to share trees with others.\n4. Pedigree Maker: This is a web-based tool that allows users to create and edit pedigrees using a simple and intuitive interface. It provides features such as the ability to add notes and attachments to individuals, and to export pedigrees in various formats.\n5. GenoPro: This is a web-based tool that allows users to create and edit family trees, including pedigrees. It provides a user-friendly interface and includes features such as the ability to add photos and stories to individuals, and to share trees with others.\nIt's important to note that these are just a few examples of web-based pedigree editors available, and there may be other options available depending on your specific needs and requirements.",
    "llama-2-7b-chat-hf_fact_raw": "1. PedigreeJS is a web-based pedigree editor that is freely available and written in JavaScript.\n2. Pedigree Draw is a web-based tool that allows the creation and editing of pedigrees with features like adding notes and exporting in various formats.\n3. Family Tree Builder is a web-based tool that enables users to create and edit family trees, including pedigrees, with the ability to add photos and stories.\n4. Pedigree Maker is a web-based pedigree editor that offers features for adding notes and exporting pedigrees.\n5. GenoPro is a web-based tool for creating and editing family trees, including pedigrees, with capabilities for adding photos, stories, and sharing trees with others.",
    "llama-2-7b-chat-hf_fact": [
      "PedigreeJS is a web-based pedigree editor that is freely available and written in JavaScript.",
      "Pedigree Draw is a web-based tool that allows the creation and editing of pedigrees with features like adding notes and exporting in various formats.",
      "Family Tree Builder is a web-based tool that enables users to create and edit family trees, including pedigrees, with the ability to add photos and stories.",
      "Pedigree Maker is a web-based pedigree editor that offers features for adding notes and exporting pedigrees.",
      "GenoPro is a web-based tool for creating and editing family trees, including pedigrees, with capabilities for adding photos, stories, and sharing trees with others."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: GenoPro is not a web-based tool; it is a genealogy software that requires download and installation on a user's computer.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are several curated databases of spider-venom toxins that have been identified and characterized through transcriptomic and genomic analyses of various arachnid species. These include:\n1. VenomDB: This database contains a comprehensive collection of venom-related sequences from various animal species, including spiders, scorpions, and insects. As of 2019, VenomDB contains over 10,000 venom-related sequences from over 100 species.\n2. ToxinDB: This database is a comprehensive collection of toxin-related sequences from various animal species, including spiders, scorpions, and insects. As of 2019, ToxinDB contains over 15,000 toxin-related sequences from over 100 species.\n3. Arachnid Venom Database (AVD): This database is specifically focused on the venom of arachnids, including spiders, scorpions, and ticks. As of 2019, AVD contains over 5,000 venom-related sequences from over 100 species.\n4. Spider Venom Database (SVD): This database is dedicated to the venom of spiders, and contains a comprehensive collection of venom-related sequences from various species of spiders. As of 2019, SVD contains over 3,000 venom-related sequences from over 100 species.\nIt is important to note that these databases are constantly updated and expanded as new research is published, so the number of sequences and species represented may change over time. Additionally, these databases often include information on the functional and structural properties of the venom components, as well as their evolutionary relationships and distribution across different species.",
    "llama-2-7b-chat-hf_fact_raw": "1. VenomDB is a database that contains venom-related sequences from various animal species including spiders, with over 10,000 sequences from over 100 species as of 2019.\n2. ToxinDB contains more than 15,000 toxin-related sequences from various animal species, including spiders and over 100 other species as of 2019.\n3. The Arachnid Venom Database (AVD) focuses on the venom of arachnids, including spiders, and contained over 5,000 venom-related sequences from over 100 species as of 2019.\n4. The Spider Venom Database (SVD) is dedicated to spider venoms and had over 3,000 venom-related sequences from various spider species as of 2019.\n5. These databases provide information on functional and structural properties, evolutionary relationships, and distribution of venom components across species.",
    "llama-2-7b-chat-hf_fact": [
      "VenomDB is a database that contains venom-related sequences from various animal species including spiders, with over 10,000 sequences from over 100 species as of 2019.",
      "ToxinDB contains more than 15,000 toxin-related sequences from various animal species, including spiders and over 100 other species as of 2019.",
      "The Arachnid Venom Database (AVD) focuses on the venom of arachnids, including spiders, and contained over 5,000 venom-related sequences from over 100 species as of 2019.",
      "The Spider Venom Database (SVD) is dedicated to spider venoms and had over 3,000 venom-related sequences from various spider species as of 2019.",
      "These databases provide information on functional and structural properties, evolutionary relationships, and distribution of venom components across species."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nThe accuracy of the specific number of sequences and species for the databases VenomDB, ToxinDB, the Arachnid Venom Database (AVD), and the Spider Venom Database (SVD) as of 2019 cannot be confirmed without access to the databases or to publication records from 2019. However, the general purpose of these databases is to provide information on various properties and characteristics of venom components, which includes functional and structural properties, evolutionary relationships, and distribution across species, making statement 5 true.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the article, there is no evidence to suggest that Axitinib prolongs survival of Pancreatic Cancer patients. In fact, the article states that the addition of Axitinib to Gemcitabine does not improve overall survival in advanced Pancreatic Cancer. The study found that the median overall survival was 85 months for the group receiving Gemcitabine plus Axitinib, and 83 months for the group receiving Gemcitabine plus Placebo, with a hazard ratio of 1014 (95% CI 0786-1309) indicating that the difference in survival between the two groups was not statistically significant.\nIt is important to note that the study was stopped early due to the futility boundary being crossed, indicating that the addition of Axitinib to Gemcitabine was not effective in improving overall survival in Pancreatic Cancer patients. The most common grade 3 or higher adverse events in the group receiving Gemcitabine plus Axitinib were hypertension, abdominal pain, fatigue, and anorexia, which were similar to those observed in the group receiving Gemcitabine plus Placebo.\nIn conclusion, based on the results of this phase 3 trial, there is no evidence to support the use of Axitinib as a treatment for Pancreatic Cancer, and further research in this area may not be fruitful.",
    "llama-2-7b-chat-hf_fact_raw": "1. The article states that the addition of Axitinib to Gemcitabine does not improve overall survival in advanced Pancreatic Cancer.\n2. The median overall survival was 85 months for the group receiving Gemcitabine plus Axitinib.\n3. The median overall survival was 83 months for the group receiving Gemcitabine plus Placebo.\n4. The addition of Axitinib to Gemcitabine was not effective in improving overall survival in Pancreatic Cancer patients, as indicated by the study being stopped early due to the futility boundary being crossed.\n5. The most common grade 3 or higher adverse events for patients receiving Gemcitabine plus Axitinib were hypertension, abdominal pain, fatigue, and anorexia.",
    "llama-2-7b-chat-hf_fact": [
      "The article states that the addition of Axitinib to Gemcitabine does not improve overall survival in advanced Pancreatic Cancer.",
      "The median overall survival was 85 months for the group receiving Gemcitabine plus Axitinib.",
      "The median overall survival was 83 months for the group receiving Gemcitabine plus Placebo.",
      "The addition of Axitinib to Gemcitabine was not effective in improving overall survival in Pancreatic Cancer patients, as indicated by the study being stopped early due to the futility boundary being crossed.",
      "The most common grade 3 or higher adverse events for patients receiving Gemcitabine plus Axitinib were hypertension, abdominal pain, fatigue, and anorexia."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The median overall survival was likely much shorter, as pancreatic cancer has a poor prognosis, and 85 months (over 7 years) would be unusually high for advanced pancreatic cancer survival. However, without specific data from the article, the exact median overall survival is UNKNOWN.\n3. FALSE [correction]: Similarly, the median overall survival was likely much shorter than 83 months for advanced pancreatic cancer; the exact figure is UNKNOWN without specific data from the article.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, MLP regulates F-actin dynamics through its self-association and actin filament cross-linking. The study found that MLP autonomously binds to, stabilizes, and bundles actin filaments independently of calcium and pH. The N-terminal LIM domain of MLP is responsible for its self-association, while the C-terminal LIM domain binds to actin filaments. Through its ability to cross-link actin filaments, MLP contributes to the maintenance of cardiomyocyte cytoarchitecture.",
    "llama-2-7b-chat-hf_fact_raw": "1. MLP regulates F-actin dynamics through self-association and actin filament cross-linking.\n2. The study indicated that MLP can bind to, stabilize, and bundle actin filaments independently of calcium and pH levels.\n3. The N-terminal LIM domain of MLP is involved in its self-association.\n4. The C-terminal LIM domain of MLP is responsible for binding to actin filaments.\n5. MLP's cross-linking of actin filaments helps maintain cardiomyocyte cytoarchitecture.",
    "llama-2-7b-chat-hf_fact": [
      "MLP regulates F-actin dynamics through self-association and actin filament cross-linking.",
      "The study indicated that MLP can bind to, stabilize, and bundle actin filaments independently of calcium and pH levels.",
      "The N-terminal LIM domain of MLP is involved in its self-association.",
      "The C-terminal LIM domain of MLP is responsible for binding to actin filaments.",
      "MLP's cross-linking of actin filaments helps maintain cardiomyocyte cytoarchitecture."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nWithout additional context or information, these statements appear to align with the known functions of muscle LIM protein (MLP), also known as CRP3 or CSRP3, which is implicated in cytoskeletal organization and myogenesis, particularly in cardiac muscle. The details regarding the N-terminal and C-terminal domains and their functions are consistent with what is understood about LIM domain protein behavior in general. MLP's role in cardiomyocyte cytoarchitecture is documented in the study of cardiac muscle biology. However, without access to the specific study or passage referenced, the assessments are based on general scientific knowledge as of the knowledge cutoff date.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are at least two types of pseudokinases in the human kinome:\n1. T-kininogen: This is the precursor protein from which the novel kinin, Met-Ile-Ser-bradykinin (Met-T-kinin), is derived through consecutive cleavage by cathepsin D and 72 kDa protease.\n2. Cathepsin D: This protease is involved in the cleavage of T-kininogen to produce Met-T-kinin.\nTherefore, the answer to the user's question is: There are at least two pseudokinases in the human kinome, T-kininogen and cathepsin D.",
    "llama-2-7b-chat-hf_fact_raw": "1. There are at least two pseudokinases in the human kinome.\n2. T-kininogen is a precursor protein for the novel kinin, Met-Ile-Ser-bradykinin (Met-T-kinin).\n3. T-kininogen is cleaved by cathepsin D and 72 kDa protease to produce Met-T-kinin.\n4. Cathepsin D is a protease involved in the cleavage of T-kininogen.",
    "llama-2-7b-chat-hf_fact": [
      "There are at least two pseudokinases in the human kinome.",
      "T-kininogen is a precursor protein for the novel kinin, Met-Ile-Ser-bradykinin (Met-T-kinin).",
      "T-kininogen is cleaved by cathepsin D and 72 kDa protease to produce Met-T-kinin.",
      "Cathepsin D is a protease involved in the cleavage of T-kininogen."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n\nExplanations:\n1. The human kinome (the complete set of protein kinases in a genome) includes numerous pseudokinases, which lack catalytic activity but have other regulatory roles. There are certainly more than two pseudokinases in the human kinome.\n2. T-kininogen is indeed a precursor protein for various kinins, including novel ones such as Met-Ile-Ser-bradykinin (Met-T-kinin).\n3. T-kininogen undergoes proteolytic cleavage by certain proteases including cathepsin D and a 72 kDa protease, leading to the production of kinins like Met-T-kinin.\n4. Cathepsin D is a well-known protease that is involved in various proteolytic processes, including the cleavage of proteins such as T-kininogen.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, here are 3 apoE mimetics:\n1. ApoE mimetic peptide (LRKLRKRLLR) - This peptide possesses the putative receptor binding domain 141-150 of apoE and is covalently linked to the class A amphipathic helical peptide 18A. It has been shown to dramatically reduce plasma cholesterol in dyslipidemic mouse and rabbit models, and recycling of the peptide increases the duration of pre-HDL formation, leading to extended anti-inflammatory and atheroprotective properties.\n2. APO-Mimetic peptide - This peptide is a synthetic mimic of the apolipoprotein E (apoE) receptor binding domain and has been shown to bind to the LDL receptor and increase the clearance of LDL cholesterol from the bloodstream.\n3. ApoE-mimetic liposomes - These are liposomes that mimic the structure and function of apoE, and have been shown to reduce cholesterol levels in the bloodstream by promoting the clearance of LDL cholesterol from the bloodstream.\nIt is important to note that these are just a few examples of apoE mimetics, and there may be other mimetics that have been developed or are in development. Additionally, the effectiveness and safety of these mimetics may vary depending on the specific composition and formulation of the mimetic, as well as the individual patient being treated.",
    "llama-2-7b-chat-hf_fact_raw": "1. The apoE mimetic peptide (LRKLRKRLLR) contains the receptor binding domain 141-150 of apoE and is linked to the class A amphipathic helical peptide 18A.\n2. The apoE mimetic peptide has been shown to reduce plasma cholesterol in dyslipidemic mouse and rabbit models.\n3. The APO-Mimetic peptide is a synthetic mimic that binds to the LDL receptor and increases the clearance of LDL cholesterol from the bloodstream.\n4. ApoE-mimetic liposomes are designed to mimic the structure and function of apoE and help in reducing cholesterol levels by promoting the clearance of LDL cholesterol.\n5. The apoE mimetic peptide (LRKLRKRLLR) enhances the duration of pre-HDL formation, leading to anti-inflammatory and atheroprotective properties.",
    "llama-2-7b-chat-hf_fact": [
      "The apoE mimetic peptide (LRKLRKRLLR) contains the receptor binding domain 141-150 of apoE and is linked to the class A amphipathic helical peptide 18A.",
      "The apoE mimetic peptide has been shown to reduce plasma cholesterol in dyslipidemic mouse and rabbit models.",
      "The APO-Mimetic peptide is a synthetic mimic that binds to the LDL receptor and increases the clearance of LDL cholesterol from the bloodstream.",
      "ApoE-mimetic liposomes are designed to mimic the structure and function of apoE and help in reducing cholesterol levels by promoting the clearance of LDL cholesterol.",
      "The apoE mimetic peptide (LRKLRKRLLR) enhances the duration of pre-HDL formation, leading to anti-inflammatory and atheroprotective properties."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The apoE mimetic peptide (LRKLRKRLLR) indeed contains the receptor binding domain 141-150 of apoE and is linked to the class A amphipathic helical peptide 18A. This peptide is designed to mimic the lipoprotein binding region of apoE and exhibit similar functional properties.\n2. TRUE: ApoE mimetic peptides have been researched for their potential to reduce plasma cholesterol levels and the statement aligns with findings from various studies conducted using dyslipidemic mouse and rabbit models.\n3. TRUE: The APO-Mimetic peptide is a synthetic peptide designed to imitate apoE functions, which includes binding to the LDL receptor. By enhancing this interaction, they can indeed increase the clearance of LDL cholesterol from the bloodstream, which is one of the mechanisms for reducing cholesterol levels.\n4. TRUE: ApoE-mimetic liposomes are constructed to mimic natural apoE's structure and function, which is known to be involved in the regulation of lipid metabolism, including promoting the clearance of LDL cholesterol, thus reducing cholesterol levels.\n5. UNKNOWN: Without specific research evidence or context for the apoE mimetic peptide (LRKLRKRLLR) concerning pre-HDL formation and its exact impact on anti-inflammatory and atheroprotective properties, this statement cannot be evaluated as true or false. The effect of apoE mimetic peptides on pre-HDL formation and anti-inflammatory processes need to be confirmed with scientific studies.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are sex differences in SAMHD1 activity. Specifically, female rats show greater and more rapid sensitization of locomotor activity and stereotyped behavior than male rats after repeated intermittent amphetamine (AMPH) treatment. This is accompanied by an elevation in resting striatal dihydroxyphenlacetic acid (DOPAC) to dopamine (DA) ratios in female, but not male rats, suggesting a sex difference in one neurochemical correlate of sensitization. Additionally, the document suggests that males are more variable and heterogeneous in their response to repeated AMPH treatment, with two neurochemically distinct subgroups, while females are not. This heterogeneity may make it more difficult to identify neurochemical correlates of sensitization in males. Overall, the document suggests that there is a sex difference in the responsiveness of brain dopamine systems to repetitive activation, which contributes to individual variation in the susceptibility to sensitization.",
    "llama-2-7b-chat-hf_fact_raw": "1. Female rats show greater and more rapid sensitization of locomotor activity and stereotyped behavior than male rats after repeated intermittent amphetamine (AMPH) treatment.\n2. There is an elevation in resting striatal dihydroxyphenylacetic acid (DOPAC) to dopamine (DA) ratios in female rats, but not in male rats, after repeated AMPH treatment.\n3. The document indicates that males show more variability and heterogeneity in their response to repeated AMPH treatment.\n4. Males have two neurochemically distinct subgroups in response to AMPH treatment, whereas females do not.\n5. There is a sex difference in the responsiveness of brain dopamine systems to repetitive activation, contributing to individual variation in the susceptibility to sensitization.",
    "llama-2-7b-chat-hf_fact": [
      "Female rats show greater and more rapid sensitization of locomotor activity and stereotyped behavior than male rats after repeated intermittent amphetamine (AMPH) treatment.",
      "There is an elevation in resting striatal dihydroxyphenylacetic acid (DOPAC) to dopamine (DA) ratios in female rats, but not in male rats, after repeated AMPH treatment.",
      "The document indicates that males show more variability and heterogeneity in their response to repeated AMPH treatment.",
      "Males have two neurochemically distinct subgroups in response to AMPH treatment, whereas females do not.",
      "There is a sex difference in the responsiveness of brain dopamine systems to repetitive activation, contributing to individual variation in the susceptibility to sensitization."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe statements provided pertain to specific scientific observations regarding the effects of amphetamine treatment on rats. Without the original document or a reliable source that verifies these findings, it is not possible to accurately determine the truth value of each statement. These types of assertions would need to be supported by data from relevant scientific studies.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it appears that RUNX2 does not inhibit astrocyte differentiation. The document discusses the role of RUNX2 in regulating osteogenic and odontoblastic differentiation, but does not mention anything about its effect on astrocyte differentiation. In fact, the document specifically highlights the role of RUNX2 in regulating ameloblast differentiation in the context of cleidocranial dysplasia (CCD), which is a genetic disorder characterized by abnormal development of bone and teeth.\nTherefore, based on the information provided in the document, it can be concluded that RUNX2 does not inhibit astrocyte differentiation.",
    "llama-2-7b-chat-hf_fact_raw": "1. RUNX2 does not inhibit astrocyte differentiation according to the document mentioned.\n2. The document discusses RUNX2's role in regulating osteogenic and odontoblastic differentiation.\n3. The document does not mention RUNX2's effect on astrocyte differentiation.\n4. RUNX2 is involved in regulating ameloblast differentiation.\n5. RUNX2 is related to the context of cleidocranial dysplasia (CCD), a genetic disorder affecting the development of bone and teeth.",
    "llama-2-7b-chat-hf_fact": [
      "RUNX2 does not inhibit astrocyte differentiation according to the document mentioned.",
      "The document discusses RUNX2's role in regulating osteogenic and odontoblastic differentiation.",
      "The document does not mention RUNX2's effect on astrocyte differentiation.",
      "RUNX2 is involved in regulating ameloblast differentiation.",
      "RUNX2 is related to the context of cleidocranial dysplasia (CCD), a genetic disorder affecting the development of bone and teeth."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: If the document discusses RUNX2's role in regulating osteogenic and odontoblastic differentiation, it's possible it does mention its effect on astrocyte differentiation, though it's stated that RUNX2 does not inhibit astrocyte differentiation.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the Cobb-Stainsby excision arthroplasty would be performed in the spine. The patient in the case study presented with a right gluteal angioma and was found to have a spinal arteriovenous malformation, which was treated with surgical excision. The excision was performed to remove the malformation and improve the patient's neurological function, which had been affected by the malformation. Therefore, the Cobb-Stainsby excision arthroplasty in this context would involve surgical excision of the malformation in the spine.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cobb-Stainsby excision arthroplasty would be performed in the spine.\n2. The patient had a right gluteal angioma.\n3. The patient was found to have a spinal arteriovenous malformation.\n4. Surgical excision was performed to remove the spinal arteriovenous malformation.\n5. The surgical excision was intended to improve the patient's neurological function.",
    "llama-2-7b-chat-hf_fact": [
      "The Cobb-Stainsby excision arthroplasty would be performed in the spine.",
      "The patient had a right gluteal angioma.",
      "The patient was found to have a spinal arteriovenous malformation.",
      "Surgical excision was performed to remove the spinal arteriovenous malformation.",
      "The surgical excision was intended to improve the patient's neurological function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Cobb-Stainsby excision arthroplasty would not be performed in the spine; it is a procedure associated with the hip.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that GRHL2 over-expression does lead to EMT. The document states that overexpression of LOXL2 (lysyl oxidase-like 2) induces EMT independent of its catalytic activity, and that LOXL2-dependent IRE1-XBP1 activation induces the expression of several EMT-TFs, including SNAI1, SNAI2, ZEB2, and TCF3. These findings suggest that GRHL2 over-expression can trigger the EMT process in cancer cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. GRHL2 over-expression leads to EMT (epithelial-mesenchymal transition).\n2. Overexpression of LOXL2 (lysyl oxidase-like 2) induces EMT independent of its catalytic activity.\n3. LOXL2-dependent IRE1-XBP1 activation induces the expression of several EMT-TFs (epithelial-mesenchymal transition transcription factors).\n4. The EMT-TFs induced by LOXL2-dependent IRE1-XBP1 activation include SNAI1, SNAI2, ZEB2, and TCF3.",
    "llama-2-7b-chat-hf_fact": [
      "GRHL2 over-expression leads to EMT (epithelial-mesenchymal transition).",
      "Overexpression of LOXL2 (lysyl oxidase-like 2) induces EMT independent of its catalytic activity.",
      "LOXL2-dependent IRE1-XBP1 activation induces the expression of several EMT-TFs (epithelial-mesenchymal transition transcription factors).",
      "The EMT-TFs induced by LOXL2-dependent IRE1-XBP1 activation include SNAI1, SNAI2, ZEB2, and TCF3."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: The statement about GRHL2 (Grainyhead-like transcription factor 2) over-expression leading to EMT (epithelial-mesenchymal transition) could be true, as GRHL2 has been implicated in the regulation of epithelial traits. However, without a specific context or supporting data, it is difficult to confirm the validity of this statement.\n\n2. UNKNOWN: The role of LOXL2 (lysyl oxidase-like 2) in inducing EMT independent of its catalytic activity may have been studied and reported in scientific literature, but without specific references or data, the truth of this statement remains uncertain.\n\n3. UNKNOWN: The connection between LOXL2-dependent IRE1-XBP1 activation and the induction of EMT-TFs (epithelial-mesenchymal transition transcription factors) could possibly be true, as these pathways may interact. However, the statement cannot be validated without appropriate context or scientific evidence.\n\n4. UNKNOWN: While SNAI1, SNAI2, ZEB2, and TCF3 are known EMT-TFs, whether they are specifically induced by LOXL2-dependent IRE1-XBP1 activation requires specific evidence, which is not provided here, making the truth of the statement indeterminable.\n\nIn summary, the statements relate to complex molecular biology topics, and their truth can only be verified in the context of current scientific research and data. Without such information, the accuracy of these statements cannot be confidently assessed.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following T-UCRs have been implicated in lung cancer:\n1. uc.306: The document states that this macrophage-derived T-UCR is upregulated in M1 cells and is involved in the Wnt pathway. Low expression of uc.306 was significantly associated with a shorter overall survival in HBV-related HCC.\nIt is important to note that this study focused on the prognosis of HBV-related HCC, and the findings may not necessarily apply to lung cancer. Further research is needed to determine the role of T-UCRs in lung cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. The T-UCR uc.306 is upregulated in M1 cells.\n2. The T-UCR uc.306 is involved in the Wnt pathway.\n3. Low expression of uc.306 was significantly associated with a shorter overall survival in HBV-related HCC.\n\n(Note: The last point mentioned is strictly related to HBV-related HCC, not lung cancer, and the implication of uc.306 in lung cancer is suggested by the phrase \"have been implicated,\" which does not inherently confirm a fact for lung cancer without the specific study detailed. Additional research is stated as necessary to determine the role of T-UCRs in lung cancer, indicating the information is not absolute for lung cancer but may be potentially relevant.)",
    "llama-2-7b-chat-hf_fact": [
      "The T-UCR uc.306 is upregulated in M1 cells.",
      "The T-UCR uc.306 is involved in the Wnt pathway.",
      "Low expression of uc.306 was significantly associated with a shorter overall survival in HBV-related HCC.",
      "ote: The last point mentioned is strictly related to HBV-related HCC, not lung cancer, and the implication of uc.306 in lung cancer is suggested by the phrase \"have been implicated,\" which does not inherently confirm a fact for lung cancer without the specific study detailed. Additional research is stated as necessary to determine the role of T-UCRs in lung cancer, indicating the information is not absolute for lung cancer but may be potentially relevant.)"
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n\nNote: The statements related to T-UCR uc.306 require domain-specific knowledge, and without the passage or scientific literature providing the context, it is difficult to confirm the veracity of specific claims about molecular biology, such as the regulation of a non-coding RNA (like T-UCR uc.306) in certain cell types or its association with survival outcomes in diseases like hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Therefore, the first two statements and the fourth statement (which is not fully provided) are marked as UNKNOWN. The third statement has been assessed as TRUE based on the specific mention of its relation to HBV-related HCC within the given statement itself.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following is what is known about the orphan receptor GPR151:\n1. GPR151 is an orphan GPCR, meaning that its function is unknown.\n2. The restricted pattern of neuronal expression in the habenula, dorsal horn of the spinal cord, and dorsal root ganglion suggests a role in nociception.\n3. There is a 49.92.9 fold increase in GPR151 mRNA expression in the dorsal root ganglion 7 days after the spared nerve injury model of neuropathic pain.\n4. GPR151 does not appear to be involved in the modulation of pain-related behaviors, as measures of acute, inflammatory, and neuropathic pain behaviors were not significantly different between GPR151 loss-of-function mutant mice and wild-type controls.\n5. Galanin, a peptide hormone, does not induce calcium signaling responses in ND7/23 cells transfected with GPR151, suggesting that galanin is unlikely to be an endogenous ligand for GPR151.\nIn summary, while the upregulation of GPR151 mRNA expression in the dorsal root ganglion after nerve injury suggests a potential role in nociception, further research is needed to determine the functional role of GPR151 in pain modulation. Additionally, galanin does not appear to be an endogenous ligand for GPR151.",
    "llama-2-7b-chat-hf_fact_raw": "1. GPR151 is an orphan GPCR.\n2. GPR151's neuronal expression pattern suggests a potential role in nociception.\n3. There is a significant increase in GPR151 mRNA expression in the dorsal root ganglion 7 days after a spared nerve injury.\n4. GPR151 loss-of-function mutant mice do not exhibit significant differences in pain-related behaviors compared to wild-type controls.\n5. Galanin does not induce calcium signaling responses in cells transfected with GPR151, indicating it is unlikely to be an endogenous ligand for this receptor.",
    "llama-2-7b-chat-hf_fact": [
      "GPR151 is an orphan GPCR.",
      "GPR151's neuronal expression pattern suggests a potential role in nociception.",
      "There is a significant increase in GPR151 mRNA expression in the dorsal root ganglion 7 days after a spared nerve injury.",
      "GPR151 loss-of-function mutant mice do not exhibit significant differences in pain-related behaviors compared to wild-type controls.",
      "Galanin does not induce calcium signaling responses in cells transfected with GPR151, indicating it is unlikely to be an endogenous ligand for this receptor."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE \n3. TRUE \n4. TRUE \n5. TRUE\n\nExplanation:\n1. GPR151 is indeed an orphan G protein-coupled receptor (GPCR), which means its endogenous ligand is not definitively known.\n2. The statement about GPR151's neuronal expression pattern suggesting a potential role in nociception (the sensory perception of pain) could be consistent with scientific findings, as the localization of receptors can provide clues about their function.\n3. An increase in GPR151 mRNA expression in the dorsal root ganglion after an injury such as spared nerve injury is a specific statement that would likely be derived from experimental results, suggesting it is true based on the given context.\n4. This statement about GPR151 loss-of-function mutant mice not exhibiting significant differences in pain-related behaviors could be true if it is referencing results from a particular study comparing these mutant mice with wild-type controls.\n5. The statement regarding galanin not inducing calcium signaling responses in cells transfected with GPR151 could be true if it reflects data from specific experiments investigating galanin as a potential ligand for GPR151. Without an endogenous ligand, such studies are important for understanding the function of orphan GPCRs.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine are:\n1. A/Hong Kong/68 (the \"reference\" attenuated strain used for measuring the index of attenuation)\n2. A/Hong Kong/68 (the same strain as above, but with a slightly better index of attenuation)\n3. Unknown (the document does not provide information on the attenuation level of the third live attenuated influenza vaccine)\nIt is important to note that the attenuation level of a vaccine strain can affect its safety and efficacy, with higher attenuation levels generally associated with better safety profiles and immune responses. However, the exact attenuation levels of the live viruses in the Fluzone intradermal quadrivalent vaccine are not explicitly stated in the provided document.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Fluzone intradermal quadrivalent vaccine contains the attenuated live virus A/Hong Kong/68.\n2. The same strain, A/Hong Kong/68, is used twice in the Fluzone intradermal quadrivalent vaccine with different indices of attenuation.\n3. There is at least one unspecified live attenuated influenza vaccine in the Fluzone intradermal quadrivalent vaccine for which the document does not provide the attenuation level.",
    "llama-2-7b-chat-hf_fact": [
      "The Fluzone intradermal quadrivalent vaccine contains the attenuated live virus A/Hong Kong/68.",
      "The same strain, A/Hong Kong/68, is used twice in the Fluzone intradermal quadrivalent vaccine with different indices of attenuation.",
      "There is at least one unspecified live attenuated influenza vaccine in the Fluzone intradermal quadrivalent vaccine for which the document does not provide the attenuation level."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine does not contain attenuated live virus; it contains inactivated (killed) viruses.\n2. FALSE [correction]: The same strain would not be used twice in the Fluzone intradermal quadrivalent vaccine. Furthermore, as it is an inactivated vaccine, there are no attenuation indices relevant for its inactivated viruses.\n3. FALSE [correction]: Since Fluzone intradermal quadrivalent vaccine contains inactivated viruses, not live attenuated viruses, the statement about unspecified live attenuated influenza vaccines and their attenuation levels is incorrect.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the part of the TNFR2 gene that is genetically associated with Systemic Lupus Erythematosus is the 5.5 kb NcoI fragment. The study found that the frequency of this fragment was significantly higher in SLE patients compared to normal controls, suggesting that the polymorphic TNF genes, including the TNFR2 gene, may play a role in the pathogenesis of SLE.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 5.5 kb NcoI fragment of the TNFR2 gene is associated with Systemic Lupus Erythematosus (SLE).\n2. A study found a higher frequency of the 5.5 kb NcoI fragment in SLE patients compared to normal controls.\n3. The polymorphic TNF genes, which include the TNFR2 gene, may be involved in the pathogenesis of SLE.",
    "llama-2-7b-chat-hf_fact": [
      "The 5.5 kb NcoI fragment of the TNFR2 gene is associated with Systemic Lupus Erythematosus (SLE).",
      "A study found a higher frequency of the 5.5 kb NcoI fragment in SLE patients compared to normal controls.",
      "The polymorphic TNF genes, which include the TNFR2 gene, may be involved in the pathogenesis of SLE."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is currently no vaccine available for peanut allergy. However, researchers have been exploring the potential of using nanoparticles as immunoadjuvants for peanut oral immunotherapy. The study mentioned in the document evaluated the adjuvant capacity of poly(anhydride) nanoparticles loaded with raw or roasted peanut proteins in oral immunization of mice. The results showed that all nanoparticle formulations induced a balanced T(H)1 and T(H)2 antibody response, accompanied by low specific IgE induction. Additionally, oral immunization with spray-dried NPs loaded with peanut proteins was associated with a significant decrease in splenic T(H)2 cytokines and enhancement of both T(H)1 and regulatory cytokines. These findings suggest that oral immunization with poly(anhydride) NPs, particularly spray-dried formulations, may lead to a pro-T(H)1 immune response, which could potentially be used as a treatment for peanut allergy. However, further research is needed to confirm these findings and to determine the safety and efficacy of this approach in humans.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is currently no vaccine available for peanut allergy.\n2. Researchers are exploring the use of nanoparticles as immunoadjuvants for peanut oral immunotherapy.\n3. The study evaluated poly(anhydride) nanoparticles loaded with peanut proteins for oral immunization in mice.\n4. All nanoparticle formulations in the study induced a balanced T(H)1 and T(H)2 antibody response with low specific IgE induction in mice.\n5. Oral immunization with spray-dried nanoparticles loaded with peanut proteins significantly decreased splenic T(H)2 cytokines and enhanced T(H)1 and regulatory cytokines in mice.",
    "llama-2-7b-chat-hf_fact": [
      "There is currently no vaccine available for peanut allergy.",
      "Researchers are exploring the use of nanoparticles as immunoadjuvants for peanut oral immunotherapy.",
      "The study evaluated poly(anhydride) nanoparticles loaded with peanut proteins for oral immunization in mice.",
      "All nanoparticle formulations in the study induced a balanced T(H)1 and T(H)2 antibody response with low specific IgE induction in mice.",
      "Oral immunization with spray-dried nanoparticles loaded with peanut proteins significantly decreased splenic T(H)2 cytokines and enhanced T(H)1 and regulatory cytokines in mice."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: As of my last update, a vaccine for peanut allergy known as Palforzia has been approved by the FDA for use in the United States to mitigate allergic reactions to peanuts for individuals aged 4 through 17 years old with a confirmed diagnosis of peanut allergy.\n2. TRUE\n3. UNKNOWN (Specifics regarding the composition of the nanoparticles and study details are not provided. Without access to the research or publication, confirming this statement is not possible.)\n4. UNKNOWN (Similarly, without details on the study and its results, the exact immune response cannot be confirmed.)\n5. UNKNOWN (This statement requires specific results from the research that cannot be validated without access to the actual study or data.)",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the mouse Fxy gene is located on the minute short arm of the mouse Y chromosome. Specifically, the gene(s) controlling primary sex determination and the expression of the male-specific antigen H-Y (Tdy and Hya, respectively) are located on this arm of the Y chromosome. Additionally, the H-Y-variant of Sxr (Sxr') arose by a partial deletion within the Sxr region.",
    "llama-2-7b-chat-hf_fact_raw": "1. The mouse Fxy gene is located on the short arm of the mouse Y chromosome.\n2. The genes controlling primary sex determination and the expression of the male-specific antigen H-Y are on the short arm of the Y chromosome.\n3. The H-Y-variant of Sxr, known as Sxr', arose from a partial deletion within the Sxr region.",
    "llama-2-7b-chat-hf_fact": [
      "The mouse Fxy gene is located on the short arm of the mouse Y chromosome.",
      "The genes controlling primary sex determination and the expression of the male-specific antigen H-Y are on the short arm of the Y chromosome.",
      "The H-Y-variant of Sxr, known as Sxr', arose from a partial deletion within the Sxr region."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The mouse Fxy gene, also known as Sry (sex-determining region Y), is located on the short arm of the mouse Y chromosome.\n2. TRUE\n3. FALSE [correction]: The H-Y-variant of Sxr, known as Sxr', is not known to have arisen from a partial deletion within the Sxr region. The phenotype of Sxr' (Sex reversal), however, is due to the presence of the Sry gene within the Sxr region on the X or an autosome. The exact genetic changes causing Sxr phenotypes can vary, and while deletions can occur within the Sxr region, the statement is too specific without further context.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-2-7b-chat-hf_response": "The basis of the MPE-seq method is the use of methidiumpropyl-EDTA (MPE), a synthetic DNA intercalator that cleaves DNA in the presence of ferrous ion and oxygen. Unlike DNase I, which does not exhibit true nonsequence-specific cleavage, MPE exhibits no sequence specificity, making it better suited for protection analysis or \"footprinting\" of specific DNA-protein complexes. In this method, MPE is used to cleave the DNA in the presence of a protein of interest, resulting in the protection of the interacting nucleotides from cleavage. By comparing the protected regions to the known sequence of the DNA, the nucleotides involved in the protein-DNA interaction can be identified.",
    "llama-2-7b-chat-hf_fact_raw": "1. Methidiumpropyl-EDTA (MPE) is a synthetic DNA intercalator used in the MPE-seq method.\n2. MPE cleaves DNA in the presence of ferrous ion and oxygen.\n3. Unlike DNase I, MPE does not exhibit sequence specificity.\n4. MPE-seq is used for protection analysis or \"footprinting\" of specific DNA-protein complexes.\n5. The MPE-seq method identifies nucleotides involved in protein-DNA interactions by comparing protected regions to the known sequence of the DNA.",
    "llama-2-7b-chat-hf_fact": [
      "Methidiumpropyl-EDTA (MPE) is a synthetic DNA intercalator used in the MPE-seq method.",
      "MPE cleaves DNA in the presence of ferrous ion and oxygen.",
      "Unlike DNase I, MPE does not exhibit sequence specificity.",
      "MPE-seq is used for protection analysis or \"footprinting\" of specific DNA-protein complexes.",
      "The MPE-seq method identifies nucleotides involved in protein-DNA interactions by comparing protected regions to the known sequence of the DNA."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nEach of these statements about Methidiumpropyl-EDTA (MPE) and the MPE-seq method is accurate, assuming no new research has provided contradictory evidence that would be unknown at this point. MPE is a DNA intercalator used in the MPE-seq method. It cleaves DNA in the presence of ferrous ion and oxygen and is nonspecific to DNA sequences, which contrasts with nucleases like DNase I that typically have sequence preferences. The MPE-seq method indeed involves protection analysis of DNA-protein complexes and identifies the nucleotides involved in protein-DNA interactions by comparing protected regions against the known DNA sequence.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, it appears that the programming language used for implementing GWAR is not explicitly mentioned. However, the document does mention the use of modern programming language concepts, which suggests that a modern programming language with support for these concepts may have been used.\nSome examples of programming languages that may have been used for implementing GWAR include:\n1. Python: Python is a popular language for data science and machine learning, and it has a large number of libraries and frameworks that support the development of decision support systems.\n2. Java: Java is a widely used language for developing enterprise-level applications, and it has a large number of libraries and frameworks that support the development of decision support systems.\n3. JavaScript: JavaScript is a popular language for web development, and it has a number of libraries and frameworks that support the development of decision support systems.\n4. C#: C# is a modern, object-oriented language developed by Microsoft, and it has a number of libraries and frameworks that support the development of decision support systems.\nWithout further information, it is difficult to determine which programming language was specifically used for implementing GWAR.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is suggestive evidence that xaliproden may improve the prognosis of amyotrophic lateral sclerosis (ALS).\nIn Study 1, the 2 mg dose of xaliproden showed a significant 30% relative risk reduction (RRR) in the time to vital capacity (VC) < 50% analysis, compared to the placebo group. Although this did not reach statistical significance, the trend suggests that xaliproden may have a beneficial effect on the progression of ALS.\nIn Study 2, there was a trend in favour of add-on 1 mg dose of xaliproden vs. placebo for time to VC < 50% or DTP, with a RRR of 12% (95% CI: -6.27, ns). The adjusted RR ratios were consistently more favourable for the xaliproden groups.\nWhile the results were not statistically significant, the data suggests that xaliproden may have a small effect on clinically noteworthy aspects of disease progression in ALS, including vital capacity. However, larger and longer-term studies are needed to confirm these findings and establish the safety and efficacy of xaliproden for the treatment of ALS.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is suggestive evidence that xaliproden may improve the prognosis of amyotrophic lateral sclerosis (ALS).\n2. Study 1 indicated a 30% relative risk reduction in the time to vital capacity less than 50% for the 2 mg dose of xaliproden compared to placebo.\n3. The results from Study 1 for xaliproden did not reach statistical significance despite the trend suggesting a beneficial effect.\n4. Study 2 showed a trend favoring the 1 mg dose of xaliproden over placebo with a 12% relative risk reduction for time to vital capacity less than 50% or DTP.\n5. Larger and longer-term studies are needed to confirm the findings and establish the safety and efficacy of xaliproden for the treatment of ALS.",
    "llama-2-7b-chat-hf_fact": [
      "There is suggestive evidence that xaliproden may improve the prognosis of amyotrophic lateral sclerosis (ALS).",
      "Study 1 indicated a 30% relative risk reduction in the time to vital capacity less than 50% for the 2 mg dose of xaliproden compared to placebo.",
      "The results from Study 1 for xaliproden did not reach statistical significance despite the trend suggesting a beneficial effect.",
      "Study 2 showed a trend favoring the 1 mg dose of xaliproden over placebo with a 12% relative risk reduction for time to vital capacity less than 50% or DTP.",
      "Larger and longer-term studies are needed to confirm the findings and establish the safety and efficacy of xaliproden for the treatment of ALS."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE\n\nRationale:\n1. Without specific data or a reference to a particular study that supports the claim, I can't confirm the accuracy of this statement.\n2. The detailed results from \"Study 1\" are not specified in widely available knowledge, and without this information, I cannot confirm if the study indicated a 30% risk reduction.\n3. Since the outcome of \"Study 1\" regarding statistical significance is not readily known, I cannot verify the truth of this statement.\n4. \"Study 2\" and its results are not specified in general knowledge, so the truthfulness of this statement regarding the 12% relative risk reduction can't be ascertained.\n5. This statement is generally true as it represents a common perspective in clinical research, where larger and longer-term studies are typically needed to confirm preliminary findings and determine the safety and efficacy of a treatment.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the transgenes are inserted in chromosome 2 and 3. Specifically, lines 12 and 2 have insertions in the 85D9/10 and 86B4/6 interband regions, respectively, while line 41 has a puffing of the transformed region that did not allow for the detection of any novel structures. Line 3 does not have a novel band, which could indicate integration into an existing band.",
    "llama-2-7b-chat-hf_fact_raw": "1. Transgenes are inserted in chromosome 2 and 3 in the case of the LiPS-A3S line.\n2. Lines 12 and 2 have insertions in the 85D9/10 and 86B4/6 interband regions, respectively.\n3. Line 41 has a puffing of the transformed region that did not allow for the detection of any novel structures.\n4. Line 3 does not have a novel band, which could indicate integration into an existing band.",
    "llama-2-7b-chat-hf_fact": [
      "Transgenes are inserted in chromosome 2 and 3 in the case of the LiPS-A3S line.",
      "Lines 12 and 2 have insertions in the 85D9/10 and 86B4/6 interband regions, respectively.",
      "Line 41 has a puffing of the transformed region that did not allow for the detection of any novel structures.",
      "Line 3 does not have a novel band, which could indicate integration into an existing band."
    ],
    "llama-2-7b-chat-hf_judge_raw": "UNKNOWN\n\nThe statements provided seem to be referencing specific scientific research findings regarding transgenic lines (perhaps genetically modified organisms or cell lines with introduced genes, known as transgenes). Without access to the original passage or research publication containing these details, it's not possible to accurately determine the truthfulness of these technical statements. Each would require specific knowledge of the genetic manipulation performed in these lines, as well as the results of any molecular or cytogenetic analyses.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are several deep learning tools that exist for predicting drug synergy:\n1. DeepSynergy: This is the tool developed in the study, which uses deep learning to predict drug synergy based on chemical and genomic information. It was shown to significantly outperform other machine learning methods in predicting novel drug combinations within the space of explored drugs and cell lines.\n2. Gradient Boosting Machines (GBM): GBM is a machine learning algorithm that is often used for predictive modeling tasks. It was included in the study as a baseline method for comparison with DeepSynergy.\n3. Random Forests (RF): RF is another machine learning algorithm that is commonly used for predictive modeling. It was also included in the study as a baseline method for comparison with DeepSynergy.\n4. Support Vector Machines (SVM): SVM is a machine learning algorithm that is commonly used for classification and regression tasks. It was included in the study as a baseline method for comparison with DeepSynergy.\n5. Elastic Nets (EN): EN is a machine learning algorithm that is a combination of GBM and RF. It was included in the study as a baseline method for comparison with DeepSynergy.\nBased on the results of the study, DeepSynergy outperformed all of these methods in predicting novel drug combinations within the space of explored drugs and cell lines. However, it is important to note that the predictive performance of these methods may be limited when extrapolating to unexplored drugs or cell lines, which suggests that there may be limitations in the size and diversity of the dataset.",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepSynergy is a deep learning tool developed to predict drug synergy using chemical and genomic information.\n2. Gradient Boosting Machines (GBM) is a machine learning algorithm used for predictive modeling.\n3. Random Forests (RF) is a machine learning algorithm used for predictive modeling.\n4",
    "llama-2-7b-chat-hf_fact": [
      "DeepSynergy is a deep learning tool developed to predict drug synergy using chemical and genomic information.",
      "Gradient Boosting Machines (GBM) is a machine learning algorithm used for predictive modeling.",
      "Random Forests (RF) is a machine learning algorithm used for predictive modeling."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the cloud-based platform that has been developed for comparing GWAS is the GWAtoolbox.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that CMB305 may not be effective against sarcomas. The document mentions that ZIMET 3164, a drug similar to CMB305, was unable to prolong the survival time of mice bearing sarcomas, including sarcoma 180 P, sarcoma 180 G, and Walker 256 carcinosarcoma. Additionally, the drug was found to exert its maximum effect when given on days -2 to +2 relative to antigenic stimulus, suggesting that it interferes with the afferent limb of the immune response. These findings suggest that CMB305 may have similar limitations in its ability to treat sarcomas as ZIMET 3164. Therefore, it is unlikely that CMB305 would be effective against sarcomas.",
    "llama-2-7b-chat-hf_fact_raw": "1. CMB305 might not be effective against sarcomas.\n2. ZIMET 3164, a drug similar to CMB305, was unable to prolong the survival time of mice with sarcomas.\n3. The tested sarcomas in the mice included sarcoma 180 P, sarcoma 180 G, and Walker 256 carcinosarcoma.\n4. ZIMET 3164 has a maximum effect when administered from days -2 to +2 relative to antigenic stimulus.\n5. ZIMET 3164 appears to interfere with the afferent limb of the immune response.",
    "llama-2-7b-chat-hf_fact": [
      "CMB305 might not be effective against sarcomas.",
      "ZIMET 3164, a drug similar to CMB305, was unable to prolong the survival time of mice with sarcomas.",
      "The tested sarcomas in the mice included sarcoma 180 P, sarcoma 180 G, and Walker 256 carcinosarcoma.",
      "ZIMET 3164 has a maximum effect when administered from days -2 to +2 relative to antigenic stimulus.",
      "ZIMET 3164 appears to interfere with the afferent limb of the immune response."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nRationale: The provided statements require specific scientific knowledge about the effectiveness of CMB305 and ZIMET 3164, their comparison, their effects on particular types of sarcomas, the timing of administering ZIMET 3164, and its mechanism of action. Without the relevant scientific context or studies, it is not possible to accurately determine the truthfulness of these statements. An expert in the field or access to the specific research data would be required to assess these claims.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the manifestations of the Saint's Triad are:\n1. Cholelithiasis (gallstones in the bile ducts)\n2. Diverticulosis (diverticula in the colon)\n3. Hiatus hernia (a protrusion of the stomach through the diaphragm)\nThese three conditions are considered to be part of the Saint's Triad because they are often found together in patients, and the incidence of the triad is higher than expected. The study found that 7 cases of the Saint's Triad were identified in 684 patients who underwent radiological examinations, which is a prevalence of 1.02%. Additionally, 86 cases of bifocal associations were found, which are combinations of the three conditions. The most common bifocal associations were cholelithiasis + diverticulosis (59 cases) and cholelithiasis + hiatus hernia (17 cases).",
    "llama-2-7b-chat-hf_fact_raw": "1. Cholelithiasis, diverticulosis, and hiatus hernia are conditions associated with Saint's Triad.\n2. Saint's Triad is characterized by the often concurrent presence of its three conditions in patients.\n3. In a study, 7 cases of the Saint's Triad were identified in 684 patients who underwent radiological examinations.\n4. The prevalence of Saint’s Triad in the study mentioned was 1.02%.\n5. The most common bifocal associations found in the study were cholelithiasis + diverticulosis (59 cases) and cholelithiasis + hiatus hernia (17 cases).",
    "llama-2-7b-chat-hf_fact": [
      "Cholelithiasis, diverticulosis, and hiatus hernia are conditions associated with Saint's Triad.",
      "Saint's Triad is characterized by the often concurrent presence of its three conditions in patients.",
      "In a study, 7 cases of the Saint's Triad were identified in 684 patients who underwent radiological examinations.",
      "The prevalence of Saint’s Triad in the study mentioned was 1.02%.",
      "The most common bifocal associations found in the study were cholelithiasis + diverticulosis (59 cases) and cholelithiasis + hiatus hernia (17 cases)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN (The specific study where this data may have come from is not provided, nor is it a widely recognized statistic)\n4. FALSE [correction]: If 7 cases of Saint's Triad were identified in 684 patients, the prevalence would be approximately \\( \\frac{7}{684} \\times 100 = 1.0235% \\), which is rounded to 1.02%. However, without the statement being exact about the rounding or providing the details, it is difficult to assert the precision of the prevalence rate.\n5. UNKNOWN (Similar to statement 3, this information is specific to a study not provided in the context.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it appears that overexpression of LY6K is not associated with a better prognosis for non-small cell lung cancer (NSCLC) patients. In fact, the information suggests that PLK1 overexpression is associated with tumor aggressiveness and a poor prognosis in NSCLC, including SCLC.\nThe document states that PLK1 is overexpressed in many tumors, including SCLC, and that its overexpression is associated with a poor prognosis. Additionally, the document mentions that the selective PLK1 inhibitor BI 6727 significantly induced the inhibition of proliferation and apoptosis in SCLC cell lines, and that treatment with BI 6727 resulted in attenuated growth and apoptosis in xenografts. These findings suggest that inhibiting PLK1 may have therapeutic potential for SCLC patients.\nTherefore, based on the information provided, it can be concluded that overexpression of LY6K is not associated with a better prognosis for NSCLC patients, and that PLK1 overexpression may be a negative prognostic factor in SCLC.",
    "llama-2-7b-chat-hf_fact_raw": "1. Overexpression of LY6K is not associated with a better prognosis for non-small cell lung cancer (NSCLC) patients.\n2. PLK1 overexpression is associated with tumor aggressiveness and a poor prognosis in NSCLC, including small cell lung cancer (SCLC).\n3. PLK1 is overexpressed in many tumors, including SCLC.\n4. The selective PLK1 inhibitor BI 6727 induced inhibition of proliferation and apoptosis in SCLC cell lines.\n5. Treatment with BI 6727 resulted in attenuated growth and apoptosis in xenografts.",
    "llama-2-7b-chat-hf_fact": [
      "Overexpression of LY6K is not associated with a better prognosis for non-small cell lung cancer (NSCLC) patients.",
      "PLK1 overexpression is associated with tumor aggressiveness and a poor prognosis in NSCLC, including small cell lung cancer (SCLC).",
      "PLK1 is overexpressed in many tumors, including SCLC.",
      "The selective PLK1 inhibitor BI 6727 induced inhibition of proliferation and apoptosis in SCLC cell lines.",
      "Treatment with BI 6727 resulted in attenuated growth and apoptosis in xenografts."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Overexpression of LY6K (Lymphocyte antigen 6 complex, locus K) is generally associated with poor prognosis in patients with non-small cell lung cancer (NSCLC). Saying it is not associated with a better prognosis is correct.\n   \n2. TRUE: Polo-like kinase 1 (PLK1) overexpression is indeed associated with tumor aggressiveness and a poor prognosis in multiple forms of cancer, including non-small cell lung cancer (NSCLC). However, the statement incorrectly includes small cell lung cancer (SCLC) as a subtype of NSCLC, which it is not; SCLC and NSCLC are distinct types of lung cancer.\n\n3. TRUE: PLK1 is known to be overexpressed in many types of tumors, including SCLC, and this is often associated with poor clinical outcomes.\n\n4. TRUE: The selective PLK1 inhibitor BI 6727 (also known as volasertib) has been reported to inhibit proliferation and induce apoptosis in cancer cell lines, including SCLC.\n\n5. TRUE: Treatment with the PLK1 inhibitor BI 6727 has been shown to result in reduced tumor growth and to induce apoptosis in cancer models, such as xenografts (where human tumor cells are implanted in another species, usually rodents, to study cancer development and treatment).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are the CDK targets that are dephosphorylated during cytokinesis:\n1. Aip1\n2. Ede1\n3. Inn1\nThese targets are identified through phosphoproteome analysis of mitotic exit and further confirmed through the use of a new tool to generate conditionally phosphorylated proteins. The study suggests that the dephosphorylation of these CDK targets is required for cytokinesis to occur properly.",
    "llama-2-7b-chat-hf_fact_raw": "1. Aip1 is a CDK target that is dephosphorylated during cytokinesis.\n2. Ede1 is a CDK target that is dephosphorylated during cytokinesis.\n3. Inn1 is a CDK target that is dephosphorylated during cytokinesis.\n4. The dephosphorylation of CDK targets Aip1, Ede1, and Inn1 is required for proper cytokinesis.\n5. Phosphoproteome analysis of mitotic exit helps identify CDK targets that are dephosphorylated during cytokinesis.",
    "llama-2-7b-chat-hf_fact": [
      "Aip1 is a CDK target that is dephosphorylated during cytokinesis.",
      "Ede1 is a CDK target that is dephosphorylated during cytokinesis.",
      "Inn1 is a CDK target that is dephosphorylated during cytokinesis.",
      "The dephosphorylation of CDK targets Aip1, Ede1, and Inn1 is required for proper cytokinesis.",
      "Phosphoproteome analysis of mitotic exit helps identify CDK targets that are dephosphorylated during cytokinesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Aip1 (an actin interacting protein) is known to be a Cyclin-dependent kinase (CDK) target that gets dephosphorylated during cytokinesis.\n2. UNKNOWN: The status of Ede1 as a CDK target that is dephosphorylated during cytokinesis cannot be confirmed without specific information, as Ede1 is an early endocytic protein and not commonly noted in such contexts.\n3. TRUE: Inn1 is a CDK substrate that is dephosphorylated during cytokinesis. It plays a role in coordinating membrane ingression with actomyosin ring contraction.\n4. TRUE: The dephosphorylation of CDK targets, such as Aip1, Ede1 (if indeed it is a CDK target), and Inn1, is generally required for their functional transition during the late stages of cell division, including cytokinesis.\n5. TRUE: Phosphoproteome analysis is a technique often used to study protein phosphorylation states, including the identification of CDK targets that are dephosphorylated during cytokinesis or cell cycle progression.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, Xanamem appears to be a term used to describe the detection and analysis of alprazolam (Xanax) and its metabolites in urine samples. The document describes a method for improving the chromatographic performance of a gas chromatographic system for the detection and identification of alprazolam and its metabolites in urine, including alpha-hydroxyalprazolam and 3-hydroxymethyl-5-methyltriazolyl chlorobenzophenone. The method was tested on urine samples from hospitalized patients who had ingested alprazolam, and the results showed that alpha-hydroxyalprazolam was present in the highest concentration and separated best from endogenous urine substances. The document also includes a single dose concentration-time study that determined the time course of alprazolam and metabolite concentrations over 48 hours in urine samples.",
    "llama-2-7b-chat-hf_fact_raw": "1. Xanamem is associated with the detection and analysis of alprazolam and its metabolites in urine samples.\n2. The document details a method to improve the chromatographic performance of a system for detecting alprazolam and its metabolites in urine.\n3. Alpha-hydroxyalprazolam and 3-hydroxymethyl-5-methyltriazolyl chlorobenzophenone are mentioned as metabolites of alprazolam.\n4. Urine samples from hospitalized patients who had ingested alprazolam indicated that alpha-hydroxyalprazolam was present in the highest concentration.\n5. A concentration-time study in the document looks at the time course of alprazolam and metabolite concentrations over 48 hours in urine samples.",
    "llama-2-7b-chat-hf_fact": [
      "Xanamem is associated with the detection and analysis of alprazolam and its metabolites in urine samples.",
      "The document details a method to improve the chromatographic performance of a system for detecting alprazolam and its metabolites in urine.",
      "Alpha-hydroxyalprazolam and 3-hydroxymethyl-5-methyltriazolyl chlorobenzophenone are mentioned as metabolites of alprazolam.",
      "Urine samples from hospitalized patients who had ingested alprazolam indicated that alpha-hydroxyalprazolam was present in the highest concentration.",
      "A concentration-time study in the document looks at the time course of alprazolam and metabolite concentrations over 48 hours in urine samples."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE: Alpha-hydroxyalprazolam and 4-hydroxymethyl-5-methyltriazolyl chlorobenzophenone are indeed mentioned as metabolites of alprazolam, but there might be a minor error in the chemical name provided. The commonly known metabolite is alpha-hydroxyalprazolam and a metabolite involving a triazolo ring, but the exact name given does not match standard nomenclature.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the role of the Hof1-Cyk3 interaction in yeast is to facilitate cytokinesis through the recruitment of Hof1 to the bud neck. The interaction between Hof1 and Cyk3 is critical for cytokinesis, as the Vrp1 fragment unable to interact with yeast WASP (Las17/Bee1) retains function in Hof1 recruitment but not in polarization of the cortical actin cytoskeleton. The Vrp1 HOT domain, which consists of three tandem proline-rich motifs flanked by serines, binds to the Hof1 SH3 domain and counteracts its inhibitory effect on cytokinesis. Therefore, the Hof1-Cyk3 interaction plays a crucial role in the proper execution of cytokinesis in yeast.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Hof1-Cyk3 interaction in yeast facilitates cytokinesis through the recruitment of Hof1 to the bud neck.\n2. The interaction between Hof1 and Cyk3 is critical for cytokinesis in yeast.\n3. The Vrp1 fragment that cannot interact with yeast WASP retains function in Hof1 recruitment to the bud neck.\n4. The phosphorylation of the Hof1 HOT domain, which consists of three tandem proline-rich motifs flanked by serines, contributes to cytokinesis.\n5. The Hof1 SH3 domain interaction with the Hof1 HOT domain counteracts an inhibitory effect on cytokinesis.",
    "llama-2-7b-chat-hf_fact": [
      "The Hof1-Cyk3 interaction in yeast facilitates cytokinesis through the recruitment of Hof1 to the bud neck.",
      "The interaction between Hof1 and Cyk3 is critical for cytokinesis in yeast.",
      "The Vrp1 fragment that cannot interact with yeast WASP retains function in Hof1 recruitment to the bud neck.",
      "The phosphorylation of the Hof1 HOT domain, which consists of three tandem proline-rich motifs flanked by serines, contributes to cytokinesis.",
      "The Hof1 SH3 domain interaction with the Hof1 HOT domain counteracts an inhibitory effect on cytokinesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The Hof1-Cyk3 interaction in yeast is known to facilitate cytokinesis, and this is consistent with what is generally understood about these proteins—that they interact and function in the coordination of cytokinesis, particularly with Hof1's recruitment to the bud neck.\n2. TRUE: Given that Hof1 is recruited to the bud neck during cytokinesis through its interaction with Cyk3 and the fact that cytokinesis is a critical process in cell division, it is reasonable to infer that the interaction is critical for cytokinesis in yeast.\n3. UNKNOWN: The statement about the function of a Vrp1 fragment lacking interaction with yeast WASP (Wiskott-Aldrich syndrome protein) in Hof1 recruitment is too specific and requires additional context or specialized knowledge in molecular biology for verification.\n4. UNKNOWN: The statement regarding the phosphorylation of the Hof1 HOT domain and its composition includes specific details that cannot be verified without additional context or access to specific scientific literature on the topic.\n5. UNKNOWN: The statement about the interaction between the Hof1 SH3 domain and the Hof1 HOT domain having a regulatory effect on cytokinesis is also too specific and cannot be easily verified without further information or expertise in the subject matter.\n",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following T-UCRs have been implicated in gastric cancer:\n1. Ubiquitin C-terminal hydrolase L1 (UCH-L1)\nThe document states that UCH-L1 belongs to the deubiquitinating enzyme family and is overexpressed in gastric cardiac adenocarcinoma (GCA), a majority of gastric cancer cases. The study also found that UCH-L1 overexpression is associated with poor prognosis in GCA patients, and silencing of UCH-L1 reduces the ability of gastric cancer cells to proliferate, form colonies, migrate, and invade. These findings suggest that UCH-L1 is a promising prognostic biomarker for gastric cancer and may play a role in the carcinogenesis of gastric cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ubiquitin C-terminal hydrolase L1 (UCH-L1) is overexpressed in gastric cardiac adenocarcinoma (GCA).\n2. UCH-L1 overexpression is associated with poor prognosis in GCA patients.\n3. Silencing of UCH-L1 reduces the ability of gastric cancer cells to proliferate, form colonies, migrate, and invade.\n4. UCH-L1 is implicated as a prognostic biomarker for gastric cancer.\n5. UCH-L1 may play a role in the carcinogenesis of gastric cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Ubiquitin C-terminal hydrolase L1 (UCH-L1) is overexpressed in gastric cardiac adenocarcinoma (GCA).",
      "UCH-L1 overexpression is associated with poor prognosis in GCA patients.",
      "Silencing of UCH-L1 reduces the ability of gastric cancer cells to proliferate, form colonies, migrate, and invade.",
      "UCH-L1 is implicated as a prognostic biomarker for gastric cancer.",
      "UCH-L1 may play a role in the carcinogenesis of gastric cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nThe provided statements regarding UCH-L1 and its association with gastric cancer, its role in cell functions relevant to cancer progression, and its potential as a prognostic biomarker are consistent with what is known from scientific research on this topic. However, it's always best to consult current scientific literature for the most up-to-date and comprehensive understanding of such topics.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the Lupus Severity Index (LSI) is a measure of the severity of liver disease, calculated by adjusting the distribution of sulfur colloid between the liver and spleen (LSI) or the liver and bone marrow (LBI) for spleen size. The LSI and LBI were found to correlate highly with each other (r = 0.753; P < 0.001) and with clinical variables such as hepatic fibrosis (r = -0.694; P < 0.001) and the Child-Pugh classification (r = 0.78; P < 0.001) in a study of 329 consecutive patients with liver disease. The severity score was defined as the arithmetic mean of the LBI and LSI. The LSI is a useful tool for evaluating the severity of liver disease and may be useful in clinical decision-making and monitoring of treatment response.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Lupus Severity Index (LSI) is a measure of the severity of liver disease.\n2. The LSI is calculated by adjusting the distribution of sulfur colloid between the liver and spleen or the liver and bone marrow.\n3. The Lupus Severity Index (LSI) and Liver Bone Index (LBI) were found to highly correlate with each other in a study (r = 0.753; P < 0.001).\n4. The Lupus Severity Index (LSI) correlates with clinical variables such as hepatic fibrosis (r = -0.694; P < 0.001) and the Child-Pugh classification (r = 0.78; P < 0.001).\n5. The severity score is defined as the arithmetic mean of the LBI and LSI.",
    "llama-2-7b-chat-hf_fact": [
      "The Lupus Severity Index (LSI) is a measure of the severity of liver disease.",
      "The LSI is calculated by adjusting the distribution of sulfur colloid between the liver and spleen or the liver and bone marrow.",
      "The Lupus Severity Index (LSI) and Liver Bone Index (LBI) were found to highly correlate with each other in a study (r = 0.753; P < 0.001).",
      "The Lupus Severity Index (LSI) correlates with clinical variables such as hepatic fibrosis (r = -0.694; P < 0.001) and the Child-Pugh classification (r = 0.78; P < 0.001).",
      "The severity score is defined as the arithmetic mean of the LBI and LSI."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Lupus Severity Index (LSI) is a measure of the severity of lupus disease, not liver disease.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout further context or information in medical literature, the details about the Lupus Severity Index (LSI), its calculation, correlation with the Liver Bone Index (LBI), and clinical variables remain unknown.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the disorders caused by de novo mutations in ZSWIM6 are:\n1. Acromelic frontonasal dysostosis (AFND): A severe frontonasal and limb malformation syndrome associated with neurocognitive and motor delay, caused by a recurrent de novo missense variant within the C-terminal Sin3-like domain of ZSWIM6.\n2. Severe-profound intellectual disability: Seven unrelated individuals with a recurrent de novo nonsense variant (c.2737C>T [p.Arg913Ter]) in the penultimate exon of ZSWIM6 have severe-profound intellectual disability and additional central and peripheral nervous system symptoms, but an absence of frontonasal or limb malformations.\nIt is important to note that these findings suggest that different variants in the same gene (ZSWIM6) can lead to distinct phenotypes, highlighting the complexity of the genetic basis of developmental disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. De novo mutations in ZSWIM6 can cause Acromelic frontonasal dysostosis (AFND).\n2. Individuals with AFND due to de novo mutations in ZSWIM6 exhibit neurocognitive and motor delays.\n3. A recurrent de novo missense variant within the C-terminal Sin3-like domain of ZSWIM6 is associated with AFND.\n4. De novo mutations in ZSWIM6 can lead to severe-profound intellectual disability in some individuals.\n5. A recurrent de novo nonsense variant (c.2737C>T [p.Arg913Ter]) in ZSWIM6 is linked to severe-profound intellectual disability and additional central and peripheral nervous system symptoms without frontonasal or limb malformations.",
    "llama-2-7b-chat-hf_fact": [
      "De novo mutations in ZSWIM6 can cause Acromelic frontonasal dysostosis (AFND).",
      "Individuals with AFND due to de novo mutations in ZSWIM6 exhibit neurocognitive and motor delays.",
      "A recurrent de novo missense variant within the C-terminal Sin3-like domain of ZSWIM6 is associated with AFND.",
      "De novo mutations in ZSWIM6 can lead to severe-profound intellectual disability in some individuals.",
      "A recurrent de novo nonsense variant (c.2737C>T [p.Arg913Ter]) in ZSWIM6 is linked to severe-profound intellectual disability and additional central and peripheral nervous system symptoms without frontonasal or limb malformations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: De novo mutations in the ZSWIM6 gene have been implicated in the etiology of Acromelic frontonasal dysostosis (AFND).\n2. TRUE: Individuals with AFND may exhibit neurocognitive and motor delays as part of their clinical presentation.\n3. TRUE: A specific recurrent de novo missense variant within the C-terminal Sin3-like domain of ZSWIM6 has been associated with AFND in some cases.\n4. TRUE: De novo mutations in ZSWIM6 can indeed lead to severe-profound intellectual disability, which has been reported in some affected individuals.\n5. UNKNOWN: Without specific literature or clinical reports available on this variant (c.2737C>T [p.Arg913Ter]) in this context, the statement's accuracy regarding its association with intellectual disability and absence of frontonasal or limb malformations cannot be determined. It is advisable to consult the latest genetic research for confirmation.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the study, the disease that can be classified using the Koos Classification is Early Onset Scoliosis (EOS). The study evaluates the reliability of the Classification of Early Onset Scoliosis (C-EOS) scheme, which is a classification system used to categorize EOS patients based on their etiology, major curve, and kyphosis. The study found excellent interobserver and intraobserver reliability of the C-EOS scheme, indicating that it can be used as a reliable tool for classifying EOS patients for clinical communication and research. Therefore, based on the information provided in the study, the disease that can be classified using the Koos Classification is Early Onset Scoliosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Koos Classification is used to classify Early Onset Scoliosis (EOS).\n2. The Classification of Early Onset Scoliosis (C-EOS) scheme categorizes EOS patients based on their etiology, major curve, and kyphosis.\n3. The study found excellent interobserver and intraobserver reliability for the C-EOS scheme.\n4. The C-EOS scheme is used for clinical communication and research purposes related to Early Onset Scoliosis.",
    "llama-2-7b-chat-hf_fact": [
      "The Koos Classification is used to classify Early Onset Scoliosis (EOS).",
      "The Classification of Early Onset Scoliosis (C-EOS) scheme categorizes EOS patients based on their etiology, major curve, and kyphosis.",
      "The study found excellent interobserver and intraobserver reliability for the C-EOS scheme.",
      "The C-EOS scheme is used for clinical communication and research purposes related to Early Onset Scoliosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. TRUE\n\nExplanation:\nThe information provided does not contain enough detail to verify the accuracy of statement 1 regarding the Koos Classification, nor details about a specific study's findings on interobserver and intraobserver reliability for the C-EOS scheme in statement 3. The remaining statements about the C-EOS scheme being used to categorize EOS patients based on their etiology, major curve, and kyphosis (statement 2), and it being used for clinical communication and research purposes (statement 4), are consistent with common practices regarding scoliosis classification systems in the medical field.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the in vivo effects of AZD8601 are as follows:\n1. Vasodilation: AZD8601 induces pronounced, sustained, and dose-dependent vasodilation in the microvasculature, as observed through multi-parametric photoacoustic microscopy.\n2. Blood flow upregulation: AZD8601 leads to increased blood flow in the microvasculature, as demonstrated by the photoacoustic imaging.\n3. Neovessel formation: AZD8601 promotes the formation of new blood vessels, as evidenced by the photoacoustic imaging and the comparison with recombinant human VEGF-A protein.\n4. Improved vascularization and tissue oxygenation: In a mouse model of diabetic wound healing, sequential dosing of AZD8601 leads to improved vascularization and tissue oxygenation of the wound bed, resulting in accelerated re-epithelialization during the early phase of diabetic wound healing, as demonstrated by the use of a boron nanoparticle-based tissue oxygen sensor.\nIn summary, AZD8601 has shown promise in improving microvascular responses and tissue oxygenation in both in vitro and in vivo settings, suggesting its potential as a therapeutic agent for various diseases, including cardiovascular medicine and wound healing.",
    "llama-2-7b-chat-hf_fact_raw": "1. AZD8601 induces pronounced, sustained, and dose-dependent vasodilation in the microvasculature.\n2. AZD8601 leads to increased blood flow in the microvasculature.\n3. AZD8601 promotes the formation of new blood vessels.\n4. In a mouse model of diabetic wound healing, sequential dosing of AZD8601 leads to improved vascularization and tissue oxygenation of the wound bed.\n5. AZD8601 results in accelerated re-epithelialization during the early phase of diabetic wound healing in a mouse model.",
    "llama-2-7b-chat-hf_fact": [
      "AZD8601 induces pronounced, sustained, and dose-dependent vasodilation in the microvasculature.",
      "AZD8601 leads to increased blood flow in the microvasculature.",
      "AZD8601 promotes the formation of new blood vessels.",
      "In a mouse model of diabetic wound healing, sequential dosing of AZD8601 leads to improved vascularization and tissue oxygenation of the wound bed.",
      "AZD8601 results in accelerated re-epithelialization during the early phase of diabetic wound healing in a mouse model."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN: Without specific scientific data or references to back up this statement about the drug AZD8601, it is not possible to verify its accuracy.\n2. UNKNOWN: Again, the effect of AZD8601 on blood flow in the microvasculature is not verifiable without relevant scientific research or clinical data.\n3. UNKNOWN: The claim that AZD8601 promotes the formation of new blood vessels needs supporting evidence from preclinical or clinical studies to be confirmed.\n4. UNKNOWN: The effect of AZD8601 on vascularization and tissue oxygenation in a mouse model of diabetic wound healing would need to be supported by experimental data or study results.\n5. UNKNOWN: The statement regarding accelerated re-epithelialization and its relation to AZD8601 in the context of diabetic wound healing in a mouse model requires specific study references to determine its validity.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, SAHFS are created through the spatial repositioning of the genome, which occurs according to certain chromatin features. These features are correlated with, but do not require, the repressive marks histone H3 trimethylated on lysine 9 (H3K9me3) and H3K27me3. The layered high-order chromatin structures (HOCS) of SAHFs are formed through the dynamic change in HOCS as SAHFs form, with the linear epigenomic profiles of these repressive marks being highly static. This suggests that the layered HOCS of SAHFs is achieved mainly through the spatial rearrangement of pre-existing heterochromatin, rather than the spreading of heterochromatin.",
    "llama-2-7b-chat-hf_fact_raw": "1. SAHFS creation involves the spatial repositioning of the genome.\n2. The creation of SAHFS is correlated with chromatin features.\n3. Repressive marks such as histone H3 trimethylated on lysine 9 (H3K9me3) and H3K27me3 are correlated with SAHFS creation but are not required.\n4. The formation of SAHFS involves dynamic changes in high-order chromatin structures (HOCS).\n5. During the formation of SAHFS, the linear epigenomic profiles of repressive marks remain highly static.",
    "llama-2-7b-chat-hf_fact": [
      "SAHFS creation involves the spatial repositioning of the genome.",
      "The creation of SAHFS is correlated with chromatin features.",
      "Repressive marks such as histone H3 trimethylated on lysine 9 (H3K9me3) and H3K27me3 are correlated with SAHFS creation but are not required.",
      "The formation of SAHFS involves dynamic changes in high-order chromatin structures (HOCS).",
      "During the formation of SAHFS, the linear epigenomic profiles of repressive marks remain highly static."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nNote: SAHFS stands for senescence-associated heterochromatin foci, which are known to be linked to the repositioning of the genome, chromatin features, and dynamic changes in chromatin structures, consistent with the description provided in the statements. However, without more specific context, it's not possible to conclusively address the details of each statement, such as the role of repressive marks or the static nature of linear epigenomic profiles. These statements generally align with what is known about SAHFS, assuming they are based on accurate scientific understanding as of the knowledge cutoff date.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the function of the PDZ domain in SATB1 is to mediate interactions with several chromatin proteins. The PDZ-like domain of SATB1, which is located in the N-terminal region of the protein, is responsible for recruiting interacting partners of SATB1 to its genomic binding sites. Overexpression of the PDZ-like domain of SATB1 in vivo resulted in de-repression of SATB1-regulated genes, indicating that the PDZ domain exerts a dominant negative effect on genes regulated by SATB1. In addition, gene expression profiling of a stable dominant negative model of SATB1 in HEK 293T cells revealed that overexpression of the PDZ-like domain resulted in the upregulation of 600 out of 19000 genes analysed, including genes involved in important signalling cascades and cellular functions. These studies suggest that the PDZ domain of SATB1 plays a critical role in global gene regulation through its interaction with other cellular proteins.",
    "llama-2-7b-chat-hf_fact_raw": "1. The PDZ domain in SATB1 mediates interactions with several chromatin proteins.\n2. The PDZ-like domain of SATB1 is located in the N-terminal region of the protein.\n3. Overexpression of the PDZ-like domain of SATB1 in vivo causes de-repression of SATB1-regulated genes.\n4. Overexpression of the PDZ-like domain in HEK 293T cells led to the upregulation of 600 out of 19000 genes analyzed.\n5. The PDZ domain of SATB1 is implicated in global gene regulation.",
    "llama-2-7b-chat-hf_fact": [
      "The PDZ domain in SATB1 mediates interactions with several chromatin proteins.",
      "The PDZ-like domain of SATB1 is located in the N-terminal region of the protein.",
      "Overexpression of the PDZ-like domain of SATB1 in vivo causes de-repression of SATB1-regulated genes.",
      "Overexpression of the PDZ-like domain in HEK 293T cells led to the upregulation of 600 out of 19000 genes analyzed.",
      "The PDZ domain of SATB1 is implicated in global gene regulation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE\n\nPlease note that while the statements regarding the PDZ domain of SATB1 and its general roles in chromatin interaction and global gene regulation are true to the understanding of molecular biology, the specifics regarding the location of the domain and the effects of its overexpression depend on detailed scientific findings which are not provided. Without access to the specific passage or scientific study these statements are referencing, statements 3 and 4 cannot be accurately confirmed or denied, hence I labeled the statement 4 as UNKNOWN due to lack of context.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "llama-2-7b-chat-hf_response": "The basis of the BLISS technique is the use of Blissymbols, a visual-gestural language system, as a facilitating technique for communication in individuals with severe verbal apraxia. The BLISS technique is based on the idea that individuals with good auditory comprehension, good visual-perceptual skills, and a high level of motivation are more successful in using Blissymbols as a means of communication. The technique involves using Blissymbols in a group setting to encourage verbal language and writing skills, even though they are not the primary focus of the therapy. The study found that the use of Blissymbols can help improve communication skills in individuals with severe verbal apraxia, and that a group therapy approach can provide needed motivation and support.",
    "llama-2-7b-chat-hf_fact_raw": "1. BLISS technique uses Blissymbols as a facilitating technique for communication in individuals with severe verbal apraxia.\n2. Blissymbols are part of a visual-gestural language system.\n3. The BLISS technique targets individuals with good auditory comprehension, good visual-perceptual skills, and a high level of motivation.\n4. BLISS technique can be used in a group setting to encourage verbal language and writing skills.\n5. The use of Blissymbols has been found to improve communication skills in individuals with severe verbal apraxia.",
    "llama-2-7b-chat-hf_fact": [
      "BLISS technique uses Blissymbols as a facilitating technique for communication in individuals with severe verbal apraxia.",
      "Blissymbols are part of a visual-gestural language system.",
      "The BLISS technique targets individuals with good auditory comprehension, good visual-perceptual skills, and a high level of motivation.",
      "BLISS technique can be used in a group setting to encourage verbal language and writing skills.",
      "The use of Blissymbols has been found to improve communication skills in individuals with severe verbal apraxia."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Blissymbols are part of a symbolic, graphical language that is particularly used in augmentative and alternative communication (AAC), not a visual-gestural language system.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, here are 3 NK3R antagonists:\n1. Compound A: The synthesis and SAR of a series of C3-alkylsulfoxide substituted quinolines as potent NK3 receptor antagonists.\n2. Compound B: These compounds have excellent NK3 functional activity, good selectivity and drug-like properties.\n3. Compound C: Several key compounds have good in vitro/in vivo DMPK characteristics, and are active in a gerbil locomotor activity model.\nIt is important to note that these are just examples of NK3R antagonists based on the information provided in the document, and there may be other compounds that also fit this category.",
    "llama-2-7b-chat-hf_fact_raw": "1. Compound A is a C3-alkylsulfoxide substituted quinoline that acts as a potent NK3 receptor antagonist.\n2. Compound B exhibits excellent NK3 functional activity, good selectivity, and drug-like properties.\n3. Compound C has good in vitro/in vivo drug metabolism and pharmacokinetics (DMPK) characteristics and is active in a gerbil locomotor activity model.",
    "llama-2-7b-chat-hf_fact": [
      "Compound A is a C3-alkylsulfoxide substituted quinoline that acts as a potent NK3 receptor antagonist.",
      "Compound B exhibits excellent NK3 functional activity, good selectivity, and drug-like properties.",
      "Compound C has good in vitro/in vivo drug metabolism and pharmacokinetics (DMPK) characteristics and is active in a gerbil locomotor activity model."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n\nExplanation: Without specific information about the structures and pharmacological profiles of Compounds A, B, and C, it is impossible to verify the accuracy of these statements. They are domain-specific and require expert knowledge in chemistry and pharmacology.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is compound 47.",
    "llama-2-7b-chat-hf_fact_raw": "1. Compound 47 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.",
    "llama-2-7b-chat-hf_fact": [
      "Compound 47 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown"
    ]
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the article, the protective efficacy of vaxchora against moderate to severe cholera is estimated to be 86.6% (95% CI: 56.7-95.8%). This means that among individuals who received two complete doses of vaxchora, 86.6% were protected against developing moderate to severe cholera, compared to 13.4% of unvaccinated individuals. The study found that vaxchora was effective in providing protection against cholera in response to an outbreak in Guinea.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protective efficacy of Vaxchora against moderate to severe cholera is estimated to be 86.6%.\n2. The confidence interval for the protective efficacy of Vaxchora is 56.7% to 95.8%.\n3. This efficacy is based on individuals who received two complete doses of Vaxchora.\n4. The study indicates that 86.6% of individuals vaccinated with Vaxchora were protected against developing moderate to severe cholera.\n5. Vaxchora was found to be effective in providing protection against cholera during an outbreak in Guinea.",
    "llama-2-7b-chat-hf_fact": [
      "The protective efficacy of Vaxchora against moderate to severe cholera is estimated to be 86.6%.",
      "The confidence interval for the protective efficacy of Vaxchora is 56.7% to 95.8%.",
      "This efficacy is based on individuals who received two complete doses of Vaxchora.",
      "The study indicates that 86.6% of individuals vaccinated with Vaxchora were protected against developing moderate to severe cholera.",
      "Vaxchora was found to be effective in providing protection against cholera during an outbreak in Guinea."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN (Without the specific study or data source, it is not possible to verify the confidence interval provided for the protective efficacy of Vaxchora.)\n3. UNKNOWN (The statement does not specify which study or trial was referenced, making it difficult to verify if the efficacy is based on individuals who received two complete doses of Vaxchora.)\n4. TRUE (Based on the initial statement that the protective efficacy is estimated to be 86.6%, it implies that 86.6% of vaccinated individuals were protected, but without more context, it is not possible to confirm the details of the study being referenced.)\n5. UNKNOWN (Without additional context or a source, it is not possible to verify the claim that Vaxchora was effective in providing protection against cholera during an outbreak in Guinea.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "llama-2-7b-chat-hf_response": "The first cholera vaccine approved in the US is Vaxchora.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vaxchora is the first cholera vaccine approved in the US.",
    "llama-2-7b-chat-hf_fact": [
      "Vaxchora is the first cholera vaccine approved in the US."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans is a genetic mutation that affects the immune system, specifically the T-cell and monocyte abnormalities. The document mentions that granulomatous disease is a common complication of CVID, and that the pathogenesis of this disease is unclear but may involve these abnormalities. Therefore, it can be inferred that the genetic mutation underlying CVID is the most common monogenic cause of this condition in Europeans.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE) is not directly addressed. The document focuses on the investigation of the IFNG gene intron (+874) polymorphism in SLE patients and healthy control subjects in a Thai population. The study found that the allele frequencies of the IFNG (+874) gene polymorphism were not significantly different between SLE patients and control subjects, but there was a significant association between the A dominance model of inheritance and arthritis in SLE patients. Therefore, the document suggests that the +874 intron polymorphism of IFNG can be used as a marker for SLE susceptibility with arthritis in the Thai population. However, the IFIT1 gene is not mentioned in the document, and it is unclear whether it plays a role in SLE.",
    "llama-2-7b-chat-hf_fact_raw": "1. The document provided discusses the IFNG gene intron (+874) polymorphism in Systemic Lupus Erythematosus (SLE) patients and healthy control subjects in a Thai population.\n2. The allele frequencies of the IFNG (+874) gene polymorphism were not significantly different between SLE patients and control subjects.\n3. There was a significant association between the A dominance model of inheritance and arthritis in SLE patients.\n4. The IFNG (+874) intron polymorphism is suggested as a marker for SLE susceptibility with arthritis in the Thai population.\n5. The role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE) is not addressed in the document.",
    "llama-2-7b-chat-hf_fact": [
      "The document provided discusses the IFNG gene intron (+874) polymorphism in Systemic Lupus Erythematosus (SLE) patients and healthy control subjects in a Thai population.",
      "The allele frequencies of the IFNG (+874) gene polymorphism were not significantly different between SLE patients and control subjects.",
      "There was a significant association between the A dominance model of inheritance and arthritis in SLE patients.",
      "The IFNG (+874) intron polymorphism is suggested as a marker for SLE susceptibility with arthritis in the Thai population.",
      "The role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE) is not addressed in the document."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout the actual document to reference, it is impossible to determine the truthfulness of the statements regarding the IFNG gene intron (+874) polymorphism, allele frequencies, associations with the A dominance model, or the role of the IFIT1 gene in SLE in a Thai population. These statements are very specific and would require the source material for verification.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "llama-2-7b-chat-hf_response": "The Liverpool Elbow Score (LES) is a newly developed, validated elbow-specific score that assesses the outcome of total elbow arthroplasty. The LES consists of a patient-answered questionnaire (PAQ) and a clinical assessment. The purpose of the study was to determine whether the PAQ portion of the LES could be used independently as a postal questionnaire for the assessment of outcome after total elbow arthroplasty, and to correlate the LES with the Mayo Elbow Performance Score (MEPS). The study found that there was an excellent response rate to the postal questionnaire (98%) and 44 elbows were available for clinical review. Good correlation was shown between the LES and the MEPS (Spearman correlation coefficient, 0.84; P < .001) and between the PAQ portion of the LES and the MEPS (Spearman correlation coefficient, 0.76; P < .001). These findings suggest that the PAQ portion of the LES can be used as a reliable and valid tool for assessing the outcome of total elbow arthroplasty by postal questionnaire.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Liverpool Elbow Score (LES) is used to assess the outcome of total elbow arthroplasty.\n2. The LES includes a patient-answered questionnaire (PAQ) and a clinical assessment.\n3. The study investigated if the PAQ portion of the LES could be used independently as a postal questionnaire.\n4. A study reported an excellent response rate of 98% to the postal questionnaire of the LES.\n5. The study found a good correlation between the LES and the Mayo Elbow Performance Score (MEPS) with a Spearman correlation coefficient of 0.84 (P < .001).",
    "llama-2-7b-chat-hf_fact": [
      "The Liverpool Elbow Score (LES) is used to assess the outcome of total elbow arthroplasty.",
      "The LES includes a patient-answered questionnaire (PAQ) and a clinical assessment.",
      "The study investigated if the PAQ portion of the LES could be used independently as a postal questionnaire.",
      "A study reported an excellent response rate of 98% to the postal questionnaire of the LES.",
      "The study found a good correlation between the LES and the Mayo Elbow Performance Score (MEPS) with a Spearman correlation coefficient of 0.84 (P < .001)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nWithout access to the specific study, I cannot verify the reported response rate or the correlation between the LES and the MEPS.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-2-7b-chat-hf_response": "Thank you for your question! The 100,000 Genomes Project is a significant initiative that aims to analyze the genomes of 100,000 individuals in the UK, including those with rare and aggressive cancers like sarcoma. The project's primary goal is to create a deep catalog of human genetic variation and develop methods to accurately discover and characterize genetic variation using new sequencing technologies.\nRegarding efforts on sarcoma, the 100,000 Genomes Project has made significant progress in understanding the genetic mutations that contribute to the development and progression of this disease. Through the analysis of genomic data from sarcoma patients, researchers have identified specific genetic mutations that are commonly found in this type of cancer. These findings have helped to improve our understanding of the molecular mechanisms underlying sarcoma and have the potential to lead to the development of new diagnostic tests and targeted therapies.\nOne of the key findings from the 100,000 Genomes Project is the identification of specific genetic mutations in sarcoma that are associated with poorer prognosis. For example, mutations in the TP53 gene, which is a tumor suppressor gene, are commonly found in sarcoma and are associated with a higher risk of recurrence and death. Similarly, mutations in the PI3K pathway, which is involved in cell signaling, are also commonly found in sarcoma and have been linked to poorer prognosis.\nIn addition to identifying genetic mutations associated with sarcoma, the 100,000 Genomes Project has also helped to identify potential new targets for therapy. For example, researchers have identified a subset of sarcoma patients who have mutations in the KRAS gene, which is a common driver of cancer growth and progression. These findings have the potential to lead to the development of new targeted therapies that can be used to treat these patients.\nOverall, the efforts of the 100,000 Genomes Project on sarcoma have significantly advanced our understanding of the genetic mutations that contribute to this disease and have the potential to lead to the development of new diagnostic tests and targeted therapies.",
    "llama-2-7b-chat-hf_fact_raw": "1. The 100,000 Genomes Project aims to analyze the genomes of 100,000 individuals in the UK, including those with rare cancers like sarcoma.\n2. The project seeks to create a catalog of human genetic variation and develop methods for accurately discovering and characterizing genetic variation using new sequencing technologies.\n3. Researchers in the project have identified specific genetic mutations in sarcoma that are commonly associated with poorer prognosis.\n4. Mutations in the TP53 gene are commonly found in sarcomas and are linked with a higher risk of recurrence and death.\n5. Mutations in the KRAS gene have been identified in a subset of sarcoma patients, which could lead to the development of new targeted therapies.",
    "llama-2-7b-chat-hf_fact": [
      "The 100,000 Genomes Project aims to analyze the genomes of 100,000 individuals in the UK, including those with rare cancers like sarcoma.",
      "The project seeks to create a catalog of human genetic variation and develop methods for accurately discovering and characterizing genetic variation using new sequencing technologies.",
      "Researchers in the project have identified specific genetic mutations in sarcoma that are commonly associated with poorer prognosis.",
      "Mutations in the TP53 gene are commonly found in sarcomas and are linked with a higher risk of recurrence and death.",
      "Mutations in the KRAS gene have been identified in a subset of sarcoma patients, which could lead to the development of new targeted therapies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE (Given that researchers in projects like the 100,000 Genomes Project often identify prognostic markers, this statement is plausible. However, without specific publication references, it is hard to confirm particular discoveries.)\n4. TRUE (TP53 is a well-known tumor suppressor gene, and its mutations are associated with various cancers, including sarcoma, where such mutations can be linked to prognosis. However, specifics would depend on research findings at the time.)\n5. FALSE [correction]: KRAS is commonly associated with other types of cancers like lung, colorectal, and pancreatic cancers, but not typically with sarcoma. However, there are different subtypes of sarcoma, and research can uncover new mutations in any cancer type. It would require referencing current research findings to confirm such a statement for sarcoma specifically.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the answer to the user's question is:\nYes, ALEX1 contains armadillo repeats. The document states that ALEX1 contains two armadillo repeat domains, indicating that it contains the characteristic armadillo repeat structure. This is consistent with the armadillo repeat protein family, which consists of proteins that contain 6 to 13 armadillo repeat domains.",
    "llama-2-7b-chat-hf_fact_raw": "1. ALEX1 contains armadillo repeats.\n2. ALEX1 contains two armadillo repeat domains.\n3. The armadillo repeat protein family consists of proteins that contain 6 to 13 armadillo repeat domains.",
    "llama-2-7b-chat-hf_fact": [
      "ALEX1 contains armadillo repeats.",
      "ALEX1 contains two armadillo repeat domains.",
      "The armadillo repeat protein family consists of proteins that contain 6 to 13 armadillo repeat domains."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: ALEX1 (ARMCX1) contains one armadillo (ARM) repeat domain.\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the following are enzymes that remove histone modifications:\n1. Histone deacetylases (HDACs): These enzymes catalyze the removal of acetyl groups from the epsilon-amino groups of conserved lysine residues in the amino terminal tail of histones. There are 18 potential HDAC enzymes in humans responsible for the removal of acetyl groups and maintenance of the equilibrium of lysine acetylation on histones.\nOther enzymes that may also remove histone modifications include:\n2. Lysine-specific demethylases (LSD1 and LSD2): These enzymes remove methyl groups from the ε-amino groups of histone H3 lysine 4 (H3K4) and histone H3 lysine 27 (H3K27), respectively.\n3. Histone-modifying enzymes: Some enzymes, such as protein arginine methyltransferases (PRMTs) and SUV39H1, have been shown to modify histones, leading to changes in chromatin structure and gene expression.\nIt is important to note that the above list is not exhaustive and there may be other enzymes that remove histone modifications, as the field is constantly evolving.",
    "llama-2-7b-chat-hf_fact_raw": "1. Histone deacetylases (HDACs) remove acetyl groups from lysine residues in the amino terminal tail of histones.\n2. There are 18 potential HDAC enzymes in humans.\n3. Lysine-specific demethylases (LSD1 and LSD2) remove methyl groups from histone H3 lysine 4 and histone H3 lysine 27, respectively.\n4. Protein arginine methyltransferases (PRMTs) are histone-modifying enzymes.\n5. SUV39H1 is an enzyme that modifies histones.",
    "llama-2-7b-chat-hf_fact": [
      "Histone deacetylases (HDACs) remove acetyl groups from lysine residues in the amino terminal tail of histones.",
      "There are 18 potential HDAC enzymes in humans.",
      "Lysine-specific demethylases (LSD1 and LSD2) remove methyl groups from histone H3 lysine 4 and histone H3 lysine 27, respectively.",
      "Protein arginine methyltransferases (PRMTs) are histone-modifying enzymes.",
      "SUV39H1 is an enzyme that modifies histones."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There are 18 HDAC enzymes known in humans, however, they are not only potential but established as such.\n3. FALSE [correction]: Lysine-specific demethylases (LSD1) targets histone H3 lysine 4 (H3K4), but LSD2 also targets H3K4, not histone H3 lysine 27 (H3K27). H3K27 is targeted by other demethylases such as UTX and JMJD3.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the study, there is no significant increase in the risk of brain tumors, including malignant and benign tumors, associated with head CT scans in children. The study found that the overall risk of malignancy and benign brain tumors was not significantly different in the group of children who underwent head CT scans compared to those who did not undergo the procedure. However, the study did find a significant increase in the risk of benign brain tumors in the group of children who underwent head CT scans.\nIt is important to note that this study only looked at the association between head CT scans and the risk of brain tumors in children, and did not establish a cause-and-effect relationship. Further research is needed to confirm these findings and to determine the long-term effects of head CT scans on brain tumor risk in children.\nIn summary, based on the information provided in the study, there is no conclusive evidence to suggest that head CT scans increase the risk of brain tumors in children. However, more research is needed to fully understand the potential risks and benefits of head CT scans in this population.",
    "llama-2-7b-chat-hf_fact_raw": "1. The study found no significant increase in the risk of malignant brain tumors associated with head CT scans in children.\n2. The study reported that children who underwent head CT scans did not have a significantly different overall risk of malignancy and benign brain tumors compared to those who did not undergo the procedure.\n3. There was a significant increase in the risk of benign brain tumors in the group of children who underwent head CT scans found by the study.\n4. The study only investigated the association between head CT scans and the risk of brain tumors in children without establishing causation.\n5. Further research is suggested by the study to confirm findings and determine the long-term effects of head CT scans on brain tumor risk in children.",
    "llama-2-7b-chat-hf_fact": [
      "The study found no significant increase in the risk of malignant brain tumors associated with head CT scans in children.",
      "The study reported that children who underwent head CT scans did not have a significantly different overall risk of malignancy and benign brain tumors compared to those who did not undergo the procedure.",
      "There was a significant increase in the risk of benign brain tumors in the group of children who underwent head CT scans found by the study.",
      "The study only investigated the association between head CT scans and the risk of brain tumors in children without establishing causation.",
      "Further research is suggested by the study to confirm findings and determine the long-term effects of head CT scans on brain tumor risk in children."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The study found no significant increase in the risk of benign brain tumors in the group of children who underwent head CT scans.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, Otx2 is associated with the primed pluripotency state. The document states that Otx2 is one of the candidate mediators of primed state-specific Oct4 binding, and that overexpression of Otx2 is sufficient to exit the naive state and induce transcription of a substantial subset of primed pluripotency-associated genes. Additionally, the document suggests that the ability of Otx2 to engage new enhancer regions is determined by its levels, cis-encoded properties of the sites, and the signaling environment. These findings indicate that Otx2 is specifically associated with the primed pluripotency state, rather than the naive pluripotency state.",
    "llama-2-7b-chat-hf_fact_raw": "1. Otx2 is associated with the primed pluripotency state.\n2. Otx2 is one of the candidate mediators of primed state-specific Oct4 binding.\n3. Overexpression of Otx2 can induce transcription of a subset of primed pluripotency-associated genes.\n4. The ability of Otx2 to engage new enhancer regions depends on its levels, cis-encoded properties of the sites, and the signaling environment.",
    "llama-2-7b-chat-hf_fact": [
      "Otx2 is associated with the primed pluripotency state.",
      "Otx2 is one of the candidate mediators of primed state-specific Oct4 binding.",
      "Overexpression of Otx2 can induce transcription of a subset of primed pluripotency-associated genes.",
      "The ability of Otx2 to engage new enhancer regions depends on its levels, cis-encoded properties of the sites, and the signaling environment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Otx2 is associated with primed pluripotency in embryonic stem cells and has been specifically linked to the primed state of pluripotency as opposed to the naïve state.\n2. TRUE: Otx2 has been identified as one of the mediators that may influence the binding of Oct4 to specific DNA sites in the primed state of pluripotency.\n3. TRUE: Overexpression of Otx2 has been shown to induce the transcription of genes that are associated with the primed pluripotency state, though it may not be a direct or universal effect for all primed state-associated genes.\n4. TRUE: The ability of Otx2 to target and engage new enhancer regions is indeed influenced by multiple factors including its own expression levels, intrinsic properties of the enhancer sites themselves, and external cellular signaling conditions.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there are 83% of DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "llama-2-7b-chat-hf_response": "Based on the information provided, here are some European influenza vaccines that are available or have been approved for use:\n1. Fluad: This is a quadrivalent vaccine that protects against four strains of influenza, including two A strains (H1N1 and H3N2) and two B strains. It is approved for use in adults aged 65 years and older.\n2. Fluarix Tetra: This is a quadrivalent vaccine that protects against the same four strains as Fluad. It is approved for use in individuals aged 3 years and older.\n3. Flulaval Quadrivalent: This is a quadrivalent vaccine that protects against the same four strains as Fluad. It is approved for use in individuals aged 6 months and older.\n4. Aggrivax: This is a quadrivalent vaccine that protects against the same four strains as Fluad. It is approved for use in individuals aged 18 years and older.\n5. GSK Bio: This is a quadrivalent vaccine that protects against the same four strains as Fluad. It is approved for use in individuals aged 6 months and older.\n6. Novartis: This is a quadrivalent vaccine that protects against the same four strains as Fluad. It is approved for use in individuals aged 6 months and older.\n7. Sanofi: This is a quadrivalent vaccine that protects against the same four strains as Fluad. It is approved for use in individuals aged 6 months and older.\n8. Pfizer: This is a quadrivalent vaccine that protects against the same four strains as Fluad. It is approved for use in individuals aged 6 months and older.\nIt's important to note that the effectiveness of these vaccines may vary depending on the strain of the virus circulating in a given year, as well as other factors such as the individual's age and health status. It's always best to consult with a healthcare professional for personalized advice on which vaccine is best for you.",
    "llama-2-7b-chat-hf_fact_raw": "1. Fluad is a quadrivalent influenza vaccine approved for use in adults aged 65 years and older.\n2. Fluarix Tetra is a quadrivalent influenza vaccine approved for use in individuals aged 3 years and older.\n3. Flulaval Quadrivalent is a quadrivalent influenza vaccine approved for use in individuals aged 6 months and older.\n4. Aggrivax is a quadrivalent influenza vaccine approved for use in individuals aged 18 years and older.\n5. Vaccine manufacturers GSK Bio, Novartis, Sanofi, and Pfizer produce quadrivalent influenza vaccines approved for use in individuals aged 6 months and older.",
    "llama-2-7b-chat-hf_fact": [
      "Fluad is a quadrivalent influenza vaccine approved for use in adults aged 65 years and older.",
      "Fluarix Tetra is a quadrivalent influenza vaccine approved for use in individuals aged 3 years and older.",
      "Flulaval Quadrivalent is a quadrivalent influenza vaccine approved for use in individuals aged 6 months and older.",
      "Aggrivax is a quadrivalent influenza vaccine approved for use in individuals aged 18 years and older.",
      "Vaccine manufacturers GSK Bio, Novartis, Sanofi, and Pfizer produce quadrivalent influenza vaccines approved for use in individuals aged 6 months and older."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: There is no quadrivalent influenza vaccine known as Aggrivax. The correct name of an approved influenza vaccine might be Afluria Quadrivalent, which is approved for use in individuals aged 6 months and older.\n5. FALSE [correction]: GSK Bio, Novartis, and Sanofi are known producers of quadrivalent influenza vaccines. However, Pfizer is not typically recognized as a manufacturer of influenza vaccines. Pfizer focuses on other types of vaccines and pharmaceutical products. It is possible that the other companies mentioned produce vaccines approved for use in individuals aged 6 months and older, but specific products and age approvals should be verified since vaccine portfolios change over time.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the answer to the user's question is:\nYes, the Paramyxovirus genome is segmented, negative-sense RNA. The document states that Paramyxoviruses have a nonsegmented negative-stranded RNA genome, which means that their genome is not divided into smaller segments. Instead, it is a single, continuous piece of RNA that is negative-sense, meaning that its sequence is complementary to the messenger RNA (mRNA) that is transcribed from it.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Paramyxovirus genome is negative-sense RNA.\n2. The Paramyxovirus genome is not segmented; it is a single, continuous piece of RNA.",
    "llama-2-7b-chat-hf_fact": [
      "The Paramyxovirus genome is negative-sense RNA.",
      "The Paramyxovirus genome is not segmented; it is a single, continuous piece of RNA."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true"
    ]
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, roflumilast cream is effective in treating cerebral inflammation following subarachnoid hemorrhage (SAH). The study shows that subcutaneous administration of roflumilast significantly improved neurological deficits, reduced blood-brain barrier permeability, brain edema, and levels of pro-inflammatory cytokines such as IL-1, IL-6, and TNF- in the brain after SAH. These findings suggest that roflumilast may be a useful treatment option for reducing cerebral inflammation and improving outcomes in patients with SAH.",
    "llama-2-7b-chat-hf_fact_raw": "1. Roflumilast cream is used in treating cerebral inflammation following subarachnoid hemorrhage (SAH).\n2. Subcutaneous administration of roflumilast can significantly improve neurological deficits after SAH.\n3. Roflumilast treatment can reduce blood-brain barrier permeability in patients with SAH.\n4. Roflumilast helps in reducing brain edema associated with SAH.\n5. The treatment with roflumilast decreases levels of pro-inflammatory cytokines such as IL-1, IL-6, and TNF-α in the brain after SAH.",
    "llama-2-7b-chat-hf_fact": [
      "Roflumilast cream is used in treating cerebral inflammation following subarachnoid hemorrhage (SAH).",
      "Subcutaneous administration of roflumilast can significantly improve neurological deficits after SAH.",
      "Roflumilast treatment can reduce blood-brain barrier permeability in patients with SAH.",
      "Roflumilast helps in reducing brain edema associated with SAH.",
      "The treatment with roflumilast decreases levels of pro-inflammatory cytokines such as IL-1, IL-6, and TNF-α in the brain after SAH."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Roflumilast is an orally administered drug primarily used for the treatment of chronic obstructive pulmonary disease (COPD). There is no widely recognized use of roflumilast cream for treating cerebral inflammation following subarachnoid hemorrhage (SAH).\n2. UNKNOWN: Without specific data or studies to reference, it is unclear if subcutaneous administration of roflumilast improves neurological deficits after SAH. Generally, roflumilast is administered orally for COPD, and its use in SAH is not well established.\n3. UNKNOWN: While there may be research on roflumilast affecting blood-brain barrier permeability, the statement cannot be confirmed as true or false without specific references to such studies in the context of SAH.\n4. UNKNOWN: The potential of roflumilast in reducing brain edema associated with SAH would need to be substantiated by clinical studies or empirical evidence specific to this use.\n5. UNKNOWN: The effect of roflumilast on pro-inflammatory cytokines in the brain after SAH would require specific biomedical research information demonstrating these effects. Without such information, the truth value of the statement cannot be determined.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, several tools have been developed for identifying and visualizing ncRNA promoters:\n1. RiboGap: This database can be used to find known ncRNAs and extract intergenic sequences of eubacteria and archaea to find conserved RNA structures upstream of given genes.\n2. Tools for the prediction of conserved RNA secondary structure: Although many of these tools are not designed specifically for identifying new ncRNAs, they can be used to predict conserved RNA structures in the database.\n3. Approaches for uncovering simple sequence motifs with regulatory roles: These approaches can be used to identify potential ncRNA promoters in the database.\n4. Extending analysis to choose the best candidate ncRNAs for experimental validation: This step can be done by using the information from the database and tools to identify the most promising ncRNA candidates for further study.\nSome of the specific tools that can be used for identifying and visualizing ncRNA promoters include:\n1. RNAfold: This tool can be used to predict the secondary structure of RNA sequences, including ncRNAs.\n2. Pfold: This tool can be used to predict the stability of RNA secondary structures, which can be useful for identifying promoter regions.\n3. RNAhybrid: This tool can be used to predict the binding affinity of RNA sequences to proteins, which can be useful for identifying potential transcription factors that bind to ncRNA promoters.\n4. Cis-BP: This tool can be used to predict the binding sites of transcription factors in the promoter region of ncRNAs.\n5. RNA-seq: This tool can be used to identify and quantify the expression levels of ncRNAs in different samples, which can be useful for identifying the most promising candidates for further study.\nOverall, these tools can be used to identify and visualize ncRNA promoters, and to prioritize the most promising candidates for experimental validation.",
    "llama-2-7b-chat-hf_fact_raw": "1. RiboGap is a database for finding known ncRNAs and extracting intergenic sequences of eubacteria and archaea.\n2. RNAfold is a tool that predicts the secondary structure of RNA sequences.\n3. Pfold is a tool used to predict the stability of RNA secondary structures.\n4. RNAhybrid predicts the binding affinity of RNA sequences to proteins.\n5. RNA-seq identifies and quantifies the expression levels of ncRNAs in different samples.",
    "llama-2-7b-chat-hf_fact": [
      "RiboGap is a database for finding known ncRNAs and extracting intergenic sequences of eubacteria and archaea.",
      "RNAfold is a tool that predicts the secondary structure of RNA sequences.",
      "Pfold is a tool used to predict the stability of RNA secondary structures.",
      "RNAhybrid predicts the binding affinity of RNA sequences to proteins.",
      "RNA-seq identifies and quantifies the expression levels of ncRNAs in different samples."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Pfold is a tool used to predict the secondary structure of RNA sequences using a probabilistic model, not specifically the stability of those structures.\n4. FALSE [correction]: RNAhybrid predicts the most favorable hybridization sites of a small RNA within a large RNA, not the binding affinity of RNA sequences to proteins.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following are some example genes that have been identified as being down-regulated in glioblastoma:\n1. COL4A1\n2. COL4A2\n3. EGFR\n4. FGFR1\n5. LAPR6\n6. MYC\n7. PDGFA\n8. SPP1\nThese genes were identified through bioinformatics analysis, including gene expression profiling and pathway analysis, and were found to be significantly down-regulated in glioblastoma compared to normal astrocytes.\nIt is important to note that the study only identified potential down-regulated genes and did not validate their expression levels experimentally. Additionally, the study focused on the analysis of gene expression profiles and did not investigate the functional implications of the down-regulated genes.\nIn summary, the study identified a list of genes that are down-regulated in glioblastoma, including COL4A1, COL4A2, EGFR, FGFR1, LAPR6, MYC, PDGFA, SPP1. These genes may be potential targets for diagnosis and treatment of glioblastoma.",
    "llama-2-7b-chat-hf_fact_raw": "1. The SWIM tool identified COL4A1 as a gene that is down-regulated in glioblastoma.\n2. The SWIM tool identified COL4A2 as a gene that is down-regulated in glioblastoma.\n3. The SWIM tool identified EGFR as a gene that is down-regulated in glioblastoma.\n4. The SWIM tool identified FGFR1 as a gene that is down-regulated in glioblastoma.\n5. The SWIM tool identified MYC as a gene that is down-regulated in glioblastoma.",
    "llama-2-7b-chat-hf_fact": [
      "The SWIM tool identified COL4A1 as a gene that is down-regulated in glioblastoma.",
      "The SWIM tool identified COL4A2 as a gene that is down-regulated in glioblastoma.",
      "The SWIM tool identified EGFR as a gene that is down-regulated in glioblastoma.",
      "The SWIM tool identified FGFR1 as a gene that is down-regulated in glioblastoma.",
      "The SWIM tool identified MYC as a gene that is down-regulated in glioblastoma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: The SWIM tool may have identified EGFR, but EGFR is generally known to be up-regulated or amplified in glioblastoma.\n4. UNKNOWN\n5. FALSE [correction]: MYC is generally known to be an oncogene that is often up-regulated in various cancers, including glioblastoma.\n\nWithout specific knowledge of the findings from the SWIM (Subgraph-wise Network Features for Scoring Impact of Mutations) tool or access to the dataset and analysis in question, it is not possible to confirm the regulation status of COL4A1, COL4A2, and FGFR1 in glioblastoma as stated in statements 1, 2, and 4. Therefore, these statements are marked as UNKNOWN.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the following R packages have been developed for studying TADs:\n1. Risa: This package is specifically designed to support the ISA-Tab format and to bridge the gap between metadata collection and curation in an ISA-compliant way and data analysis using the R environment. It offers functionality for parsing ISA-Tab datasets into R objects, augmenting annotation with extra metadata, interfacing with domain-specific R packages, suggesting potentially useful R packages available in Bioconductor, and saving back to ISA-Tab files augmented with analysis-specific metadata from R.\n2. ISATab: This package provides a simple and efficient way to read and write ISA-Tab files, which are used to represent experimental metadata in a standardized format. It offers functions for parsing and generating ISA-Tab files, as well as for manipulating and analyzing the data stored in these files.\n3. ISAtools: This package provides a collection of tools for working with ISA-Tab files, including functions for parsing, generating, and manipulating ISA-Tab data. It also offers tools for analyzing and visualizing ISA-Tab data, as well as for creating and manipulating ISA-Tab datasets.\n4. TAD: This package provides a set of tools for working with TAD (Transcriptome Assembling Database) files, which are used to represent transcriptome data in a standardized format. It offers functions for parsing and generating TAD files, as well as for manipulating and analyzing the data stored in these files.\nThese packages are all available through the Bioconductor platform, which is a collaborative open source project that provides a framework for the analysis and interpretation of genomic data. By using these packages, researchers can easily work with TADs and other types of experimental metadata, and can take advantage of the many tools and resources available through Bioconductor to analyze and interpret their data.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Risa package supports the ISA-Tab format and interfaces with R for data analysis.\n2. The ISATab package provides functions for reading and writing ISA-Tab files in R.\n3. ISAtools is an R package that offers tools for manipulating and visualizing ISA-Tab data.\n4. The TAD R package includes tools for parsing and generating files for transcriptome data.\n5. All these R packages are available through the Bioconductor platform.",
    "llama-2-7b-chat-hf_fact": [
      "The Risa package supports the ISA-Tab format and interfaces with R for data analysis.",
      "The ISATab package provides functions for reading and writing ISA-Tab files in R.",
      "ISAtools is an R package that offers tools for manipulating and visualizing ISA-Tab data.",
      "The TAD R package includes tools for parsing and generating files for transcriptome data.",
      "All these R packages are available through the Bioconductor platform."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: It appears there might be a confusion with the correct name of the package. The correct package for this description is likely \"ISAtools\", not \"ISAtools\", which is consistent with ISA-Tab data manipulation and visualization.\n4. UNKNOWN\n5. UNKNOWN\n\nNote: While it's possible to provide a general assumption of the availability of bioinformatics packages like Risa, ISATab, and the potential \"ISAtools\" on Bioconductor, due to the lack of specificity in the statement about the exact package names (e.g., ISAtools could be a typo) and the ever-changing nature of software repositories, the veracity of these packages being available on Bioconductor cannot be confirmed without current and exact information. Hence, the true or false status of statement 5 is unknown without additional context or an up-to-date check on the Bioconductor platform.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the bioconductor tool that has been developed for accessing bacterial regulatory networks is likely \"population control\" circuit. This tool is a synthetic circuit that regulates cell density through a feedback mechanism based on quorum sensing, which was observed in the microfluidic bioreactor using Escherichia coli. The ability to monitor the dynamics of bacterial populations over hundreds of hours in a controlled environment suggests that this tool can provide valuable insights into the regulation of bacterial behavior and the interactions between bacteria and their environment.",
    "llama-2-7b-chat-hf_fact_raw": "1. A bioconductor tool has been developed for accessing bacterial regulatory networks.\n2. The tool is referred to as a \"population control\" circuit.\n3. The \"population control\" circuit regulates cell density through a feedback mechanism.\n4. The feedback mechanism of the circuit is based on quorum sensing.\n5. The circuit was observed in a microfluidic bioreactor using Escherichia coli.",
    "llama-2-7b-chat-hf_fact": [
      "A bioconductor tool has been developed for accessing bacterial regulatory networks.",
      "The tool is referred to as a \"population control\" circuit.",
      "The \"population control\" circuit regulates cell density through a feedback mechanism.",
      "The feedback mechanism of the circuit is based on quorum sensing.",
      "The circuit was observed in a microfluidic bioreactor using Escherichia coli."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE (assuming the statement correctly reflects current developments, but without the specific name of the tool, this assumes that such a tool exists as Bioconductor is known for providing tools in computational biology)\n2. FALSE [correction]: The term \"population control\" circuit could be misleading without context. Bioconductor tools are typically computational packages for analyzing biological data, not directly referred to as \"population control\" circuits, which may imply a physical or synthetic biology construct.\n3. UNKNOWN (while quorum sensing is a mechanism for regulating cell density through feedback, without specific reference to the tool or the implementation, it's unclear whether this statement correctly describes the function of a specific bioconductor tool)\n4. UNKNOWN (same as above; quorum sensing is a feedback mechanism seen in bacteria for communication based on cell density, but without specific details, it's not clear if this is related to the bioconductor tool mentioned)\n5. UNKNOWN (this statement could be true if referring to an experiment or observation made with a specific bioconductor tool and Escherichia coli in a microfluidic bioreactor, but without more information, it's impossible to verify the accuracy of the statement)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the end products of the shikimate pathway are:\n1. Aromatic amino acids: The shikimate pathway produces three aromatic amino acids, including phenylalanine, tyrosine, and tryptophan.\n2. Secondary metabolites: Many secondary metabolites, such as antibiotics, anticancer agents, and natural pigments, are derived from the shikimate pathway.\nIn particular, the document highlights the potential of Scheffersomyces stipitis, a yeast species, for producing shikimate and its derivatives due to its superior xylose utilization efficiency. The authors report producing shikimate at a level of 3.11 g/L, which is the highest among shikimate pathway products in yeasts. This work represents a new exploration towards expanding the current collection of microbial factories for the production of valuable compounds.",
    "llama-2-7b-chat-hf_fact_raw": "1. The shikimate pathway produces the aromatic amino acids phenylalanine, tyrosine, and tryptophan.\n2. Secondary metabolites such as antibiotics, anticancer agents, and natural pigments are derived from the shikimate pathway.\n3. Scheffersomyces stipitis is a yeast species that can produce shikimate and its derivatives.\n4. Scheffersomyces stipitis has been reported to produce shikimate at a level of 3.11 g/L.\n5. Scheffersomyces stipitis has superior xylose utilization efficiency.",
    "llama-2-7b-chat-hf_fact": [
      "The shikimate pathway produces the aromatic amino acids phenylalanine, tyrosine, and tryptophan.",
      "Secondary metabolites such as antibiotics, anticancer agents, and natural pigments are derived from the shikimate pathway.",
      "Scheffersomyces stipitis is a yeast species that can produce shikimate and its derivatives.",
      "Scheffersomyces stipitis has been reported to produce shikimate at a level of 3.11 g/L.",
      "Scheffersomyces stipitis has superior xylose utilization efficiency."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN (Such specific numerical data would require a direct reference to a scientific study or paper to verify its accuracy.)\n5. TRUE (Scheffersomyces stipitis, previously known as Pichia stipitis, is known for its capability to efficiently ferment xylose to ethanol, which is considered a superior xylose utilization efficiency among naturally occurring yeasts.)",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-2-7b-chat-hf_response": "Yes, cabergoline can be used to treat Nelson's syndrome. The information provided in the document suggests that cabergoline treatment can normalize plasma ACTH levels and induce the disappearance of the pituitary tumor in patients with Nelson's syndrome. In the case presented, the patient was treated with cabergoline at a dose of 1 mg/week for 6 months, followed by dose escalation to 2 mg/week, which resulted in normalization of plasma ACTH levels and the disappearance of the pituitary adenoma. The treatment was withdrawn after 3 months, and plasma ACTH levels significantly increased. However, when the patient resumed cabergoline treatment at the dose of 2 mg/week, plasma ACTH levels were normalized again. These findings suggest that cabergoline may be a valid therapeutic alternative for the treatment of Nelson's syndrome.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cabergoline can be used to treat Nelson's syndrome.\n2. Cabergoline treatment has the potential to normalize plasma ACTH levels in patients with Nelson's syndrome.\n3. Cabergoline treatment can induce the disappearance of the pituitary tumor in patients with Nelson's syndrome.\n4. In the specific case presented, the patient was initially treated with cabergoline at a dose of 1 mg/week for 6 months.\n5. After escalating the dose to 2 mg/week, the patient's plasma ACTH levels normalized, and the pituitary adenoma disappeared.",
    "llama-2-7b-chat-hf_fact": [
      "Cabergoline can be used to treat Nelson's syndrome.",
      "Cabergoline treatment has the potential to normalize plasma ACTH levels in patients with Nelson's syndrome.",
      "Cabergoline treatment can induce the disappearance of the pituitary tumor in patients with Nelson's syndrome.",
      "In the specific case presented, the patient was initially treated with cabergoline at a dose of 1 mg/week for 6 months.",
      "After escalating the dose to 2 mg/week, the patient's plasma ACTH levels normalized, and the pituitary adenoma disappeared."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cabergoline is typically used to treat hyperprolactinemia and Parkinson's disease by inhibiting prolactin secretion and as an adjunct therapy for acromegaly to suppress growth hormone secretion. Nelson's syndrome involves the growth of an ACTH-secreting pituitary tumor after bilateral adrenalectomy for Cushing's disease. Treatment options for Nelson's syndrome may include surgery, radiation therapy, and sometimes steroidogenesis inhibitors, but cabergoline is not a standard treatment for Nelson's syndrome.\n\n2. FALSE [correction]: There is limited evidence available regarding the use of cabergoline in patients with Nelson's syndrome, and it is not typically used to normalize plasma ACTH levels in patients with Nelson's syndrome. While its role in treating Nelson's syndrome is not established, some studies suggest that dopamine agonists like cabergoline might reduce ACTH levels in some cases, but this is not a typical or widely accepted treatment for normalizing ACTH in Nelson's syndrome.\n\n3. FALSE [correction]: The disappearance of a pituitary tumor in patients with Nelson's syndrome is not a typical outcome of cabergoline treatment. The main treatment for a pituitary tumor in the context of Nelson's syndrome often involves surgery and/or radiotherapy. Medications may be used, but cabergoline is not commonly used for this purpose, and evidence for its efficacy in this regard is minimal.\n\n4. UNKNOWN: Without specific information from the passage provided, it is not possible to confirm or deny the detail about the initial treatment dose.\n\n5. UNKNOWN: Similar to statement 4, the information provided is not sufficient to determine the truthfulness of the outcomes described. Without additional data or evidence, the response to the patient's treatment cannot be verified.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the paper, the main manifestation of Liebenberg syndrome is the transformation of the upper limbs to reflect lower limb characteristics. This is evident from the radiological features in the upper limbs of all affected members of the family, which are almost identical to the phenotype in the mouse model with ectopic expression of Pitx1 in the forelimbs. The authors suggest that the area of deletion contains a regulatory sequence that suppresses the expression of PITX1 in the upper limb buds, leading to the transformation of the upper limbs to resemble the lower limbs.",
    "llama-2-7b-chat-hf_fact_raw": "1. Liebenberg syndrome primarily manifests as the transformation of the upper limbs to reflect lower limb characteristics.\n2. Affected family members with Liebenberg syndrome show radiological features in their upper limbs that are similar to those found in a mouse model.\n3. The mouse model used for comparison exhibits ectopic expression of Pitx1 in the forelimbs.\n4. The research suggests that a deletion within a regulatory sequence leads to suppressed expression of PITX1 in the upper limb buds of those with Liebenberg syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Liebenberg syndrome primarily manifests as the transformation of the upper limbs to reflect lower limb characteristics.",
      "Affected family members with Liebenberg syndrome show radiological features in their upper limbs that are similar to those found in a mouse model.",
      "The mouse model used for comparison exhibits ectopic expression of Pitx1 in the forelimbs.",
      "The research suggests that a deletion within a regulatory sequence leads to suppressed expression of PITX1 in the upper limb buds of those with Liebenberg syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The research suggests that a deletion within a regulatory sequence leads to ectopic (misplaced) expression of PITX1 in the upper limb buds of those with Liebenberg syndrome, not suppressed expression.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "llama-2-7b-chat-hf_response": "Based on the information provided in Document-0, the following are orally bioavailable MPS1 kinase inhibitors:\n1. MPI-0479605: As mentioned in the document, this purine-based lead compound has been optimized for its biological activity, novelty, selectivity, and oral bioavailability.\n2. MPS1 inhibitor 1: The document mentions that efforts were made to optimize the biochemical activity and cytotoxicity of MPS1 inhibitors in the HCT-116 cell line. While the specific compound used in the study is not mentioned, it is likely that this compound is an MPS1 inhibitor with improved oral bioavailability.\n3. MPS1 inhibitor 2: Similarly, the document mentions that another MPS1 inhibitor was optimized for its oral bioavailability in mice. While the name of this compound is not provided, it is likely to be another orally bioavailable MPS1 inhibitor.\nIt is important to note that these are the only MPS1 kinase inhibitors mentioned in the document, and there may be other compounds with similar properties that have not been disclosed. Additionally, the document does not provide detailed information on the chemical structure or properties of these compounds, so further research may be necessary to fully understand their mechanism of action and potential side effects.",
    "llama-2-7b-chat-hf_fact_raw": "1. MPI-0479605 is an orally bioavailable MPS1 kinase inhibitor that has been optimized for its biological activity, novelty, selectivity, and oral bioavailability.\n2. MPS1 inhibitor 1 is implied to have improved oral bioavailability based on optimization efforts for biochemical activity and cytotoxicity in the HCT-116 cell line.\n3. MPS1 inhibitor 2 was optimized for its oral bioavailability in mice, according to the document.\n4. The document specifically mentions only the above MPS1 kinase inhibitors, suggesting they are the only ones disclosed within it.\n5. The chemical structure or properties of MPI-0479605, MPS1 inhibitor 1, and MPS1 inhibitor 2 are not detailed in the document provided.",
    "llama-2-7b-chat-hf_fact": [
      "MPI-0479605 is an orally bioavailable MPS1 kinase inhibitor that has been optimized for its biological activity, novelty, selectivity, and oral bioavailability.",
      "MPS1 inhibitor 1 is implied to have improved oral bioavailability based on optimization efforts for biochemical activity and cytotoxicity in the HCT-116 cell line.",
      "MPS1 inhibitor 2 was optimized for its oral bioavailability in mice, according to the document.",
      "The document specifically mentions only the above MPS1 kinase inhibitors, suggesting they are the only ones disclosed within it.",
      "The chemical structure or properties of MPI-0479605, MPS1 inhibitor 1, and MPS1 inhibitor 2 are not detailed in the document provided."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: Without knowing the full content of the document, it cannot be confirmed that these are the only MPS1 kinase inhibitors mentioned; the word \"disclosed\" suggests there might be others mentioned in the document.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is no evidence to suggest that golimumab was tested for diabetes. The document is focused on the efficacy and safety of golimumab in patients with rheumatoid arthritis (RA), and does not mention anything about diabetes. Therefore, I must conclude that golimumab has not been tested for diabetes.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is no evidence to suggest that golimumab was tested for diabetes according to the provided document.\n2. The document discussed the efficacy and safety of golimumab in patients with rheumatoid arthritis (RA).\n3. The document does not mention anything about diabetes in the context of golimumab testing.",
    "llama-2-7b-chat-hf_fact": [
      "There is no evidence to suggest that golimumab was tested for diabetes according to the provided document.",
      "The document discussed the efficacy and safety of golimumab in patients with rheumatoid arthritis (RA).",
      "The document does not mention anything about diabetes in the context of golimumab testing."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, it is likely that progeria is caused by an autosomal recessive gene. The document mentions that Hutchinson-Gilford Progeria Syndrome (HGPS), a premature aging disorder, is caused by mutations in the LMNA gene, which encodes the nuclear scaffold proteins lamin A and C. The document also mentions that LMNA-linked progerias can be grouped into two classes: processing-deficient, early onset \"typical\" progerias and processing-proficient \"atypical\" progeria syndromes. The document goes on to describe a previously unrecognized progeria syndrome with prominent cutaneous and cardiovascular manifestations, which the authors suggest should be called LMNA-associated cardiocutaneous progeria syndrome (LCPS). The mutation that causes LCPS is a heterozygous c.899A>G (p.D300G) mutation in the LMNA gene, which is predicted to alter the coiled-coil domain of lamin A/C. The document also notes that the proband demonstrated cancer susceptibility, a phenotype rarely described for LMNA-based progeria disorders.\nBased on this information, it is likely that progeria is caused by an autosomal recessive gene because the mutation that causes HGPS and other LMNA-linked progerias is inherited in an autosomal recessive manner. The fact that LCPS is a previously unrecognized progeria syndrome that is caused by a different mutation in the LMNA gene also supports the idea that progeria is caused by an autosomal recessive gene. Additionally, the document mentions that typical and atypical progerias may converge upon a common mechanism to cause premature aging disease, which suggests that progeria may be caused by a single gene that affects different tissues in different ways.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hutchinson-Gilford Progeria Syndrome (HGPS) is caused by mutations in the LMNA gene.\n2. The LMNA gene encodes nuclear scaffold proteins lamin A and C.\n3. LMNA-linked progerias can be divided into processing-deficient, early onset \"typical\" progerias and processing-proficient \"atypical\" progeria syndromes.\n4. LMNA-associated cardiocutaneous progeria syndrome (LCPS) is caused by a heterozygous c.899A>G (p.D300G) mutation in the LMNA gene.\n5. The proband with LMNA-associated cardiocutaneous progeria syndrome demonstrated cancer susceptibility, a phenotype that is rarely described for LMNA-based progeria disorders.",
    "llama-2-7b-chat-hf_fact": [
      "Hutchinson-Gilford Progeria Syndrome (HGPS) is caused by mutations in the LMNA gene.",
      "The LMNA gene encodes nuclear scaffold proteins lamin A and C.",
      "LMNA-linked progerias can be divided into processing-deficient, early onset \"typical\" progerias and processing-proficient \"atypical\" progeria syndromes.",
      "LMNA-associated cardiocutaneous progeria syndrome (LCPS) is caused by a heterozygous c.899A>G (p.D300G) mutation in the LMNA gene.",
      "The proband with LMNA-associated cardiocutaneous progeria syndrome demonstrated cancer susceptibility, a phenotype that is rarely described for LMNA-based progeria disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN\n\nGiven the information provided and to the best of my knowledge, the statements about the LMNA gene and its association with Hutchinson-Gilford Progeria Syndrome (HGPS) and its encoding of lamin A and C, as well as the classification of progerias, are true. However, without specific scientific literature references for statements 4 and 5, it is not possible to confirm the accuracy of the specific mutation described or the association with cancer susceptibility in patients with LMNA-associated cardiocutaneous progeria syndrome. These statements remain unknown unless further context or evidence is provided.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "llama-2-7b-chat-hf_response": "Based on the information provided, the common variants at 12q14 and 12q24 associated with lung cancer are:\n1. Variant on chromosomal region 15q24-25.1, marked by rs1051730: This variant is associated with an increased risk of lung cancer, with a 5.0% higher frequency in cases than in controls (P = 1.68 x 10(-7); odds ratio (OR), 1.24; 95% confidence interval (95% CI), 1.14-1.35).\n2. Variant on 15q24-25.1, marked by rs481134: This variant is associated with a reduced risk of lung cancer, with a 4.4% lower frequency in cases than in controls (P = 7.39 x 10(-7); OR, 0.80; 95% CI, 0.73-0.87).\nThe second variant on 15q24-25.1, marked by rs481134, explains an additional 13.2% of population attributable risk for lung cancer.\nTherefore, the common variants at 12q14 and 12q24 associated with lung cancer are rs1051730 and rs481134 on chromosomal region 15q24-25.1.",
    "llama-2-7b-chat-hf_fact_raw": "1. The variant marked by rs1051730 on chromosomal region 15q24-25.1 is associated with an increased risk of lung cancer.\n2. The frequency of the variant rs1051730 is 5.0% higher in lung cancer cases than in controls.\n3. The odds ratio for the variant rs1051730 is 1.24 with a 95% confidence interval of 1.14-1.35.\n4. The variant marked by rs481134 on chromosomal region 15q24-25.1 is associated with a reduced risk of lung cancer.\n5. The frequency of the variant rs481134 is 4.4% lower in lung cancer cases than in controls.",
    "llama-2-7b-chat-hf_fact": [
      "The variant marked by rs1051730 on chromosomal region 15q24-25.1 is associated with an increased risk of lung cancer.",
      "The frequency of the variant rs1051730 is 5.0% higher in lung cancer cases than in controls.",
      "The odds ratio for the variant rs1051730 is 1.24 with a 95% confidence interval of 1.14-1.35.",
      "The variant marked by rs481134 on chromosomal region 15q24-25.1 is associated with a reduced risk of lung cancer.",
      "The frequency of the variant rs481134 is 4.4% lower in lung cancer cases than in controls."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: The variant marked by rs1051730 on chromosomal region 15q24-25.1 is indeed associated with an increased risk of lung cancer.\n2. UNKNOWN: The frequency difference of 5.0% for rs1051730 between lung cancer cases and controls cannot be assessed without specific study data. The statement is too specific without reference to such data.\n3. UNKNOWN: The given odds ratio with its confidence interval for rs1051730 cannot be verified without access to particular study findings.\n4. UNKNOWN: Without specific scientific evidence provided, it cannot be determined if the variant marked by rs481134 is associated with a reduced risk of lung cancer.\n5. UNKNOWN: Similarly to statement 2, the frequency difference of 4.4% for rs481134 between lung cancer cases and controls cannot be evaluated without pertinent study data.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the ligands of the Roundabout (Robo) receptors are likely to be guidance cues that activate Rho GTPases, such as Cdc42 and Rac1, in endothelial cells. These Rho GTPases play a crucial role in regulating cellular behavior and directionality during vascular development. The study suggests that Robo4, in particular, mediates attraction-signaling mechanisms through Rho GTPases in vertebrate vascular guidance. Therefore, the ligands of Robo4 are likely to be molecules that interact with Robo4 and activate these Rho GTPases, leading to changes in cellular behavior and directionality. Some examples of potential ligands of Robo4 could include:\n1. Chemokines: Chemokines are signaling molecules that are involved in directing cell migration and differentiation during vascular development. Some chemokines, such as CXCL12, have been shown to interact with Robo1 and Robo2, which are other members of the Robo family of receptors. It is possible that Robo4 also interacts with chemokines in a similar manner.\n2. Netrin: Netrin is a guidance cue that is involved in directing cell migration and differentiation during vascular development. Netrin has been shown to interact with Robo1 and Robo2, and it is possible that Robo4 also interacts with Netrin.\n3. Ephrin: Ephrin is a guidance cue that is involved in directing cell migration and differentiation during vascular development. Ephrin has been shown to interact with Robo1 and Robo2, and it is possible that Robo4 also interacts with Ephrin.\n4. Other unknown ligands: There may be other ligands of Robo4 that have not yet been identified. Further research is needed to determine the full range of ligands that interact with Robo4 and activate Rho GTPases in endothelial cells.\nIn summary, the ligands of Robo4 are likely to be guidance cues that activate Rho GTPases, such as Cdc42 and Rac1, in endothelial cells. These ligands may include chemokines, Netrin, Ephrin",
    "llama-2-7b-chat-hf_fact_raw": "1. Ligands of the Roundabout (Robo) receptors activate Rho GTPases like Cdc42 and Rac1 in endothelial cells.\n2. Robo4 mediates attraction-signaling mechanisms through Rho GTPases in vertebrate vascular guidance.\n3. Chemokines such as CXCL12 have been shown to interact with Robo1 and Robo2, implying potential interaction with Robo4.\n4. Netrin is a guidance cue that has been shown to interact with Robo1 and Robo2, and may also interact with Robo4.\n5. Ephrin is another guidance cue that has been shown to interact with Robo1 and Robo2, suggesting a possible interaction with Robo4.",
    "llama-2-7b-chat-hf_fact": [
      "Ligands of the Roundabout (Robo) receptors activate Rho GTPases like Cdc42 and Rac1 in endothelial cells.",
      "Robo4 mediates attraction-signaling mechanisms through Rho GTPases in vertebrate vascular guidance.",
      "Chemokines such as CXCL12 have been shown to interact with Robo1 and Robo2, implying potential interaction with Robo4.",
      "Netrin is a guidance cue that has been shown to interact with Robo1 and Robo2, and may also interact with Robo4.",
      "Ephrin is another guidance cue that has been shown to interact with Robo1 and Robo2, suggesting a possible interaction with Robo4."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE: Ligands of the Roundabout (Robo) receptors, such as Slit proteins, are known to activate Rho GTPases like Cdc42 and Rac1 in cells, and this signaling pathway is important in various cellular processes including those in endothelial cells.\n2. TRUE: Robo4 has been associated with signaling pathways in endothelial cells that mediate attractive guidance mechanisms through the activation of Rho GTPases, which are critical for the proper guidance and patterning of the vascular system in vertebrates.\n3. UNKNOWN: While chemokines such as CXCL12 (also known as SDF-1) are known to interact with their respective chemokine receptors (such as CXCR4), and there may be crosstalk between different guidance cue families, the statement specifically mentions CXCL12 interaction with Robo1 and Robo2, and an implication for Robo4. Without specific evidence, the potential interaction of CXCL12 with Robo4 remains uncertain.\n4. UNKNOWN: Netrin is indeed a guidance cue known to interact with receptors like DCC and UNC5 family members, and has been reported to interact with Robo1 and Robo2; however, whether Netrin directly interacts with Robo4 has not been clearly established and requires further scientific evidence to confirm such interaction.\n5. UNKNOWN: Ephrin engages in signaling interactions with Eph receptors, and while there may be some research indicating interactions with Robo1 and Robo2, the statement about ephrin suggesting a possible interaction with Robo4 remains speculative without clear evidence or citation of specific data.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, there is evidence to suggest that TFII-I (also known as TFIIIC) plays a role in megakaryopoiesis. The document mentions that a mutant form of TFIIIC, tau131-DeltaTPR2, was selectively suppressed in vivo by overexpression of B\", but not Brf1 or TATA-binding protein. This suggests that TFIIIC may be involved in the recruitment of B\", which is a transcription factor that plays a role in megakaryopoiesis.\nAdditionally, the document states that the mutant factor preincubated at restrictive temperature bound DNA efficiently but lost transcription factor activity, and that the in vitro transcription defect was abolished at high concentrations of B\". This suggests that TFIIIC may play a role in the assembly of the transcription initiation complex on class III genes during megakaryopoiesis.\nOverall, while the document does not directly address the role of TFII-I in megakaryopoiesis, the information provided suggests that TFIIIC may play a role in the recruitment of transcription factors involved in this process.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFII-I (also known as TFIIIC) is suggested to play a role in megakaryopoiesis.\n2. A mutant form of TFIIIC, tau131-DeltaTPR2, was selectively suppressed in vivo by overexpression of B\", a transcription factor involved in megakaryopoiesis.\n3. The mutant factor tau131-DeltaTPR2 bound DNA efficiently but lost transcription factor activity when preincubated at a restrictive temperature.\n4. The in vitro transcription defect of tau131-DeltaTPR2 was abolished at high concentrations of B\".\n5. TFIIIC may be involved in the assembly of the transcription initiation complex on class III genes during megakaryopoiesis.",
    "llama-2-7b-chat-hf_fact": [
      "TFII-I (also known as TFIIIC) is suggested to play a role in megakaryopoiesis.",
      "A mutant form of TFIIIC, tau131-DeltaTPR2, was selectively suppressed in vivo by overexpression of B\", a transcription factor involved in megakaryopoiesis.",
      "The mutant factor tau131-DeltaTPR2 bound DNA efficiently but lost transcription factor activity when preincubated at a restrictive temperature.",
      "The in vitro transcription defect of tau131-DeltaTPR2 was abolished at high concentrations of B\".",
      "TFIIIC may be involved in the assembly of the transcription initiation complex on class III genes during megakaryopoiesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: TFII-I (Transcription Factor II-I) and TFIIIC are different entities. TFII-I has been suggested to play a role in megakaryopoiesis, but TFIIIC is a separate transcription factor involved in the transcription of Class III genes.\n2. UNKNOWN (This statement likely refers to specific experimental results which cannot be verified without the appropriate context or reference material.)\n3. UNKNOWN (Similar to statement 2, this refers to specific experimental details that require additional context to verify the truthfulness.)\n4. UNKNOWN (We would need additional context from the passage which contains the experimental details to determine the truthfulness of this statement.)\n5. FALSE [correction]: TFIIIC is involved in the assembly of the transcription initiation complex on Class III genes, but the context refers to general functions of TFIIIC and not necessarily within the specific context of megakaryopoiesis.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, atenolol is metabolized by CYP2D6. The study found that the activity of CYP2D6 increases during pregnancy, which may lead to increased metabolism of drugs metabolized by this enzyme, including atenolol. The study also found that genetic variation in CYP2D6 can affect the metabolism of drugs, and that poor metabolizers have a different metabolic profile compared to extensive metabolizers. Therefore, it can be concluded that atenolol is metabolized by CYP2D6, and that the activity of this enzyme may be influenced by genetic and hormonal factors during pregnancy.",
    "llama-2-7b-chat-hf_fact_raw": "1. Atenolol is metabolized by CYP2D6.\n2. The activity of CYP2D6 increases during pregnancy.\n3. Increased CYP2D6 activity may lead to increased metabolism of drugs metabolized by this enzyme.\n4. Genetic variation in CYP2D6 can affect the metabolism of drugs.\n5. Poor metabolizers have a different metabolic profile compared to extensive metabolizers regarding drugs metabolized by CYP2D6.",
    "llama-2-7b-chat-hf_fact": [
      "Atenolol is metabolized by CYP2D6.",
      "The activity of CYP2D6 increases during pregnancy.",
      "Increased CYP2D6 activity may lead to increased metabolism of drugs metabolized by this enzyme.",
      "Genetic variation in CYP2D6 can affect the metabolism of drugs.",
      "Poor metabolizers have a different metabolic profile compared to extensive metabolizers regarding drugs metabolized by CYP2D6."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Atenolol is not significantly metabolized by CYP2D6; it is primarily excreted unchanged in the urine.\n2. TRUE\n3. TRUE: If the activity of CYP2D6 increases, it can lead to increased metabolism of drugs that are metabolized by this enzyme, potentially reducing their effectiveness.\n4. TRUE: Genetic variation in the CYP2D6 enzyme can result in different metabolic capacities, which in turn can affect how drugs are metabolized.\n5. TRUE: Poor metabolizers have decreased metabolic activity of CYP2D6 compared to extensive metabolizers, which can lead to different drug plasma levels and responses.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "llama-2-7b-chat-hf_response": "Based on the information provided, here are some versions of ExpansionHunter:\n1. PROLANG: This is an improved version of the PROSOFT program, with new commands and enhancements to the old ones. It is an open software that can be easily expanded by users with BASIC programming experience.\n2. PROSOFT: This is the original version of ExpansionHunter, which was later improved and updated to create PROLANG.\nNote: These are the two versions of ExpansionHunter that are mentioned in the provided information.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, ADAMTS18 plays a crucial role in hormone receptor signaling in breast cancer. The study found that ADAMTS18 is silenced or downregulated in breast cancer cell lines, and its expression is reduced in primary breast tumor tissues compared to adjacent non-cancer tissues. The study also found that ADAMTS18 promoter methylation is frequent in breast tumors, and demethylation treatment can restore ADAMTS18 expression in silenced breast cell lines.\nThe study suggests that ADAMTS18 plays a tumor suppressor role in breast cancer by inhibiting cell migration and invasion. Ectopic expression of ADAMTS18 in breast tumor cells resulted in inhibition of breast cancer metastasis in a nude mouse model. Mechanistic studies showed that ADAMTS18 inhibits epithelial-mesenchymal transition (EMT), which is a process that is involved in the development of cancer stem cells and the progression of cancer. ADAMTS18 also inhibits the phosphorylation levels of AKT and p65, which are key signaling molecules in hormone receptor signaling.\nOverall, the study suggests that ADAMTS18 plays a critical role in hormone receptor signaling in breast cancer by inhibiting the activation of AKT and NF-κB signaling pathways. The methylation of ADAMTS18 could be a potential tumor biomarker for breast cancer, and the restoration of ADAMTS18 expression may provide a new therapeutic strategy for the treatment of breast cancer.",
    "llama-2-7b-chat-hf_fact_raw": "1. ADAMTS18 is often silenced or downregulated in breast cancer cell lines.\n2. ADAMTS18 expression is typically reduced in primary breast tumor tissues compared to adjacent non-cancer tissues.\n3. ADAMTS18 promoter methylation is frequent in breast tumors.\n4. Demethylation treatment can restore ADAMTS18 expression in silenced breast cell lines.\n5. Ectopic expression of ADAMTS18 in breast tumor cells inhibited breast cancer metastasis in a nude mouse model.",
    "llama-2-7b-chat-hf_fact": [
      "ADAMTS18 is often silenced or downregulated in breast cancer cell lines.",
      "ADAMTS18 expression is typically reduced in primary breast tumor tissues compared to adjacent non-cancer tissues.",
      "ADAMTS18 promoter methylation is frequent in breast tumors.",
      "Demethylation treatment can restore ADAMTS18 expression in silenced breast cell lines.",
      "Ectopic expression of ADAMTS18 in breast tumor cells inhibited breast cancer metastasis in a nude mouse model."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE\n\nNote: Statements 1 through 5 are consistent with scientific observations that have been reported regarding the ADAMTS18 gene in the context of cancer research. ADAMTS18 is known to be downregulated in various cancers, including breast cancer, often due to promoter methylation. Treatments that target methylation can restore the expression of such genes, and reintroducing the gene can have effects on tumor behavior, including metastasis. However, specific studies would need to be cited to confirm each statement.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "llama-2-7b-chat-hf_response": "Based on the information provided in the document, the mode of action of Thiazovivin is not directly related to its ability to inhibit selectively the NAD-dependent oxidations by rat brain homogenates. Instead, Thiazovivin exhibits depression of the central nervous system (CNS) activity, which in some cases is associated with an increase in respiration. Additionally, Thiazovivin potentiates the sleeping time of mice when administered in a dose of 100 mg/kg. These findings suggest that Thiazovivin may have a sedative or anxiolytic effect on the central nervous system, which could contribute to its anticonvulsant activity.",
    "llama-2-7b-chat-hf_fact_raw": "1. Thiazovivin's mode of action is not directly related to its ability to inhibit selectively the NAD-dependent oxidations by rat brain homogenates.\n2. Thiazovivin exhibits depression of central nervous system (CNS) activity.\n3. Thiazovivin is associated with an increase in respiration in some cases.\n4. Thiazovivin potentiates the sleeping time of mice when administered in a dose of 100 mg/kg.\n5. Thiazovivin may have a sedative or anxiolytic effect on the central nervous system.",
    "llama-2-7b-chat-hf_fact": [
      "Thiazovivin's mode of action is not directly related to its ability to inhibit selectively the NAD-dependent oxidations by rat brain homogenates.",
      "Thiazovivin exhibits depression of central nervous system (CNS) activity.",
      "Thiazovivin is associated with an increase in respiration in some cases.",
      "Thiazovivin potentiates the sleeping time of mice when administered in a dose of 100 mg/kg.",
      "Thiazovivin may have a sedative or anxiolytic effect on the central nervous system."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nThe details provided in the statements regarding Thiazovivin are highly specific and seem to be related to pharmacological effects and mechanisms of action. Without the appropriate scientific research text or context to reference, it is not possible to accurately verify or correct these statements. Thiazovivin is not a widely known drug or compound with readily available information, especially to the public or in general knowledge databases as of my last update. Therefore, specialized knowledge in pharmacology, access to specific scientific studies, or detailed information on Thiazovivin would be required to assess the truthfulness of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  }
]